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ABSTRACT 
The blood-brain barrier restricts the passage of many drugs into the brain. This restrictive barrier is 
created by the presence of many features, such as the tight junctions between the brain capillary 
endothelial cells and efflux transporter proteins (e.g., P-glycoprotein), all of which limit the 
transport of many compounds into the brain. In the early phase of drug development, cell based in 
vitro models are used to predict blood-brain barrier permeability of new drug candidates. In order 
to make appropriate predictions, it is important to be aware of the usefulness and limitations of 
these in vitro models. In addition, the relevance of the in vitro models needs to be assessed against 
their in vivo counterparts. Primary bovine brain microvessel endothelial cells (BBMECs) have been 
used as an in vitro blood-brain barrier model, since primary cells most closely represent the in vivo 
situation. However, the functionality of the efflux proteins and the in vivo relevance of the 
monocultured BBMECs have not been comprehensively assessed. Therefore, the general objective 
of this study was to evaluate the suitability of the monocultured BBMEC model for use in drug 
permeability studies. 
The BBMEC model was confirmed as being leaky. One reason for this could be the partial 
perinuclear localization of the tight junction protein occludin. P-glycoprotein was found to be 
expressed and correctly localized in the monocultured BBMECs. However, P-glycoprotein 
expression was significantly higher in the BBMECs cultured on filter inserts. Although P-
glycoprotein was shown to be functional in the BBMECs, no efflux was detected in the 
bidirectional transport studies. The molecular descriptors determining the passive drug 
permeability across the BBMEC model were similar with those present in epithelial cell models, 
suggesting that there are no clear differences between passive drug permeability in the endothelial 
and epithelial cell models when drugs need to be classified into different categories. In addition, no 
clear differences were found in the in vitro-in vivo correlations between BBMEC model and 
epithelial cell models, indicating that the predictive value of endothelial and epithelial cell models 
is similar when passive transport of drugs is being evaluated in vitro. 
In conclusion, the monocultured BBMEC model was able to predict the in vivo brain entry of 
mainly passively transported drugs. In addition, undetected efflux suggests that the use of BBMEC 
model may pose a high risk of obtaining false negative results for drug candidates that are 
potential P-glycoprotein substrates. However, BBMECs are suitable for evaluating cellular 
mechanisms, such as in cellular uptake studies, where the tightness of the cell monolayer is not 
crucial. 
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TIIVISTELMÄ 
 
Veri-aivoeste rajoittaa useiden lääkeaineiden kulkua aivoihin. Tämä este muodostuu mm. aivojen 
kapillaariverisuonien endoteelisolujen välisistä tiiviistä liitoksista ja effluksipumppuproteiineista 
(esim. P-glykoproteiini), jotka rajoittavat useiden aineiden kulkua veri-aivoesteen läpi. 
Lääkekehityksen alkuvaiheessa uusien lääkeaine-ehdokkaiden veri-aivoeste läpäisevyyttä 
ennustetaan ns. in vitro -solumalleilla. On tärkeää tietää solumallien hyödyt ja rajoitukset. 
Solumallien antamaa tulosta täytyy verrata in vivo -eläinmallin antamaan tulokseen, jotta 
solumalleilla voidaan tehdä oikeita ennusteita. Naudan aivojen mikrosuonien 
primääriendoteelisoluja (BBMEC) on käytetty veri-aivoesteen solumallina, koska ne edustavat 
tarkimmin veri-aivoestettä. Yksisolukasvatetun BBMEC-mallin effluksipumppuproteiinien 
toiminnallisuutta ja relevanssia in vivo -eläinmallien antamiin tuloksiin ei ole arvioitu kattavasti. 
Tästä syystä tutkimuksen päätavoitteena oli arvioida yksisolukasvatetun BBMEC-mallin 
soveltuvuutta lääkeaineiden läpäisevyystutkimuksiin. 
Tulokset varmistivat BBMEC-solumallin olevan vuotava. Mahdollinen syy vuotavuuteen voi 
olla tiivisliitosproteiini okkludiinin osittainen sijainti tuman läheisyydessä. P-glykoproteiini 
ilmentyi ja sijoittui oikein solukalvolle yksisolukasvatuksessa BBMEC-mallissa mutta P-
glykoproteiinin ilmentyminen oli merkitsevästi korkeampi kasvatusinserttikalvolla kasvatetuissa 
BBMEC-soluissa. P-glykoproteiinin osoitettiin olevan toiminnallinen mutta sitä ei havaittu 
kaksisuuntaisissa kuljetuskokeissa. Molekyylin kemiallisia ominaisuuksia kuvailevat tuntomerkit, 
jotka määrittävät lääkeaineen passiivisen läpäisevyyden BBMEC-mallin yksisolukerroksen läpi, 
havaittiin olevan samanlaiset kuin epiteelisolumalleilla. Tämä viittaa siihen, että lääkeaineiden 
passiivisessa läpäisevyydessä ei ole selviä eroja endoteelisolumallin ja epiteelisolumallien välillä, 
kun lääkeaineet luokitellaan eri luokkiin. Tutkimuksessa havaittiin myös, että in vitro-in vivo 
korrelaatioissa ei ollut selviä eroja BBMEC-mallin ja epiteelisolumallien välillä. 
Endoteelisolumallin ja epiteelisolumallien ennustearvo on samankaltainen, kun arvioidaan 
pääasiassa lääkeaineiden passiivista kulkeutumista. 
Yksisolukasvatetun BBMEC-mallin osoitettiin ennustavan pääasiassa lääkeaineiden passiivista 
aivokulkeutumista. Lisäksi BBMEC-mallin käyttäminen lääkeaine-ehdokkaiden, jotka ovat 
mahdollisesti P-glykoproteiinin substraatteja, veri-aivoesteläpäisevyyden ennustamiseen voi 
aiheuttaa riskin väärien negatiivisten tulosten saamiseen. BBMEC-malli soveltuu kuitenkin 
solumekanismien tutkimiseen, kuten soluunottokokeisiin, joissa solukerroksen tiiviys ei ole 
pääasiallinen vaatimus. 
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1 Introduction 
More than three hundred years ago, in 1695, the first experimental evidence for impermeability 
of cerebral blood vessels was observed by Humphrey Ridley, cited in Liddelow (2011). Ridley 
described that wax and mercury injected into bloodstream did not tint the nerves but had 
stained the ramifications of blood vessels in them (Liddelow, 2011). Almost two centuries later, 
Paul Ehrlich noted that an intravenously injected dye did not stain the brain, although other 
organs were dyed (Ehrlich, 1885). Ehrlich assumed that it was caused by weak binding affinity 
of the dye in the brain. Further experiments completed by Ehrlich’s student Edwin Goldmann 
in 1913 revealed that trypan blue dye injected into cerebro-spinal fluid stained the brain but not 
the peripheral tissues, cited in Liddelow (2011). These results pointed to the existence of the 
barrier between the blood and central nervous system (CNS) (Hawkins and Davis, 2005, 
Liddelow, 2011). 
Subsequently, two fundamental features of a blood-brain barrier were appreciated (Reese 
and Karnovsky, 1967). Firstly, the uniform formation of tight junctions between the endothelial 
cells. Secondly, the low frequency of vesicles in the endothelial cells of the blood-brain barrier. 
All the above experiments and several other investigations that were conducted in the elapsing 
years were significant in the discovery of the concept of the blood-brain barrier (Roy and 
Sherrington, 1890, Dermietzel and Krause, 1991, Liddelow, 2011). 
In order to be effective, a drug needs to reach its target site and maintain an adequate 
therapeutic concentration to if it is to achieve its desired pharmacological response. Drug 
targeting into the brain is challenging due to the blood-brain barrier. The blood-brain barrier 
selectively regulates the transport of the compounds into and out of the brain (Risau and 
Wolburg, 1990). Conventional commonly used CNS drugs are almost exclusively small-
molecular weight drugs (Pardridge, 2002). The majority of drugs, in some estimates as many as 
98 % and none of the large-molecular drugs, are not able to permeate across the blood-brain 
barrier (Pardridge, 2002, Pardridge, 2005). This is one reason why many CNS diseases do not 
currently have effective drugs (Pardridge, 2005). However, the suggestion that only a few drugs 
enter the brain has been criticized as also large drugs are able to cross the blood-brain barrier in 
vivo (Fagerholm, 2007). Therefore, understanding the complex nature of the blood-brain barrier 
is an important part of the development of novel drugs for CNS diseases and disorders. 
Drug development is time-consuming and costly (Stoner et al., 2004, Paul et al., 2010) and 
therefore in order to reduce the cost and time required for drug development, many 
technologies including in vitro, in vivo and in silico models can be applied to predict the 
properties of a drug candidate in the early drug development in the pharmaceutical industry 
(Stoner et al., 2004). Recently, cell based in vitro models have been developed for use in drug 
permeability studies both to speed up early drug development and decrease the number of 
animal experiments. These in vitro models should closely resemble the brain endothelium and 
to exhibit relevant in vivo blood-brain barrier properties (e.g., tight paracellular barrier and 
correct localization and functionality of the efflux proteins). In addition, the relevance of the cell 
models against in vivo counterpart needs to be assessed to allow reliable predictions based on in 
vitro data. 
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2 Review of the Literature 
2.1 NEUROVASCULAR UNIT AND BLOOD-BRAIN BARRIER 
2.1.1 Neurovascular unit 
In the human brain, there are over 100 billion capillaries; the length of these capillaries stretches 
over 600 km (Pardridge, 2005). The brain capillaries are the smallest vessels in the vascular 
system with a diameter of only 3-7 µm (Figure 1) (Rodríguez-Baeza et al., 2003). The surface area 
of the brain capillary endothelial cells that are creating the barrier between the blood and brain 
tissue has been estimated to be 12-20 m2 in human (Pardridge, 2005, Krämer et al., 2009). 
 
 
Figure 1. Scanning electron micrograph showing human brain vessels from the cerebral cortex (1) pial vessels, 
(2) long cortical artery, (3) middle cortical artery, (4) superficial capillary zone, (5) middle capillary zone, and 
(6) deep capillary zone. Scale bar 0.86 mm. (Rodríguez-Baeza et al., 2003). Reprinted with the kind permission 
of John Wiley & Sons, Inc. 
 
The brain capillary endothelial cells are encircled by several cell types that act as a secondary 
barrier around the endothelium. These cells include pericytes, astrocytes, neurons and together 
with the endothelial cells they form a structure called the neurovascular unit (Figure 2). 
Astrocytes encircle 90 % of the abluminal side of endothelial cells, control the cerebral blood 
flow by constricting the cerebrovasculature (Mulligan and MacVicar, 2004) whereas neuronal 
activity will stimulate the astrocytes to evoke arteriole dilatation (Zonta et al., 2003). In addition, 
cell culture studies have shown that factors released from astrocytes are able to upregulate the 
tight junction resistance (Rubin et al., 1991a, Raub, 1996), induce enzyme activities such as 
alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (DeBault and Cancilla, 1980, 
Hayashi et al., 1997, Sobue et al., 1999) and elevate messenger ribonucleic acid (mRNA) levels of 
relevant blood-brain barrier features, such as transferrin receptor, P-glycoprotein and glucose 
transporter 1 (GLUT1) (Hayashi et al., 1997). In addition, upregulation of low density 
lipoprotein receptor was observed when the brain endothelial cells were cocultured with 
astrocytes in vitro (Dehouck et al., 1994). 
Pericytes are supporting cells located at the microvascular wall alongside the endothelial 
cells. Pericytes are the closest cell type adjacent to the brain endothelial cells and they share a 
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common basal lamina (Figure 2). The understanding of the biology of pericytes has increased in 
recent years (for review see Shepro and Morel, 1993, Dalkara et al., 2011, Kamouchi et al., 2011). 
The pericytes have contractile activity controlling the capillary diameter and thus, they can 
modulate the cerebral blood flow at the capillary level (Peppiatt et al., 2006, Hamilton et al., 
2010, Fernández-Klett et al., 2010). Pericytes also regulate endothelial cell differentiation and 
proliferation, e.g., during angiogenesis (for review see Shepro and Morel, 1993). In addition, cell 
culture studies have shown that factors secreted by pericytes can increase claudin-5 expression 
in the brain endothelial cells, thus, enhancing the tightness of the blood-brain barrier (Shimizu 
et al., 2012). 
Neurons are closely associated with brain capillaries (Park et al., 2003, Iadecola, 2004). The 
neuronal processes release several vasoactive agents, such as nitric oxide, acetylcholine, γ-
aminobutyric acid, noradrenaline, dopamine and serotonin (Fergus and Lee, 1997, Iadecola, 
1998, Iadecola, 2004, Lok et al., 2007) which regulate local intracerebral blood flow. 
The direct cell contacts and signaling pathways at the neurovascular unit modulate multiple 
brain microvascular functions, e.g., cerebral blood flow and maintain the essential functions of 
the blood-brain barrier. It is very likely that there are several other interactions between the cells 
of the neurovascular unit but they are still poorly understood. The structure and regulation of 
the neurovascular unit have been reviewed in detail elsewhere (Ballabh et al., 2004, McCarty, 
2005, Correale and Villa, 2009, Abbott et al., 2010). 
 
Figure 2. Structure of the neurovascular unit. Modified form Abbott et al., 2006. 
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2.1.2 Structure and function of the blood-brain barrier 
The blood-brain barrier is a feature of brain blood capillary vessels that are lined with a thin 
layer of endothelial cells. Since the primary role of the blood-brain barrier is to maintain the 
homeostasis between blood and brain by restricting cell, fluid and ionic transport, the brain 
endothelial cells are distinct from other endothelial cells in the body. This barrier is made up of 
three barriers; physical, transport and metabolic barrier, and it is controlling compounds to 
enter and leave brain by selectively supplying for essential nutrients and removing brain-borne 
metabolites (Risau and Wolburg, 1990, Abbott, 2005, Deli, 2007). 
 
Physical barrier 
One of the hallmarks of the blood-brain barrier is the restrictive paracellular barrier composed 
of a continuous network of tight junctions between the endothelial cells (Reese and Karnovsky, 
1967, Nagy et al., 1984). These are created by the presence of several tight junction specific 
proteins, such as occludin (Furuse et al., 1993, Hirase et al., 1997), zonula occludens 1 (ZO-1) 
(Watson et al., 1991, Furuse et al., 1994), claudin-1 and claudin-5 (Liebner et al., 2000). In 
addition, adherens junctions composed of Ca2+-dependent cadherin proteins promote also the 
adhesion between the endothelial cells (Schulze and Firth, 1993, Staddon et al., 1995). The 
expression levels of occludin in the endothelial cells have been reported to vary between 
different tissues, with the highest expression being detected in the brain endothelial cells 
(Hirase et al., 1997). Thus, the brain capillaries are substantially tighter than peripheral blood 
vessels (Abbott et al., 2008) and paracellular transport of compounds between the brain 
endothelial cells is efficiently restricted. Tight junctions are able to prevent the transport of 
small ions, such as Na+ and Cl-. The transendothelial electrical resistance (TEER) of the blood-
brain barrier in vivo has been shown to be 1000-2000 Ωcm2 in rats and frogs (Crone and Olesen, 
1982, Butt et al., 1990) but it may be even much higher, 8000 Ωcm2 in rats (Smith and Rapoport, 
1986). For comparison, frog mesenteric blood capillaries have a resistance of only ~2 Ωcm2 
(Crone and Christensen, 1981) and frog muscle capillaries ~30 Ωcm2 (Olesen and Crone, 1983) 
highlighting the fact that the resistance in the brain capillaries is dramatically higher than in the 
peripheral capillaries. 
 
Transport barrier 
Since the paracellular transport of compounds is efficiently restricted by the blood-brain barrier, 
there are many essential molecules that are needed by neurons but which cannot pass passively 
from blood to brain. These compounds require specific transporter proteins in order to gain 
access into the brain. The blood-brain barrier contains numerous transporter proteins and 
transcytosis mechanisms that mediate the efflux and uptake of various compounds across the 
brain capillary endothelial cells (see section 2.2.2). 
 
Metabolic barrier 
Many of the enzymes expressed in the mammalian blood-brain barrier, hinder the access of 
compounds into the brain. Several enzymes have been demonstrated to be highly expressed in 
the brain endothelial cells, e.g., ALP, γ-glutamyl transpeptidase, cholinesterase, phosphoprotein 
phosphatase, aminopeptidases, carboxypeptidases, angiotensin converting enzyme, dipeptidyl 
peptidases, monoamine oxidase, dopa decarboxylase and cytochrome P450 enzymes (CYP) (for 
review see Brownlees and Williams, 1993, Dermietzel and Krause, 1991, Bertler et al., 1966). 
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2.2 TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER 
There are many different transport mechanisms to help and hinder compounds to cross the 
blood-brain barrier 1) passive paracellular and transcellular diffusion, 2) active carrier mediated 
transport, 3) active efflux transport, 4) endocytosis (specific receptor-mediated and absorptive 
endocytosis) (Figure 3) for review see (Neuwelt, 2004, Pardridge, 2005, Abbott et al., 2010). 
 
 
 
Figure 3. Transport routes across the blood-brain barrier. A) passive paracellular diffusion (small water soluble 
molecules), B) passive transcellular diffusion (lipid soluble, non-polar molecules), C) active carrier mediated 
transport (essential polar molecules; glucose, amino acids, nucleosides), D) active efflux transporters (lipid 
soluble, non-polar molecules and conjugates, drugs and xenobiotics), E) adsorptive endocytosis (cationized 
albumin), F) specific receptor-mediated endocytosis (transferrin, insulin). Modified from Neuwelt, 2004, Abbott 
et al., 2010. 
2.2.1 Passive permeability 
Passive diffusion is a process where a compound moves down its concentration gradient and it 
does not require any expenditure of energy. The passive paracellular diffusion passes through 
the cellular tight junctions between the endothelial cells (i.e., the paracellular pathway, Figure 
3A) and passive transcellular diffusion occurs across the cell membrane (i.e., the transcellular 
pathway Figure 3B). The paracellular pathway is negligible in the blood-brain barrier due to the 
occlusive tight junctions. Therefore, the brain permeability of low permeability compounds, e.g., 
sucrose, mannitol and inulin (tracers for paracellular tightness) is negligible (Ferguson and 
Woodbury, 1969, Ohno et al., 1978). Permeability coefficient of sucrose into the brain in vivo is ~3 
× 10-8 cm/s (Ohno et al., 1978). Whereas, high permeability compounds crossing the blood-brain 
barrier in vivo via passive transcellular diffusion, the permeability coefficients are several orders 
of magnitudes higher; e.g., antipyrine 33 × 10-6 cm/s and ethanol >100 × 10-6 cm/s (Crone, 1965). 
The basis of the molecule’s possibility to cross the blood-brain barrier is strongly linked to its 
molecular properties, since the majority of the molecules capable of diffusing from the blood 
into the brain need to be transported across the endothelial cells. It is generally accepted that 
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four basic molecular properties are strongly associated with the capability to permeate across 
cell membranes; these are known as Lipiski’s rule of five (Lipinski et al., 1997). 
In the blood-brain barrier, the physicochemical properties associated with the drug 
permeability across the blood-brain barrier are comparable to Lipinski’s rule of five, which was 
developed for the estimation of oral absorption potential; lipophilicity (logarithm of the 
octanol/water partition coefficient, LogP), number of hydrogen-bond donor (HBD) groups 
(defined as hydrogen atom connected to electronegative atoms such as nitrogen or oxygen) and 
number of hydrogen-bond acceptor (HBA) groups (described as electronegative atoms with a 
lone pair of electrons), polar surface area (PSA) and molecular weight (MW) (Rapoport and 
Levitan, 1974, Abraham et al., 1994, Gratton et al., 1997, Fischer et al., 1998, Kelder et al., 1999, 
Abraham, 2004, Pardridge, 2005, Fu et al., 2008) (Table 1). Physicochemical properties are 
commonly considered as interdependent (Hitchcock and Pennington, 2006). If a compound’s 
ability to transport across blood-brain barrier is estimated based on physicochemical properties, 
the combination of the physicochemical properties should be considered instead of individual 
molecular properties alone. 
 
Table 1. Physicochemical properties for increased potential of higher blood-brain barrier passive 
transcellular permeability and oral absorption. 
Physicochemical property blood-brain barrier oral absorption 
Octanol/water partition coefficient (LogP) 
2-5a, <3b <5c 
Hydrogen-bond donors (HBD) 
<3a, <4b <5c 
Hydrogen-bond acceptors (HBA) 
<8b <10c 
Polar surface area (PSA, Å2) 
<90a <140d 
Molecular weight (MW, Da) <500
a, <450b <500c 
a Hitchcock and Pennington, 2006; b Reichel, 2006; c Lipinski et al., 1997; d Veber et al., 2002. 
 
Lipophilicity 
The molecule needs to possess sufficient lipophilicity in order to be able to partition into the 
endothelial cell membranes (Oldendorf, 1974). The lipophilicity of the molecule can be 
quantified by LogP (Leo et al., 1971). LogP is defined as the ratio of the concentration of neutral 
species of compound in octanol and water at equilibrium. Compounds with low LogP values 
(e.g., LogP -1 = 1:10 octanol:water) are hydrophilic. Conversely, compounds with high LogP 
values (e.g., LogP 3 = 1000:1 octanol:water) are lipophilic. Lipophilic molecules move readily 
from the blood to the endothelial cell membrane and, thus, LogP has been used as a general 
predictor of the blood-brain barrier permeability (Rapoport and Levitan, 1974). For example, the 
diffusion of lipophilic drug diazepam (experimental LogP 2.99 (Wang et al., 1997)) into the brain 
is rapid and its movement across the blood-brain barrier does not appear to be restricted 
(Ramsay et al., 1979). In contrast, sucrose is very hydrophilic (experimental LogP -3.67 (Leo et 
al., 1971)) and its brain penetration is negligible (Ohno et al., 1978). Lipophilicity depends also 
on the molecular forces between the drug and the phase into which it is partitioning, e.g., the 
cell membrane, since the ionic attractive and repulsive interactions have also an impact; 
lipophilicity = hydrophobicity – polarity + ionic interactions (for review see Liu et al., 2011). 
Traditionally, drug delivery into the brain has been improved by making the drug molecule 
more lipophilic by covering the hydrophilic parts with lipids and by adding hydrophobic 
groups (Abbott and Romero, 1996, Pardridge, 2002). There are limitations to increasing the 
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lipophilicity of the novel drug, e.g., these may be its rapid distribution into the other organs, 
increased binding to plasma proteins and decreased biological activity. 
 
Hydrogen-bonding 
The capability to form hydrogen-bonds has been recognized as an important factor in brain 
penetration of drugs, and the brain penetration of a drug can be improved by reducing the 
overall hydrogen-bonding interactions (Young et al., 1988). The hydrogen-bonding capability is 
known to decrease the in vivo brain distribution and to reduce the brain permeability of drugs 
(Abraham et al., 1994, Gratton et al., 1997). 
 
Polarity 
An increased polarity of compounds decreases the blood-brain partitioning (Norinder et al., 
1998) and blood-brain permeability (Abraham et al., 1994, Gratton et al., 1997, Abraham, 2004). 
PSA is the surface area occupied by polar atoms, mainly nitrogen and oxygen, and the 
hydrogen atoms attached to these polar atoms. PSA reflects also a drug’s capability to form 
hydrogen bonds. The increase of PSA of drugs has been shown to decrease brain penetration 
(Kelder et al., 1999). 
 
Molecular weight and size 
In general, small molecules with MW less than 400-500 Da have a better potential to cross the 
blood-brain barrier than larger molecules (Pardridge, 2005). In addition, the drug permeation 
across the blood-brain barrier decreases by 100-fold when the cross-sectional area of the drug is 
increased from 52 Å2 (e.g., drug with MW of 200 Da) to 105 Å2 (e.g., drug with MW of 450 Da) 
(Fischer et al., 1998, Pardridge, 2005). Generally, passive permeation across the blood-brain 
barrier becomes reduced when the cross-sectional area of the drug molecule is ≥70-80 Å2 
(Fischer et al., 1998, Seelig, 2007). 
2.2.2 Active transport 
Active transporters can be grouped into two classes, adenosine triphosphate (ATP)-binding 
cassette (ABC) and solute-carrier (SLC) transporters. ABC transporters are efflux membrane 
proteins transporting substrates from the intracellular compartment and/or lipid leaflets of the 
cell membrane back to the extracellular compartment of the cells (Higgins and Gottesman, 1992, 
Matheny et al., 2001, Kimura et al., 2007). The efflux transporters require energy from ATP 
hydrolysis to allow them to transport substrates across the cell membranes against a 
concentration gradient. Many SLC transporters are influx or bidirectional transporters that can 
either facilitate diffusion of substrates down the concentration gradients across the cell 
membranes, or they use energy originating from the inorganic or small ions to provide the 
driving force for the transport processes against the concentration gradient (Russel, 2010). Many 
transporters are highly expressed at the blood-brain barrier and they are intended to protect the 
brain from endogenous and exogenous toxins as well as supply nutrients into the brain, 
respectively (Pardridge, 2005). 
 
ABC transporters 
There are 49 ABC transporter genes in the human genome; these are grouped into seven 
subfamilies named from A to G (gene families ABCA-ABCG) (Vasiliou et al., 2009). The first 
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characterized and the best studied glycosylated efflux protein is the multidrug resistance 
protein 1 (MDR1, gene ABCB1) designated as P-glycoprotein by Juliano and Ling (Juliano and 
Ling, 1976). In addition, multidrug resistance-associated proteins (MRPs, ABCC gene family) 
and breast cancer resistance protein (BCRP, gene ABCG2) were identified in multidrug resistant 
cells (Cole et al., 1992, Krishnamachary and Center, 1993, Doyle et al., 1998). Although the efflux 
proteins were initially found to contribute the multidrug resistance in tumor cells, the 
pioneering work in the field of multidrug resistance proceeded when Schinkel et al. generated 
P-glycoprotein knockout mice and demonstrated the protective role of P-glycoprotein in 
various tissues in vivo (Schinkel et al., 1994, Schinkel et al., 1995). 
The efflux proteins are expressed in many human tissues, e.g., liver, intestine, kidney and 
pancreas (Thiebaut et al., 1987, Flens et al., 1996, Maliepaard et al., 2001a). The main role of the 
efflux transporters is to transport a wide variety of lipid soluble molecules out of the cells. The 
function of the efflux proteins has been related to many phases of the pharmacokinetics of the 
drugs; absorption from the gastrointestinal tract (Benet et al., 1999, Floren et al., 1997), 
distribution into different compartments in the body, such as brain and placenta (Schinkel et al., 
1994, Young et al., 2003) and excretion from the liver and kidneys (Charuk et al., 1994, Faber et 
al., 2003). 
The first observation of the expression of P-glycoprotein in the endothelial cells in the human 
blood-brain barrier was made by Cordon-Cardo et al. in 1989; these workers speculated that P-
glycoprotein would have a physiological role in the regulation of drug transport into CNS 
(Cordon-Cardo et al., 1989). It was found that luminally located P-glycoprotein in the blood-
brain barrier acted as a protective mechanism restricting the penetration of harmful 
compounds, such as bilirubin and cortisol into the brain (Ueda et al., 1992, Watchko et al., 1998). 
Strong expression of P-glycoprotein has also been found in other blood-tissue barriers, such as 
the blood-testis barrier and the blood-placental barrier (Cordon-Cardo et al., 1989, MacFarland 
et al., 1994). At present, at least six efflux transporters have been detected in the blood-brain 
barrier, these being mainly located on the luminal side of the brain capillary endothelial cells. 
These efflux proteins are P-glycoprotein, MRP1, MRP2, MRP4, MRP5 and BCRP (Figure 4) (for 
review see Abbott et al., 2010, Neuwelt et al., 2011). The efflux transporters are not restricted 
only to capillary endothelial cells (Figure 4) since also other cell types of the neurovascular unit 
express several efflux transporters (Kim et al., 2006, Kooij et al., 2011, Gibson et al., 2012, Chen et 
al., 2013). 
 
SLC transporters 
Currently, 55 SLC gene families with at least 362 putatively protein-coding genes have been 
found in the human genome (He et al., 2009). The SLC transporters at the blood-brain barrier are 
important in the transport of many essential polar molecules, since these molecules are not able 
to diffuse passively across the cell membranes (for review see Ohtsuki and Terasaki, 2007, 
Abbott et al., 2010). SLC transporters expressed in the blood-brain barrier include energy 
transport systems, such as GLUT1 (gene SLC2A1), monocarboxylic acid transporter 1 (MCT1, 
gene SLC16A1) and amino acid transport systems, e.g., large neutral amino acid transporter 1 
(LAT1, genes SLC3A2 and SLC7A5) (Figure 4). In addition, several other SLC transporters are 
expressed in the blood-brain barrier, e.g., organic anion transport systems (organic anion 
transporters, OAT2-3, genes SLC22A7,8; organic anion transporting polypeptides, OATPs, 
SLCO gene family); organic cation transport systems (organic cation transporters, OCT2-3, 
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genes SLC22A2,3) and nucleoside transporters (concentrative nucleoside transporters, CNT2-3, 
genes SLC28A2,3 and equilibrative nucleoside transporters, ENT1-2, genes SLC29A1,2) (Figure 
4). 
SLC transporters, such as LAT1 (Gynther et al., 2008, Peura et al., 2013) and GLUT1 (Gynther 
et al., 2009), have been proposed as attractive transfer routes to allow drugs to gain access to the 
brain. LAT1 has higher transport capacity and it is less specific for its substrates than GLUT1 
and, thus, LAT1 is more promising system for improved drug delivery into the brain (Abbott 
and Romero, 1996, Rautio et al., 2013). However, competition of amino acids from consumed 
food may lead to some limitations in the use of LAT1 system (del Amo et al., 2008). For example, 
the clinical response of levodopa which uses LAT system for transport across the intestinal wall 
and blood-brain barrier, is affected by the presence of amino acids in the plasma derived from 
dietary proteins (Carter et al., 1989). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Transporters in the blood-brain barrier and in the neurovascular unit. P-gp, P-glycoprotein; MRP1-5, 
Multidrug resistance associated proteins 1-5; BCRP, Breast cancer resistance protein; OATPs, Organic anion 
transporting polypeptides; OAT2,3, Organic anion transporter 2,3; OCT2,3, Organic cation transporter 2,3; 
ENT1,2, Equilibrative nucleoside transporter 1,2; CNT1-3, Concentrative nucleoside transporter 1-3; GLUT1, 
Glucose transporter 1; LAT1, Large neutral amino acid transporter 1; MCT1, Monocarboxylic acid transporter 1. 
Modified form Ohtsuki and Terasaki, 2007, Abbott et al., 2010, Neuwelt et al., 2011. Arrows indicate the 
direction of transport (Abbott et al., 2010, Zlokovic, 2011, Omidi and Barar, 2012). 
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Clinically important transporters in drug disposition 
The understanding of the drug transporters has grown tremendously in recent years. The 
influence of efflux transporters in drug disposition in the body, their effect on multidrug 
resistance and drug-drug interactions related to inhibition of efflux transporters have been 
subjects of great interest for the past 10 years (Gottesman et al., 2002, Marzolini et al., 2004, 
Zhang et al., 2006a, Giacomini et al., 2010, Han, 2011, Maeda and Sugiyama, 2013). Today, 
several ABC and SLC transporters (e.g., P-glycoprotein, BCRP, OATPs, OCTs, OATs) have been 
identified as clinically important key transporters related to the pharmacokinetics of different 
drugs. These clinically important transporters are also expressed in the blood-brain barrier 
(Figure 4). Therefore, the transport of drugs undertaken by these transporters (efflux and/or 
influx) may be more extensively affected in the tight blood-brain barrier than in the leakier 
organs, since paracellular transport is negligible in the blood-brain barrier. 
Recently, the regulatory authorities have released guidelines for the pharmaceutical industry 
on the prediction of the transporter mediated drug-drug interactions of drug candidates 
(European Medicines Agency, Guideline on the Investigation of Drug Interactions, 2012; U.S. 
Food and Drug Administration, Guidance for Industry (draft), Drug Interaction Studies-Study 
Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, 2012). 
Moreover, an International Transporter Consortium was established in 2007 to reach a 
consensus on the role of the clinically important transporters in drug safety and efficacy (Huang 
et al., 2010). The consortium has published recommendations (Giacomini et al., 2010), provided 
follow up commentaries, issued directions for the future recommendations and has discussed 
recent regulatory draft guidance documents (Tweedie et al., 2013, Zamek-Gliszczynski et al., 
2012). These documents are important advances in the identification and assessment of 
clinically important drug-transporter interactions. 
2.2.3 Endocytosis 
A low level of endocytosis is a hallmark of the blood-brain barrier in vivo (Reese and 
Karnovsky, 1967, Goldstein et al., 1986, Risau and Wolburg, 1990). This has also been 
demonstrated in vitro primary bovine endothelial cells (Guillot et al., 1990, Raub and Audus, 
1990). Therefore, only a small amount molecular trafficking across the blood-brain barrier is 
mediated by endocytosis. However, adsorptive endocytosis and specific receptor-mediated 
endocytosis (Figure 3) (Pardridge, 2002) may be important drug delivery pathways for polar 
and large molecule drugs and peptides into the brain (Abbott and Romero, 1996, Bickel et al., 
2001, Smith and Gumbleton, 2006). 
 
2.3 EFFECTS OF CNS DISEASES ON THE FUNCTION OF THE BLOOD-BRAIN 
BARRIER 
The tight junctions play an important role in the blood-brain barrier. Changes in the expression 
and localization of these proteins can have a strong influence on blood-brain barrier function 
and they have been suggested to be associated with the pathology of many neurological 
disorders (for review see Bednarczyk and Lukasiuk, 2011). There is also emerging evidence that 
also efflux transporters may play a role in the pathogenesis of neurodegenerative diseases 
(Cirrito et al., 2005, Kortekaas et al., 2005, Tai et al., 2009). The altered functions of the blood-
brain barrier and the neurovascular unit are both contributing factors to pathogenesis and the 
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consequence of CNS diseases (Hawkins and Davis, 2005). Currently, it is generally accepted 
that neuronal cell damage is not the only trigger in the pathogenesis of CNS diseases, but the 
damage at the level of neurovascularies may also contribute to the initiation and progression of 
the disease (Zlokovic, 2011, Stanimirovic and Friedman, 2012). At the moment, however, the 
molecular basis of the neurovascular link to the pathology is still poorly understood. In this 
connection, it is recommended that diagnostic and drug therapy strategies should be focused on 
the neurovascular unit in order to discover drug targets and develop novel drugs for CNS 
diseases and disorders (Stanimirovic and Friedman, 2012). 
Brain ischemia has been shown to reduce the integrity of the blood-brain barrier (Albayrak et 
al., 1997, Lorberboym et al., 2006) and increased paracellular permeability contributes to the 
formation of brain edema (Castejón, 2012). An insufficient oxygen and glucose supply after an 
ischemic stroke is a trigger for multiple pathophysiological processes that cause injuries to 
endothelial cells, neurons and glia (Doyle et al., 2008). The cell death is a result from complex 
chain of events, e.g., acidosis, oxidative stress, periinfarct depolarization and apoptosis. 
Multiple sclerosis is an inflammatory demyelinating disease whose origin is still unknown. A 
key factor may be a complex inflammatory cascade initiating the migration of activated 
leucocytes into the brain (for review see Minagar and Alexander, 2003). This inflammatory 
cascade is the most significant reason for the decrease in the numbers of tight junctions between 
the brain capillary endothelial cells and the loss of blood-brain barrier intergrity (for review see 
Minagar and Alexander, 2003, Bednarczyk and Lukasiuk, 2011). Recently, altered expression of 
the efflux transporters, such as decreased expression of P-glycoprotein in blood-brain barrier 
and increased expression of both P-glycoprotein and MRP1 in reactive astrocytes, in multiple 
sclerosis brain tissue was reported and interpreted as evidence for the pathological role of efflux 
transporters (Kooij et al., 2011). 
Alzheimer’s disease is a progressive neurodegenerative disease characterized by neuronal loss, 
development of neurofibrillary tangles and deposition of amyloid plaques composed of 
amyloid-β peptides (Aβ) (for review see Skaper, 2012, Wilcock, 2012). Alzheimer’s disease is 
age-dependent (for review see Candore et al., 2006). There is evidence that the blood-brain 
barrier becomes leakier when the brain ages suggesting that a dysfunction of the blood-brain 
barrier may be present in the early stage of Alzheimer’s disease (Starr et al., 2009, Viggars et al., 
2011). Etiology of the Alzheimer’s disease is complex; Aβ deposition is the major pathological 
feature but inflammation and oxidative stress also contribute to the pathogenesis of Alzheimer’s 
disease (Skaper, 2012). Brain biopses from patients with Alzheimer’s diseases have revealed that 
abnormalities at the blood-brain barrier (e.g., diminished numbers of mitochondria in the 
endothelial cells, abnormal interendothelial junctions and pericytes adjacent but not 
surrounding the endothelium) can lead to a leakier blood-brain barrier (Stewart et al., 1992). 
Aβ1-42 has also been shown to weaken the blood-brain barrier integrity in vitro by disrupting 
tight junction localization and this phenomenon is believed to contribute to the development of 
Alzheimer’s disease (Marco and Skaper, 2006). In addition, two efflux transporters, BCRP and 
P-glycoprotein, have been shown to be involved in the transport of Aβ across the blood-brain 
barrier both in vitro and in vivo (Vogelgesang et al., 2002, Cirrito et al., 2005, Tai et al., 2009) 
indicating that increased accumulation of Aβ into the brain may have been attributable to 
reduced functionality of these efflux transporters. 
Parkinson’s disease is a progressive neurodegenerative disease associated with the loss of 
nigrostriatal dopaminergic neurons. However, the mechanisms underlying the 
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neurodegenerative process in Parkinson’s disease are not fully understood (Kortekaas et al., 
2005). It has been hypothesized that inflammation, oxidative stress and disruption of the blood-
brain barrier may all play their part in the pathogenesis of Parkinson’s disease (Chen et al., 2008, 
McGeer and McGeer, 2008). In addition, environmental toxins may have a role in the 
pathogenesis of Parkinson’s disease. Their brain penetration because of the reduced activity or 
expression of P-glycoprotein has been postulated as contributing to the pathogenesis (Kortekaas 
et al., 2005). P-glycoprotein function in the blood-brain barrier decreases with ageing (Toornvliet 
et al., 2006, Bartels et al., 2009, Bauer et al., 2009). A dysfunction of P-glycoprotein with ageing 
could be a contributing factor for the development of neurodegenerative disorders, such as 
Parkinson’s disease. In addition, genetic polymorphisms in the MDR1 gene among ethnic 
populations may be one factor for increasing or decreasing the risk of Parkinson’s disease (Lee 
et al., 2004, Tan et al., 2005). 
 
2.4 MODELS FOR THE BLOOD-BRAIN BARRIER 
Many different models are available for drug transport studies across the blood-brain barrier. 
These models can be classified into in vitro, in vivo and in silico models. All of these models have 
advantages and limitations that will be described in more detail in the subsequent sections. 
2.4.1 In vitro primary cells 
In an attempt to speed up the early drug development process and reduce the number of 
animal experiments in the characterization of drug candidates, cell based in vitro models have 
been developed. In order to predict reliably the in vivo blood-brain barrier permeability of 
drugs, an in vitro model should closely resemble the brain endothelium and exhibit relevant 
blood-brain barrier properties (e.g., tight paracellular barrier, appropriate expression and 
functionality of efflux proteins and specific enzymes). Therefore, primary cells isolated from 
brain tissue have been considered to be the closest in vitro substitute for the in vivo blood-brain 
barrier (Gumbleton and Audus, 2001). The viable microvessels derived from the rat brain tissue 
can be considered to be the first in vitro model of blood-brain barrier (Joó and Karnushina, 
1973). In the early 1980s, rat and bovine brain endothelial cells were successfully grown under 
cell culture conditions (Bowman et al., 1981, Bowman et al., 1983). Thereafter, primary brain 
endothelial cells have been isolated from several mammalian species, e.g., rodents. 
 
Table 2. Selected endothelial cell and blood-brain barrier markers. Modified from Deli, 2007. 
Endothelial cell markers Blood-brain barrier specific markers 
von Willebrandt factor/Factor VIII antigen 
(vWF) 
tight junction proteins (e.g., ZO-1, occludin, claudins) 
acetylated low-density lipoprotein uptake tight junction functions (low permeability of paracellular 
markers, such as sucrose; high TEER) 
vasoactive mediators (nitric oxide, 
endothelins, angiotensins) 
enzymes (e.g., ALP, γ-glutamyl-transpeptidase, monoamine 
oxidase A and B, COMT) 
cell adhesion molecules (e.g., vascular cell 
adhesion molecule-1) 
active transporters (e.g., GLUT1, LAT1, P-glycoprotein, MRPs, 
BCRP) 
lectin binding transport receptors (e.g., insulin receptor, transferrin receptor) 
ZO-1, zonula occludens 1; TEER, transendothelial electrical resistance; ALP, alkaline phosphatase; COMT, 
catechol-O-methyl-transferase; GLUT1, glucose transporter 1; LAT1, large neutral amino acid transporter 1; 
MRPs, multidrug resistance-associated proteins, BCRP, breast cancer resistance protein. 
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Bovine brain microvessel endothelial cells (BBMECs) 
The BBMECs have been applied as an in vitro blood-brain barrier model (Baranczyk-Kuzma et 
al., 1986, Audus and Borchardt, 1987, Audus et al., 1990, Audus et al., 1996). BBMECs have been 
extensively characterized in terms of endothelial cell and blood-brain barrier markers (Table 2) 
including ALP, catechol-O-methyl-transferase (COMT), γ-glutamyl transpeptidase and von 
Willebrandt factor/Factor VIII antigen (vWF) (Audus and Borchardt, 1986, Baranczyk-Kuzma et 
al., 1986, Méresse et al., 1989, Audus et al., 1990) and uptake of acetylated low density 
lipoprotein (Tao-Cheng et al., 1987, Stolz and Jacobson, 1991). In addition, expression of the 
tight junction proteins (occludin, ZO-1, claudin-1 and claudin-5) (Culot et al., 2008) and efflux 
transporters (P-glycoprotein, MRP1, MRP4 and MRP5) have been characterized in the BBMECs 
at the protein level (Tsuji et al., 1992, Beaulieu et al., 1995, Fontaine et al., 1996, Huai-Yun et al., 
1998, Zhang et al., 2000, Zhang et al., 2004). BBMECs have also been shown to express MRP3, 
MRP6 and BCRP at the mRNA level but they lack MRP2 (Zhang et al., 2000, Warren et al., 2009). 
The functionality of efflux proteins has been demonstrated in the BBMECs with cellular 
uptake assays (Tsuji et al., 1992, Joly et al., 1995, Lechardeur and Scherman, 1995, Sun et al., 2001, 
Silverstein et al., 2004, Rice et al., 2005, Bachmeier et al., 2006, Iwanaga et al., 2011). These afore-
mentioned studies indicate that the BBMECs express functional proteins relevant to the 
function of the blood-brain barrier. 
The permeability values for several model compounds as well as undisclosed molecules have 
been reported in the BBMEC model, but the tightness of the monocultured BBMECs has been 
shown to be highly variable (4 to 85 × 10-6 cm/s, Table 3) (Pardridge et al., 1990, Eddy et al., 1997, 
Glynn and Yazdanian, 1998, Cecchelli et al., 1999, Johnson and Anderson, 1999, Polli et al., 2000, 
Otis et al., 2001, Karyekar et al., 2003, Rice et al., 2005). Monocultured BBMECs exhibit a rather 
leaky paracellular barrier which may limit their use in drug permeability studies. 
BBMECs have also been cultured under an astrocyte conditioned medium (ACM) (Rubin et 
al., 1991b), co-cultured with rat astrocytes (Tao-Cheng et al., 1987) or in combination with agents 
that increase the cyclic adenosine monophosphate (cAMP) levels (e.g., cAMP analogs, forskolin 
and cholera toxin) (Rubin et al., 1991b), since the astrocytic factors and increased cAMP levels 
have been shown to enhance tight junctions in vitro. Therefore, co-cultures containing both 
BBMECs and rat astrocytes have also been used as an in vitro drug permeability model 
(Dehouck et al., 1990, Dehouck et al., 1992, Cecchelli et al., 1999, Lundquist et al., 2002). The 
tightness of the co-cultured BBMEC model has been shown to be better (permeability of sucrose 
8.3 to 13 × 10-6 cm/s) than that of the monocultured BBMEC model (permeability of sucrose 32 × 
10-6 cm/s) (Dehouck et al., 1995, Lundquist et al., 2002). In addition, it has been shown that P-
glycoprotein expression is increased in the BBMECs when co-cultured with astrocytes (Fenart et 
al., 1998, Gaillard et al., 2000) indicating the inducible effect of astrocytic factors on P-
glycoprotein expression. However, co-culture does not considerably increase the functionality 
of P-glycoprotein (Gaillard et al., 2000). Recently, a combination of different culture medium 
supplements (ACM, cAMP derivative, dexamethasone, cAMP phosphodiesterase inhibitor) has 
been shown to improve the tightness of the BBMEC co-culture model (permeability of mannitol 
0.5-0.9 × 10-6 cm/s) (Helms et al., 2010, Helms et al., 2012). This model seems to be the tightest in 
vitro blood-brain barrier model so far. However, this is still two orders of magnitude leakier 
than the blood-brain barrier in vivo (Ohno et al., 1978). 
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Table 3. Permeability coefficient of sucrose across the selected in vitro models. 
In vitro 
model 
Experimental 
set-up 
Permeability 
coefficient × 106 
(cm/s) 
Reference 
BBMEC side-by-side Papp 18-53 Eddy et al., 1997, Johnson and Anderson, 
1999, Otis et al., 2001, Rice et al., 2005 
BBMEC filter insert Papp 4-39 
 
Polli et al., 2000, Johnson and Anderson, 
1999, Karyekar et al., 2003 
BBMEC filter insert Pe 9.1-85 Pardridge et al., 1990, Glynn and 
Yazdanian, 1998, Cecchelli et al., 1999 
PBMEC side-by-side Papp 39-80 Huwyler et al., 1996, Zhang et al., 2006b 
PBMEC filter insert Pe 0.34
# Lohmann et al., 2002 
PBMEC filter insert Papp 4.0
§-4.2 Hoheisel et al., 1998, Franke et al., 1999 
PBMEC filter insert Papp 0.5
#-1.0# Hoheisel et al., 1998, Franke et al., 1999 
HBMEC filter insert Pe 17
*-50 Megard et al., 2002 
HBMEC filter insert Papp <8
*-22* Garberg et al., 2005, Mabondzo et al., 2010 
hCMEC/D3 filter insert Pe 28 Weksler et al., 2005, Poller et al., 2008 
Caco-2 filter insert Papp 1.4-1.7 Yazdanian et al., 1998, Garberg et al., 2005 
MDCKII-MDR1 filter insert Papp 0.3-0.4 Garberg et al., 2005, Mashayekhi et al., 
2010 
in vivo rat intravenous 
injection 
Pin vivo 0.03 Ohno et al., 1978 
Papp, apparent permeability coefficient; Pe, permeability across cell monolayer (1/Pe=1/Ptotal-1/Pfilter); 
* co-
culture with astrocytes; # serum free conditions supplemented with hydrocortisone; § serum containing 
conditions supplemented with hydrocortisone; Pin vivo, cerebrovascular permeability in vivo. 
 
Porcine brain microvessel endothelial cells (PBMECs) 
Few years after development of the BBMEC model, endothelial cells were also isolated from 
porcine brain (Tontsch and Bauer, 1989). Thereafter, PBMECs have been used as an in vitro 
blood-brain barrier model (Huwyler et al., 1996, Drewe et al., 1999), especially in Europe due to 
the issue of the bovine spongiform encephalopathy in cattle (Gumbleton and Audus, 2001). 
PBMECs display a tighter paracellular route after culturing under serum-free and 
hydrocortisone supplemented culture media (Table 3) (Hoheisel et al., 1998, Tilling et al., 1998, 
Franke et al., 1999, Franke et al., 2000, Lohmann et al., 2002). Thus, the tightness of the PBMEC 
model appears to be promising. However, a limited amount of data is available describing the 
characteristics of PBMECs cultured under serum-free and hydrocortisone supplemented culture 
conditions. Drug permeability data is also scarce, only drug permeability of seven model drugs 
(Lohmann et al., 2002), MDR1 and BCRP gene expression at the mRNA level and functionality 
of BCRP have been demonstrated (Eisenblätter et al., 2003). 
PBMECs have also been cultured with ACM (Zhang et al., 2006b) and co-cultured with rat 
astrocytes (Cohen-Kashi Malina et al., 2009). Co-culturing with astrocytes has improved the 
tightness of the paracellular barrier (permeability of sucrose 0.2 × 10-6 cm/s, TEER >1000 Ωcm2 
were achieved in a filter insert system with a low stirring action) (Cohen-Kashi Malina et al., 
2009). Under well stirred conditions, however, PBMECs cultured with serum and ACM but 
without hydrocortisone have possessed a higher paracellular barrier (Huwyler et al., 1996, 
Zhang et al., 2006b) than PBMECs cultured under serum-free hydrocortisone supplemented 
medium (Table 3). The expressions of the transporters (MDR1, LAT1, LAT2, BCRP, MRP1 and 
MRP4) have been detected in the PBMECs cultured with ACM at the mRNA level (Zhang et al., 
2006b). However, the functionality of the transporters has not been sufficiently assessed in 
PBMECs. 
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Rat brain microvessel endothelial cells (RBMECs) 
The tightness of the monocultured RBMECs (permeability of sucrose 2-11 × 10-6 cm/s) 
(Parkinson and Hacking, 2005, Perrière et al., 2007) is comparable to that of BBMEC or PBMEC 
models (Table 3). However, the disadvantage of the RBMECs is the low endothelial cell number 
per animal. In addition, the high abundance of pericytes in the primary RBMECs limits the use 
of RBMECs in comparison to those of BBMECs, PBMECs or human primary brain microvessel 
endothelial cells (HBMECs) (Parkinson and Hacking, 2005). The high amount of pericytes may 
physically interrupt the formation of endothelial cell monolayer and, thus, the tightness of the 
monolayer will increase. RBMECs have been used in drug uptake studies (Sun et al., 2006, 
Qiang et al., 2008) and drug transport studies (Perrière et al., 2007, Li et al., 2009). 
In addition to co-cultures consisting of RBMECs with astrocytes (Perrière et al., 2007) and 
RBMECs with astrocytes and pericytes (Nakagawa et al., 2009) have been established. The 
permeability of sucrose has been reported to be as low as 1.4 × 10-6 cm/s when RBMECs were co-
cultured with astrocytes in the presence of hydrocortisone and cAMP supplements (Perrière et 
al., 2007). Recently, however, RBMECs co-cultured with astrocytes and pericytes did not display 
P-glycoprotein mediated efflux of known substrates (Hellinger et al., 2012), suggesting that the 
tightness of the RBMEC model is inducible by astrocytic factors and different culture medium 
supplements, but the functionality of the active transport mechanisms is still difficult to reach. 
 
Human brain microvessel endothelial cells 
The first isolation of microvessel endothelial cells from human brains occurred in 1991 with 
samples from autopsy (Dorovini-Zis et al., 1991). HBMECs have been characterized in terms of 
adhesion molecules (Wong and Dorovini-Zis, 1995, Wong and Dorovini-Zis, 1996, Stins et al., 
1997, Easton and Dorovini-Zis, 2001) and several endothelial cell markers (e.g., vWF, strong 
ALP activity, uptake of acetylated low density lipoprotein, γ-glutamyl-transpeptidase, Table 2) 
(Stins et al., 1997, Omari and Dorovini-Zis, 2001). In addition, the expressions of the transporter 
genes (MDR1, MRP2, MRP1, MRP4, MRP5, MRP6, LAT1, GLUT1, MCT1) were detected at the 
mRNA level in the HBMECs (Umeki et al., 2002, Eilers et al., 2008, Warren et al., 2009). However, 
there is still some controversy concerning MDR1 and MRP2 expression at mRNA level in the 
HBMECs, since in some reports, gene expressions of MDR1 (Umeki et al., 2002) or MRP2 
(Warren et al., 2009) were not detected. The presence of functional MRP mediated efflux and 
functional amino acid transporters has been reported in the HBMECs as assessed in uptake 
studies (Umeki et al., 2002, Eilers et al., 2008). 
The permeability of sucrose was lower in the HBMECs co-cultured with human astrocytes 
(~20 × 10-6 cm/s) (Megard et al., 2002, Garberg et al., 2005) than in the monocultured HBMECs (50 
× 10-6 cm/s) (Megard et al., 2002) highlighting the important role of astrocytes in determining the 
tightness of human brain endothelial cells in vitro. Recently, the co-culture model of HBMECs 
has been further characterized; expression of GLUT1, LAT1 and MDR1, MRP1, MRP4, MRP5, 
BCRP at mRNA level, good paracellular tightness (Table 3) and functionality of the efflux 
transporters have been demonstrated (Mabondzo et al., 2010). The HBMEC model appears to be 
promising as an in vitro model for human blood-brain barrier. In addition, the application of the 
HBMEC model has been further developed by dynamic in vitro models with a hollow fibre 
technique to include flow shear stress (Siddharthan et al., 2007, Cucullo et al., 2011). However, 
the disadvantage of HBMEC model is the limited availability of the human brain tissue, ethical 
problems and high expense for screening of drug candidates. 
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2.4.2 In vitro cell lines 
Human brain endothelial cell line (hCMEC/D3) 
The immortal human brain endothelial cell line, hCMEC/D3, has been derived from HBMECs, 
and it possess many endothelial and blood-brain barrier markers, e.g., tight junction proteins 
ZO-1 and claudin-5 (Table 2) (Weksler et al., 2005). Furthermore, expression of the efflux 
transporters (MDR1, MRP1-5, BCRP) has been demonstrated in the hCMEC/D3 cells at the 
mRNA level and expression of P-glycoprotein, MRP1, MRP4, BCRP at the protein level 
(Weksler et al., 2005, Poller et al., 2008, Dauchy et al., 2009, Ohtsuki et al., 2013). The functionality 
of the efflux transporters P-glycoprotein, MRP and BCRP was demonstrated in the absence of 
astrocytes (Poller et al., 2008, Dauchy et al., 2009). At present, hCMEC/D3 cells form a rather 
leaky cell monolayer (permeability of sucrose 27 × 10-6 cm/s) and there are rather few studies 
reporting drug permeability values for some compounds (n=11, mainly passively transported 
drugs) in the hCMEC/D3 cell model (Weksler et al., 2005, Poller et al., 2008). Therefore, more 
drug permeability data is needed to characterize the drug permeability properties across 
hCMEC/D3 cell model. Attempts have also been made to develop a hCMEC/D3 based co-
culture model (Hatherell et al., 2011, Weksler et al., 2013). The advantage of the hCMEC/D3 cells 
is that these cells are easy to grow. In addition, hCMEC/D3 cells have been reported to be 
suitable for use in the hollow fibre technique which incorporates flow shear stress and thus they 
may represent a more realistic in vitro system (Cucullo et al., 2008). However, the drastic loss of 
the expression of several relevant blood-brain barrier proteins (e.g., tight junction proteins and 
efflux transporters) as assessed at the mRNA level in hCMEC/D3 cells, as well as HBMECs, 
compared to freshly isolated brain endothelial cells (Urich et al., 2012), and the low TEER values 
seem to be major challenges to the widespread use of hCMEC/D3 cells (Hatherell et al., 2011, 
Weksler et al., 2013). 
 
Rat and mouse brain microvessel endothelial cell lines 
There are several immortalized rat endothelial cell lines available (for review see Roux and 
Couraud, 2005) and one of the most commonly used is the rat endothelial cell line (RBE4) which 
has also been characterized in terms of the enzymatic activities of ALP and γ-glutamyl-
transpeptidase (Roux et al., 1994) and the functionality of P-glycoprotein via a cellular uptake 
assay (El Hafny et al., 1997). The major limitation of RBE4 cells is the poor cell monolayer 
tightness (permeability of sucrose 214 × 10-6 cm/s) (Rist et al., 1997) which is not adequate for 
drug permeability studies. This reduces the feasibility of this model for screening (Roux and 
Couraud, 2005) but it can be used for mechanistic studies. 
In addition, several mouse brain endothelial cell lines have been established (Tatsuta et al., 
1992, Omidi et al., 2003, Yang et al., 2007). Similarly to the situation with rat brain endothelial 
cell lines, the mouse brain endothelial cell lines do not provide adequate tightness to permit 
drug permeability testing (Yang et al., 2007). As a result, mouse brain endothelial cell lines are 
not widely used for screening purposes. 
 
Human colorectal adenocarcinoma cell line (Caco-2) 
Caco-2 cells are epithelial cells isolated from male colorectal adenocarcinoma (Fogh et al., 1977). 
Caco-2 cells have been shown to represent a suitable epithelial model of intestinal transport 
studies (Hidalgo et al., 1989). Passive absorption of drugs across Caco-2 cells has been studied 
reflecting the in vivo absorption characteristics in rats and humans (Artursson, 1990, Artursson 
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and Karlsson, 1991, Ranaldi et al., 1992). Currently, Caco-2 cell model is widely used as an in 
vitro model for oral absorption both in academia and pharmaceutical industry (Hayeshi et al., 
2008). Caco-2 model has also been used for prediction of the blood-brain barrier permeability of 
drugs (Garberg et al., 2005, Hellinger et al., 2012). However, there is still only a limited number 
of reports investigating the use of Caco-2 as an in vitro model for blood-brain barrier. 
P-glycoprotein mediated transport in the Caco-2 cells has been studied extensively by using 
known P-glycoprotein substrates such as paclitaxel, digoxin and vinblastine (Hunter et al., 1993, 
Cavet et al., 1996, Walle and Walle, 1998). The gene expression levels of efflux transporters (e.g., 
MDR1, MRPs) in the Caco-2 cells were similar to those present in human intestine, with the 
exception of BCRP the levels of which were found to be ~100-fold lower in Caco-2 cells than in 
human intestine (Taipalensuu et al., 2001). Despite promising results, the expression of P-
glycoprotein varies as a function of cell passage, culture conditions and cell differentiation 
(Hosoya et al., 1996, Anderle et al., 1998, Goto et al., 2003). 
Caco-2 cells express many enzymes (Prueksaritanont et al., 1996). ALP is a brush border 
enzyme localized at the apical membrane in the Caco-2 cells (Hidalgo et al., 1989) and, thus, it is 
a widely used marker for Caco-2 enterocytic differentiation. The levels of CYP3A4 enzyme 
expression are very low in the Caco-2 cells when compared to those in human intestinal 
enterocytes (Prueksaritanont et al., 1996, Nakamura et al., 2003) and this is a well known 
limitation of Caco-2 cells. Therefore, genetically modified and chemically induced Caco-2 cells 
have been developed to increase the expression of drug metabolizing enzymes and P-
glycoprotein (Schmiedlin-Ren et al., 1997, Döppenschmitt et al., 1999, Eneroth et al., 2001, 
Korjamo et al., 2005, Hellinger et al., 2012). 
One main drawback of Caco-2 cells is their long differentiation time (≥21 days) (Yuan et al., 
2009). In addition, Caco-2 cells are known to exhibit high variability between laboratories due to 
different origin of the cells and culture conditions (Behrens and Kissel, 2003, Hayeshi et al., 
2008). Thus, the inter-laboratory variability in the expression of transporters and enzymes has 
been studied confirming that the results emerging from different laboratories using Caco-2 cell 
are not identical (Hayeshi et al., 2008). Due to the several limitations of Caco-2 cells in screening, 
also other cell models have been developed, such as Madin-Darby Canine Kidney (MDCK) 
cells, to be used as alternative in vitro models for prediction of drug absorption. 
 
Madin-Darby Canine Kidney cell line 
MDCK cells were isolated from a female cocker spaniel (for review see Dukes et al., 2011). 
MDCK cells display clear apical-basolateral polarity with well-defined cell junctions and, thus, 
they are widely used as an in vitro epithelial cell model (Dukes et al., 2011). Two sub-types (type 
I and II) have been isolated from parental MDCK strain; MDCKI cells from low passage (~60) 
and MDCKII cells from high passage (~113). The most striking difference between these two 
sub-types is that MDCKI form monolayers with high TEER (>4000 Ωcm2) whereas MDCKII cell 
monolayers exhibit low TEER (<200 Ωcm2) (Barker and Simmons, 1981). The enzymatic 
activities of ALP and γ-glutamyl-transpeptidase have been measured from MDCK cells 
(Veronesi, 1996). Since these enzymes are also expressed at the blood-brain barrier (Table 2) the 
MDCK cells have been proposed to represent a useful in vitro model for screen xenobiotics that 
disrupt the blood-brain barrier in vivo (Veronesi, 1996). 
The advantage of the MDCK cells over Caco-2 cells is their shorter culture time (4 days vs. 21 
days) (Irvine et al., 1999). The drug permeability across the MDCK model has also been 
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compared with Caco-2 model showing that the permeability of drugs was comparable (Irvine et 
al., 1999). In addition, the MDCK model and BBMEC model are able to place in a similar rank 
order drugs into low, medium and high permeability categories, although the leakiness was 
higher in the BBMEC model than in MDCK model (Polli et al., 2000). These experiments indicate 
that MDCK cells may be valid substitute for Caco-2 or BBMEC cells for prediction of gut 
absorption or blood-brain barrier permeability. 
Generally, MDCK type II cell line transfected with the human MDR1 gene, encoding for 
human P-glycoprotein (MDCKII-MDR1), MRP1 or MRP2 genes have been used to evaluate the 
involvement of efflux transporters in intestinal drug absorption (Guo et al., 2002, Luo et al., 2002, 
Troutman and Thakker, 2003, Varma et al., 2005, Shirasaka et al., 2008, Thiel-Demby et al., 2009). 
In addition, MDCK(I,II)-MDR1 cells have been used to study P-glycoprotein mediated transport 
(Lentz et al., 2000, Polli et al., 2001, Mahar Doan et al., 2002, Troutman and Thakker, 2003, Tran et 
al., 2004, Bentz et al., 2005, Acharya et al., 2006, Acharya et al., 2008). 
2.4.3 Comparison of in vitro models 
Tightness 
Sucrose is the most commonly used compound to represent as a low permeability molecule in 
the characterization of the tightness of the in vitro models for blood-brain barrier. A comparison 
between the tightness of the selected monocultured in vitro models is shown in Table 3. Other 
common characteristics of the in vitro models and advantages and limitations of the in vitro 
models based on an interpretation of the literature have been included in Table 4. 
The paracellular tightness seems to be highly variable between the laboratories in the 
primary monocultured endothelial cell models (BBMECs and PBMECs), as well as between the 
endothelial and epithelial in vitro models. One of the tightest endothelial cell model available is 
PBMECs cultured under serum-free medium and supplemented with hydrocortisone (Papp of 
sucrose 0.5-1.0 × 10-6 cm/s) (Hoheisel et al., 1998, Franke et al., 1999). However, in serum 
containing culture medium, the Papp of sucrose in the PBMECs is extremely variable ranging 
from 4.2-8 × 10-6 cm/s in filter insert system (Franke et al., 1999) to 39-80 × 10-6 cm/s in well-
stirred conditions (Huwyler et al., 1996, Zhang et al., 2006b). A similar variation in the tightness 
of the BBMECs has been observed; 4-39 × 10-6 cm/s in filter insert system (Johnson and 
Anderson, 1999, Polli et al., 2000, Karyekar et al., 2003) to 18-53 × 10-6 cm/s in well-stirred 
conditions (Eddy et al., 1997, Johnson and Anderson, 1999, Otis et al., 2001, Rice et al., 2005). 
These observations demonstrate that primary endothelial cell models are both sensitive to 
culture conditions affecting the paracellular barrier between the endothelial cells but they also 
suffer from high inter-laboratory variation. 
The epithelial cell models are generally tighter than the endothelial cell models (Table 3). 
Apparently the higher Papp value of sucrose in the Caco-2 than in the MDCKII-MDR1 may 
partly be explained by the brush-border enzyme, sucrase-isomaltase, expressed in the Caco-2 
cells (Pinto et al., 1983). Metabolism of the [14C]sucrose leads to the formation of [14C]metabolites 
(i.e., glucose and fructose) and in fact the Papp of [14C]metabolites are being measured in the 
Caco-2 cells (Garberg et al., 2005). Although rather tight in vitro models (Papp <1 × 10-6 cm/s) are 
available, the in vitro models are still several orders of magnitude leakier (Pardridge et al., 1990, 
Avdeef, 2011) than the blood-brain barrier in vivo (~3 × 10-8 cm/s) (Ohno et al., 1978) suggesting 
that the tightness of the blood-brain barrier in vivo is extremely difficult to mimic in vitro. 
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Efflux transporters 
In the brain endothelial cells of many species, there is the apical (luminal) localization of P-
glycoprotein, MRP1, MRP2, MRP4, MRP5 and BCRP and basolateral (abluminal) localization of 
MRP1 and MRP4. However, there may be species differences in the expression of MRP2 in the 
brain endothelial cells since no significant expression of MRP2 was detected in human, rat, 
mouse, porcine or bovine brain endothelial cells at the mRNA level (Warren et al., 2009). 
Whereas the apical localization of MRP2 has been demonstrated in brain capillaries isolated 
from rat (Miller et al., 2000) or HBMECs at the mRNA level (Eilers et al., 2008). Thus, the MRP2 
expression in the blood-brain barrier is still controversial. 
In comparison, Caco-2 model express MDR1, BCRP, MRP1-5 at mRNA level (Taipalensuu et 
al., 2001). Apically localized intestinal efflux transporters are P-glycoprotein, BCRP, MRP2 and 
MRP4, whereas the basolaterally localized intestinal efflux transporters are MRP1, MRP3-5 
(Takano et al., 2006, for review see Custodio et al., 2008, Giacomini et al., 2010). In addition, the 
MDCKII-MDR1 model overexpresses human P-glycoprotein and canine MRP2 at the protein 
level and canine MDR1, MRP1, MRP2, MRP5 at the mRNA level. The apically localized efflux 
proteins in kidney epithelial cells are P-glycoprotein, MRP2, MRP4 and BCRP, whereas MRP1, 
MRP3 and MRP5 localize basolaterally (Schinkel and Jonker, 2003). 
The most notable differences between the localization of efflux transporters in the brain 
endothelial cell models and models of intestinal or kidney origin (Caco-2, MDCKII-MDR1) is 
the apical localization of MRP1 and MRP5 (MRP1 also basolaterally) in the brain endothelial 
cells, but there is basolateral localization in intestinal and kidney cells. In addition, MRP3 has 
been detected only at low mRNA levels in the brain endothelial cells but instead MRP3 is 
localized basolaterally in the intestinal and kidney cells. The differences between endothelial 
and epithelial cells models highlight the fact that the non-brain originating cells may not 
express the transporters or they are not correctly localized and, thus, they do not model the in 
vivo blood-brain barrier adequately. Furthermore, all known efflux transporters have not been 
thoroughly characterized in the brain endothelial cell models from different species or epithelial 
cell models, at either the protein level or their subcellular localization (apical vs. basolateral). 
Therefore, it is not possible to conduct a detailed comparison of the localization of efflux 
transporters between the cell models. The differences in the expression and localization of efflux 
transporters may disturb the permeability of those drugs that are potential transporter 
substrates, when non-brain originating cell models are used in prediction of blood-brain barrier 
permeability of new drug candidates. 
 
Anatomy and physiology of endothelial and epithelial cells 
Endothelial and epithelial cells form different types of tissues and have distinct functions in 
vivo. The endothelial cells that form the inner lining of the blood vessels maintain vascular 
homeostasis, control the transfer of many molecules and have many metabolic and synthetic 
functions (Sumpio et al., 2002). The epithelial cells in nephrons have a pivotal role in kidney 
function. Renal tubular epithelial cells participate in concentrating the glomerular filtrate into 
urine (Baud, 2003). The major function of the differentiated enterocytes (intestinal epithelial 
cells) in vivo is to digest and absorb nutrients and water from ingested food (Delie and Rubas, 
1997) but also to protect the organism against luminal pathogens (Gibson et al., 1996). 
Brain endothelial cells, intestinal epithelial cells and renal tubular epithelial cells are 
morphologically very different. Brain endothelial cells are >100 μm long and spindle-shaped 
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with the height of the cells ranging from 0.2-2 μm and they does not have microvilli 
(Lechardeur and Scherman, 1995, Cecchelli et al., 1999, Nakagawa et al., 2009, Hellinger et al., 
2012). At confluency, Caco-2 cells are thin and tall (~6.4×30 μm) with long microvilli (~1.2 μm) 
(Hidalgo et al., 1989). Recently, it was shown that Caco-2 cells, grown in a culture medium 
supplemented with vinblastine (to increase P-glycoprotein expression), were 8-15 μm high 
(Hellinger et al., 2012) a value that is clearly shorter than that reported previously (Hidalgo et al., 
1989). In fact, the cellular dimensions may vary extensively due to the heterogeneity of the 
Caco-2 cells (Delie and Rubas, 1997). MDCKII cells are wider and shorter (~8×10 μm) with 
longer microvilli (~1-1.5 μm) (Barker and Simmons, 1981) than Caco-2 cells, but it was recently 
claimed that MDCKII-MDR1 cells are higher (10-20 μm) (Hellinger et al., 2012) than the parental 
MDCKII cells. 
There are also differences in the phospholipid composition of cell membranes between 
BBMECs, Caco-2 and MDCKII cells. The determinants of cell membrane fluidity are: 1) 
phosphatidylcholine to sphingomyelin ratio, 2) the unsaturated to saturated ratio of 
phospholipids, 3) the cholesterol to phospholipid ratio (Shinitzky and Barenholz, 1974, Williams 
et al., 1988). Higher ratios increase the membrane fluidity and increase passive permeability. In 
the BBMECs, all of these three ratios are lower (Siakotos and Rouser, 1969, Bénistant et al., 1995, 
Di et al., 2009) than in the Caco-2 (Dias et al., 1992) or MDCKII cells (Hansson et al., 1986). Thus, 
the BBMECs cell membrane should be less fluid, more rigid and less permeable than the 
membrane in Caco-2 or MDCKII cells. 
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2.4.4 In vivo methods 
Intravenous injection 
An intravenous injection is considered the most physiological approach to study brain uptake 
since physiological conditions are maintained (for review see Bickel, 2005). The drug can be 
administered intravenously either as a bolus injection or as an infusion (Smith, 1989). Blood 
samples are collected at selected time points and plasma drug concentrations are determined. 
The total drug concentrations in the brain tissue and total blood or plasma concentrations are 
determined at the end of the experiment. The ratio between the total concentrations in brain and 
plasma, i.e., the in vivo partition coefficient, Kp = Cbrain/Cblood or the logarithm of the partition 
coefficient (LogBB = log Cbrain/Cblood), is an estimate of the extent of drug delivery to the brain 
(Liu et al., 2008, Hammarlund-Udenaes, 2010). Nonspecific binding in brain tissue and blood is 
a significant component of this parameter (Liu et al., 2008). The in vivo influx clearance [CLin or 
Kin = (Ctotal,brain - Cplasma × intravascular volume of the brain) / (study time × Cplasma)] is an estimate 
of the rate of transport of drug across the blood-brain barrier (Hammarlund-Udenaes et al., 
2008). The disadvantages of this method are that different animals are needed for each data 
point and sensitive, specific and selective analytical methods are required (for review see Bickel, 
2005, Kuhnline Sloan et al., 2012). 
 
Brain uptake index 
In the brain uptake index (BUI) method (Oldendorf, 1970), the [3H]-drug to be studied is 
administered as a rapid bolus injection simultaneously with the [14C]-reference compound into 
the carotid artery. Concentrations of the drug and the reference compound are determined in 
the brain and in the injected solution at a single time point. The ratio of drug to reference 
compound is calculated [BUI% = ([14C]brain/[3H]brain)/([14C]injected/[3H]injected)]. BUI% measures the 
rate of transport into brain based on the total concentrations of the drug in the brain at the early 
time points (5-15 sec) after drug injection (Cecchelli et al., 2007, Hammarlund-Udenaes et al., 
2008). The advantage of the BUI method is that it is a rapid procedure which avoids peripheral 
metabolic artifacts. Generally, however, BUI is relatively insensitive in vivo method with which 
to differentiate between the compounds with low and high brain uptake (for review see Bickel, 
2005). 
 
In situ brain perfusion 
The in situ brain perfusion technique, in the rat and in the mouse (Takasato et al., 1984, Dagenais 
et al., 2000, Murakami et al., 2000), is considered as a gold standard for measuring blood-brain 
barrier permeability in vivo. The Kin can be estimated by the in situ brain perfusion technique 
and this parameter is commonly converted to permeability-surface area product (Chikhale et al., 
1994). The permeability-surface area product parameter relates to total brain and total blood 
concentrations describing the drug influx rate into the brain. In this technique, the peripheral 
metabolism of a drug is excluded by direct infusion of the compound into the blood vessels to 
the brain. This technique has a better ability to differentiate compounds in terms of their blood-
brain barrier permeability than other techniques, e.g., BUI method. The disadvantage of this 
method is that it is labor intensive (Kuhnline Sloan et al., 2012). In addition, the high drug 
concentrations in the perfusion fluid may saturate the transport mechanism(s) and, thus, the 
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passive diffusion may be the predominant transport mechanism measured with this technique 
(Di et al., 2009). 
 
In vivo brain microdialysis 
The microdialysis technique was originally developed for monitoring extracellular 
neurotransmitter levels in the brain (Benveniste and Hüttemeier, 1990). In vivo brain 
microdialysis has also been applied for pharmacokinetic studies of drug transport across the 
blood-brain barrier (for review see de Lange et al., 1997). Microdialysis probes can be implanted 
in both the brain and peripheral tissues. The microdialysis probes are perfused with a 
physiological solution, and the driving force for drug diffusion across the semi-permeable 
membrane in the probe is the concentration gradient from brain tissue to perfusate (Elmquist 
and Sawchuk, 1997). In vivo brain microdialysis is a direct technique with which to assess 
unbound drug concentrations (Liu et al., 2008). 
The rate of transport (CLin) can be estimated by the in vivo brain microdialysis technique 
(Hammarlund-Udenaes et al., 1997, Hammarlund-Udenaes et al., 2008). The extent of the drug 
concentration between brain and blood can be assessed by the unbound partition coefficient 
[Kp,uu = the area under the unbound concentration-time curve (AUC)unbound,brain,extracellular fluid (ECF) / 
AUCunbound,blood] at steady state (for review see Jeffrey and Summerfield, 2007, Hammarlund-
Udenaes et al., 2008). Kp,uu can also reveal whether or not the drug undergoes active transport 
into the brain (Boström et al., 2006, Jeffrey and Summerfield, 2007). Values less than unity are 
evidence of poor permeability, efflux transport, metabolism or extracellular fluid bulk flow 
which are all factors which can influence the unbound drug brain concentration. Kp,uu values 
above unity would suggest that active influx transporters at the blood-brain barrier are 
enhancing the drug brain uptake. If the drug transport across the blood-brain barrier is 
dominated by passive diffusion, then the Kp,uu value will be close to unity (Hammarlund-
Udenaes et al., 2008). 
The in vivo brain microdialysis technique has also been used to compare overall drug 
exposure of new drug candidates in the brain after a single systemic dose (Jalkanen et al., 2011). 
An in vivo unbound brain/blood ratio can be calculated from the unbound AUC in brain ECF 
and blood (Jalkanen et al., 2011). The unbound brain/blood ratio is determined after a single 
dose. As a result, the unbound brain blood/blood ratio describes mainly the rate of the drug 
transport across the blood-brain barrier. In addition, in in vivo brain microdialysis, the AUC 
brain parameter describes also the distribution from the extracellular fluid into intracellular 
compartments, as well as the metabolism and elimination of the drug from the brain. Similarly, 
the AUC parameter in the blood takes into account the kinetics of absorption, distribution, 
metabolism and elimination throughout the body. 
The advantage of the in vivo brain microdialysis method is that the unbound concentrations 
can be determined and individual concentration-time profiles can be constructed. The 
disadvantage of this method is the invasive nature of the insertion of the probe into the brain 
which may evoke blood-brain barrier damage (for review see de Lange et al., 1997, Bickel, 2005). 
Furthermore, in vivo microdialysis is not suitable for highly lipophilic compounds due to 
compound adhesion to the perfusion tubing. 
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In vivo methods to assess the permeability of drugs across the blood-brain barrier 
The intravenous injection approach, the BUI method, the in situ brain perfusion technique and 
the in vivo brain microdialysis method are able to estimate the permeability of drugs across the 
blood-brain barrier (Hammarlund-Udenaes et al., 2008). One technique which measures only 
the blood-brain barrier permeability is the in situ brain perfusion technique. However, the 
weakness of the intravenous injection, BUI and in situ brain perfusion method is that the total 
brain and total blood concentrations are measured. It is generally accepted that the unbound 
drug is the form which is able to cross the blood-brain barrier and exert the pharmacological 
response (Hammarlund-Udenaes et al., 2008). Therefore, the in vivo brain microdialysis method, 
which assesses the unbound drug concentrations on both sides of the blood-brain barrier, is 
currently considered the most relevant method. 
2.4.5 In silico methods 
Prediction of brain penetration of drugs by computational approaches is a fast and valuable tool 
in early drug discovery, since in silico methods are rather easy and quick to perform without 
even the need to synthesize the molecules. However, it is important to remember that a large 
amount of experimental data is needed before one can construct predictive in silico models and 
to validate them (van de Waterbeemd and Gifford, 2003). It is possible to predict blood-brain 
barrier permeation by assigning drugs into two classes (brain penetrating drugs or low/absent 
brain penetrating drugs) based on their molecular structure (Crivori et al., 2000). The molecular 
properties that have been found to influence the blood-brain barrier permeability of drugs are 
mainly polarity (hydrophilic regions and polar regions), hydrogen-bonding capability and their 
distribution within the drug, with a smaller role for hydrophobic interactions (Crivori et al., 
2000). 
Many in silico models are based on LogBB, which describes drug partitioning between blood 
and brain tissue (Young et al., 1988). The in silico models based on LogBB data have been 
comprehensively reviewed earlier (for review see Norinder and Haeberlein, 2002, Clark, 2003). 
There is a consensus about the molecular properties that determine the partitioning between the 
blood and brain; polarity and hydrogen bonding capability correlate negatively with LogBB 
(i.e., increasing polarity and hydrogen-bonding reduce brain penetration), whereas higher 
lipophilicity and small molecular size seems to correlate positively with LogBB. The correlation 
between LogBB and charge, molecular shape or flexibility is less clear (for review see Clark, 
2003). There are several concerns associated with the use of LogBB value as an in vivo measure 
(Bickel, 2005, Goodwin and Clark, 2005). First, LogBB value is highly affected by drug binding 
to plasma and brain tissue proteins and, thus, it does not reflect the blood-brain barrier 
permeability process but partitioning between these tissues. Second, LogBB is quantified from 
total brain tissue concentrations which may not show a good correlation with the unbound 
concentration and, thus, pharmacologically active concentrations in the brain. Third, the LogBB 
should have been determined at steady state which is often violated in the data sets (Bickel, 
2005). Therefore, the experimental data used for the development of the in silico models should 
be relevant and reflect the actual process which one intends to predict. 
The lack of in vivo blood-brain barrier permeability data (e.g., permeability-surface area 
product determined with in situ brain perfusion technique) has clearly limited the development 
of in silico predictive models based on this parameter, and only a few reports have generated 
these kinds of models (Gratton et al., 1997, Abraham, 2004, Liu et al., 2004). These studies have 
25 
 
 
revealed that the molecular properties related to polarity, hydrogen bonding and lipophilicity 
are important for blood-brain barrier permeability. In addition, Fridén’s model (an in silico 
model based on the Kp,uu parameter) has increased the understanding about unbound drug 
brain exposure; it highlighted that hydrogen bonding was the most important determinant for 
Kp,uu, demonstrating that addition of two HBAs to the molecule decreased the brain exposure by 
half (Fridén et al., 2009). All in silico models together indicate that hydrogen bonding is the most 
important determinant for drug permeability across the blood-brain barrier. In contrast to 
previous in silico models based on LogBB, lipophilicity was not correlated with the unbound 
brain exposure in vivo (Fridén et al., 2009). Since the unbound drug concentrations mainly 
determine the blood-brain barrier permeability in vivo, the kinds of approaches which take into 
account the unbound drug concentrations appear to be very promising. 
 
In silico modeling of the P-glycoprotein interactions 
P-glycoprotein is an important membrane transporter in in vivo drug disposition and its 
presence has a broad impact on absorption, distribution, metabolism and excretion. Therefore, 
attempts have been made to clarify the molecular attributes that are required for the P-
glycoprotein interactions (Stouch and Gudmundsson, 2002). The interaction of compounds with 
the P-glycoprotein is a complex process. In the hydrophobic vacuum cleaner model, P-
glycoprotein has been proposed to have a flexible drug binding pocket to which its substrates 
gain access from the membrane bilayer (Higgins and Gottesman, 1992). Therefore, P-
glycoprotein substrates need to partition into the membrane before they can interact with the P-
glycoprotein. As a result, its substrates are typically hydrophobic but in reality, the mechanism 
of the transport is not well understood. 
Fixed spatial separation of two and three HBA groups of 2.5±0.3 Å and 4.6±0.6 Å have been 
suggested to be required for an interaction with P-glycoprotein (Seelig, 1998a, Seelig, 1998b). 
However, these rules based on the spatial separation of HBA are too simple to define P-
glycoprotein substrates and inhibitors. Quantitative structure-activity relationship analysis has 
been employed to determine the descriptors that are important for P-glycoprotein substrates 
assayed by using in vitro MDCKII-MDR1 assay (Gombar et al., 2004). It was claimed that the 
larger size of a molecule and its ability to partition into membranes increase its ability to act as a 
P-glycoprotein substrate. In addition, many studies have tried to develop the structure-based 
prediction models for P-glycoprotein substrates or inhibitors (for review see Chen et al., 2012). 
However, the multiple binding sites of P-glycoprotein (Shapiro and Ling, 1997, Martin et al., 
2000, Aller et al., 2009) and a broad variety of compounds known to interact with P-glycoprotein 
complicate the in silico prediction of the P-glycoprotein substrates and inhibitors. Thus, more 
studies and broader data are still needed to predict P-glycoprotein interactions in silico. 
 
2.5 IN VITRO-IN VIVO CORRELATIONS 
The cell models need to be assessed against in vivo counterpart to allow reliable predictions of 
blood-brain barrier permeability based on in vitro data. Therefore, several in vitro-in vivo 
correlation studies have been conducted for the BBMECs, Caco-2 and MDCK cell models (Table 
5) and other endothelial cell-based cell models from different species (Table 6). 
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BBMEC model 
Both monocultured BBMECs and BBMECs co-cultured with astrocytes have been used for drug 
permeability studies and the in vitro permeability values have been correlated with different in 
vivo counterparts (Table 5). Generally, good correlations have been obtained between in vitro 
and in vivo parameters. However, it is noteworthy that no correlation was found when a higher 
number of model drugs (n=22) including passively transported compounds and transporter 
protein substrates were incorporated into the evaluation of the in vitro-in vivo correlation 
between BBMECs co-cultured with astrocytes and the mouse brain uptake assay as the in vivo 
method (Garberg et al., 2005). This indicates that no generalizations about the in vitro-in vivo 
correlation results can be made as yet. 
 
PBMEC model 
Drug permeability across PBMECs cultured under ACM has been correlated with in vivo brain 
permeability in the rat (Table 6) (Zhang et al., 2006b). PBMECs cultured with ACM have shown 
very similar in vitro permeability properties and in vitro-in vivo correlation as monocultured 
BBMECs. 
 
HBMEC model 
The permeability properties of drugs in the HBMEC model were compared to human in vivo 
parameter determined by clinical positron emission tomography (Table 6) (Mabondzo et al., 
2010). The coefficient of determination (r2) between in vivo and in vitro parameters was good 
(r2=0.90, n=6) whereas a significantly lower in vitro-in vivo correlation (r2=0.12, n=18) was found 
when mouse was used as the experimental animal in the in vivo determination (Table 6) 
(Garberg et al., 2005). 
 
Caco-2 model 
The relevance of Caco-2 model for the prediction of blood-brain barrier permeability in vivo has 
been evaluated (Table 5) (Garberg et al., 2005, Hellinger et al., 2012). Recently, Caco-2 cells 
cultured with vinblastine supplementation (to increase P-glycoprotein expression) were found 
to yield a better in vitro-in vivo correlation (r2=0.72) than the wild type Caco-2 model (r2=0.61) 
(Hellinger et al., 2012). 
 
MDCKII-MDR1 model 
MDCK(I,II)-MDR1 cells have been used to estimate the drug permeability across the blood-
brain barrier in vivo (Table 5) (Wang et al., 2005, Di et al., 2009, Hellinger et al., 2012). So far, 
however, there is no consensus about the suitability of these cells as an in vitro model for the 
blood-brain barrier. There are some workers who have claimed that MDCKII-MDR1 cells may 
not even be able to estimate the passive drug permeability across blood-brain barrier, although 
this model is excellent for studying P-glycoprotein mediated transport of drugs in vitro (Di et al., 
2009). Nonetheless, there are other reports stating that these cells could be used as a simple and 
fast model for the purpose of screening CNS drugs (Hellinger et al., 2012, Wang et al., 2005). 
More studies are needed to clarify the suitability of the MDCK-MDR1 model for prediction of 
drug permeability across blood-brain barrier in vivo. 
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Relatively good in vitro-in vivo correlations have been demonstrated between all in vitro cell 
models and different in vivo methods in drug permeability across the blood-brain barrier when 
a relatively limited number of model compounds (n<13) have been included in the in vitro-in 
vivo correlation analysis. Unfortunately, a trend toward lower correlations is observed when 
higher numbers of model compounds (n=22-46) are included in the analysis, suggesting that in 
vitro models may not be able to predict very well the permeability of drugs using multiple 
transport mechanisms to cross the blood-brain barrier in vivo. In addition, in the in vitro-in vivo 
correlation studies, usually the same model drugs are commonly used and many of them have 
no therapeutic CNS indications. 
The reported correlations with a limited number of compounds are very similar but there is 
no consensus about whether endothelial or epithelial cell models are better. This suggests that 
the prediction power of the cell models is limited to the model drugs being chosen. However, 
the lack of standardized experimental conditions makes it difficult to compare different in vitro 
methods between laboratories. Furthermore, the different in vivo methods applied in the in 
vitro-in vivo correlation studies make it difficult to compare even the reported in vitro-in vivo 
correlations. Most of the in vivo methods measure the total drug concentrations at a single time 
point but with in vivo microdialysis it is possible to measure the unbound drug concentrations 
at several time points in the same animal. 
 
Table 5. In vitro-in vivo correlations between the BBMEC, Caco-2 and MDCK cell models and several 
in vivo methods. 
in vitro model 
(parameter) 
in vivo method 
(parameter) 
in vitro-in vivo 
correlation¥ 
Reference 
BBMECsS-b-S (Pe) Rat, in situ brain perfusion 
(Pe,in vivo) 
r=0.85, n=13,*,#  
 
Pardridge et al., 1990 
BBMECsco-culture, maximal 
extraction (%) compared to 
reference 
Rat, BUI, maximal extraction 
(%) compared to reference 
r=0.88, n=10,§ Dehouck et al., 1992 
BBMECsFI (Ptrans,in vitro) Rat, in situ brain perfusion 
(Ptrans,in vivo) 
in vitro reflects in vivo, 
n=5 
Saheki et al., 1994 
BBMECsFI (Pe corrected to 
Pe,sucrose) 
Rat, injection to left 
ventricle, single pass 
cerebral extraction (E)  
r=0.96, n=7 Pirro et al., 1994 
BBMECsFI (Pe) Rat, BUI, maximal extraction 
(%) compared to reference 
r=0.96, n=9 
r=0.93, n=9,†,‡ 
Dehouck et al., 1995, 
Cecchelli et al., 1999 
BBMECsco-culture (Pe) Rat, BUI, maximal extraction 
(%) compared to reference 
r=0.90, n=9 Dehouck et al., 1995, 
Cecchelli et al., 1999 
BBMECsFI (Papp) Rat, intravenous injection to 
tail vein (brain:plasma ratio) 
r=0.66, n=10 Polli et al., 2000 
BBMECsS-b-S (Papp) Rat, microdialysis (CLin) good correlation, n=8 Otis et al., 2001, 
Hansen et al., 2002 
BBMECsco-culture (Pe) Rat, BUI (%) 
Rat, in situ brain perfusion 
and intravenous injection 
technique (Pe,in vivo) 
r=0.93 BUI, n=12 
r=0.95 Pe,in vivo, n=13,
$ 
Lundquist et al., 
2002 
BBMECsFI,ACM (Pe) Rat, in situ brain perfusion 
(Pe,in vivo) 
r2=0.81 (r=0.90), 
n=10,* 
Culot et al., 2008 
BBMECsco-culture (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
r2=0.74 (r=0.86), 
n=10 (passive) 
r2=0.52, (r=0.72), n=22 
(all compounds) 
Garberg et al., 2005 
 
 
 
 
 
(Continued.) 
28 
 
 
Table 5. In vitro-in vivo correlations between the BBMEC, Caco-2 and MDCK cell models and 
several in vivo methods. (Continued.) 
in vitro model 
(parameter) 
in vivo method 
(parameter) 
in vitro-in vivo 
correlation¥ 
Reference 
BBMEC data from (Johnson 
and Anderson, 1999, 
Garberg et al., 2005, Rice 
et al., 2005, Lundquist et 
al., 2002) (Pe) 
Rodent, in situ brain 
perfusion (log Pc,in situ) 
r2=0.09, (r=0.30), 
n=46,† 
r2=0.58, (r=0.76), 
n=19,£ 
Avdeef, 2011 
 
 
 
 
 
Caco-2 (Papp)  Rat, BUI (%) r=0.68, n=10,
$ 
Lundquist et al., 
2002 
Caco-2 (Pe,AB/Pe,BA) Human, positron emission 
tomography (plasma-brain 
exchange parameter) 
r2=0.17, (r=0.41), n=5 Mabondzo et al., 
2010 
Caco-2 (Papp,BA/Papp,AB) Rat, brain penetration 
(Cbrain/Cblood) 
no correlation Faassen et al., 2003 
Caco-2 (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
r2=0.86, (r=0.93), n=10 
(passive) 
r2=0.34, (r=0.58), n=22 
(all compounds) 
Garberg et al., 2005 
Caco-2 (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
corrected with tissue binding 
r2=0.61, (r=0.78), n=10 Hellinger et al., 2012 
Caco-2vinblastine (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo 
corrected with tissue binding)  
r2=0.72, (r=0.85), n=10 Hellinger et al., 2012 
 
 
MDCK (Papp) Rat, in situ brain perfusion 
(Kin) 
r=0.93, n=16 Polli et al., 2000 
MDCK (Papp) Rat, injection to tail vein 
(brain:plasma ratio) 
r=0.80, n=10 Polli et al., 2000 
MDCK (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
r2=0.65, (r=0.81), n=10 
(passive) 
r2=0.46, (r=0.68), n=22 
(all compounds) 
Garberg et al., 2005 
MDCK-MDR1 (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
r2=0.64, (r=0.80), n=10 
(passive) 
r2=0.37, (r=0.61), n=22 
(all compounds) 
Garberg et al., 2005 
MDCK-MDR1 (Papp) different in vivo methods 
(CNS+/-) 
good correlation Wang et al., 2005 
MDCKII-MDR1 (Papp) Rat, in situ brain perfusion 
(P) 
r2=0.0071, (r=0.08), 
n=37 
 
Di et al., 2009 
MDCKII-MDR1 (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo 
corrected with tissue binding) 
r2=0.78, (r=0.88), 
n=10, † 
Hellinger et al., 2012 
¥ r2 converted as r by equation √r2; S-b-S side-by-side diffusion chambers; Pe, permeability across cell monolayer 
(1/Pe=1/Ptotal-1/Pfilter); 
* parameters normalized for molecular weight ln[Pe×√MW] or log[Pe×√MW]; 
# two 
molecules (L-dopa and glucose) were not included in the analysis due to their active transport mechanisms; co-
culture endothelial cells co-cultured with astrocytes; BUI, brain uptake index; § diazepam was not included due to 
the rate-limiting step of filter permeability; FI filter inserts; † parameters log normalized; ‡ imipramine excluded 
from the analysis due to the sequestration into the BBMECs; Papp, apparent permeability coefficient; 
$ 
parameters normalized for molecular weight ln[BUI×√MW] and ln[Pe or Papp ×√MW]; 
ACM astrocyte conditioned 
medium; £ corrected for paracellular and aqueous boundary layer; AB, apical-to-basolateral direction; BA, 
basolateral-to-apical direction; vinblastine cells cultured under 10 nM vinblastine. 
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Table 6. In vitro-in vivo correlations between endothelial cell-based cell models from different 
species and several in vivo methods. 
in vitro model 
(parameter) 
in vivo method 
(parameter) 
in vitro-in vivo 
correlation¥ 
Reference 
HBMECsco-culture (Pe,AB/Pe,BA) Human, positron emission 
tomography  (plasma-brain 
exchange parameter) 
r2=0.90, (r=0.95), n=6 Mabondzo et al., 
2010 
HBMECsco-culture (Pe) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
r2=0.05, (r=0.22), n=9 
(passive) 
r2=0.12, (r=0.35), n=18 
(all compounds) 
Garberg et al., 2005 
hCMEC/D3 (Pe) Rat and mouse, in situ brain 
perfusion, (Kin) 
r=0.94, n=5 Weksler et al., 2005 
PBMEC (Pe) Rat, in situ brain perfusion 
(logPS) 
r2=0.60, (r=0.77), n=16 
(all compounds) 
r2=0.89, (r=0.94), 
n=13,* 
Zhang et al., 2006b 
RBMECco-culture (Pe) Rat and mouse, in situ brain 
perfusion, (Kin) 
r=0.94, n=10 Perrière et al., 2007 
RBMECco-culture (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
corrected with fu,brain/fu,pasma 
(in vitro) 
r2=0.80, (r=0.89), 
n=10,# 
Hellinger et al., 2012 
MBEC4 (Papp) Mouse, intravenous injection 
to tail vein (Papp,in vivo) 
low correlation Garberg et al., 2005 
PAMPA-BBB (Pe,pampa) Rat, in situ brain perfusion 
(P) 
r2=0.47, (r=0.69), n=37 Di et al., 2009 
¥ r2 converted as r by equation √r2; co-culture cells co-cultured with astrocytes or with astrocytes and pericytes; 
Pe, permeability across cell monolayer (1/Pe=1/Ptotal-1/Pfilter); AB, apical-to-basolateral direction; BA, 
basolateral-to-apical direction; Papp, apparent permeability coefficient; 
* phenylalanine, leucine and gabapentin 
were not included in the analysis due to the active transport mechanism; # parameters log normalized. 
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2.6 CONCLUSIONS FROM THE REVIEW OF THE LITERATURE 
During the past decades, several in vitro, in vivo and in silico models have been introduced to 
permit the prediction of blood-brain barrier permeability. Clear progress in the development of 
the in vitro blood-brain barrier models has been gained during the last 10 years. However, all of 
these models have their own advantages but also limitations. Therefore, the choice of the model 
for prediction of blood-brain barrier permeability represents a compromise between high 
throughput with low predictive value and low throughput with high predictive value (Braun et 
al., 2000). In vitro models have been considered to have a higher throughput in screening 
experiments but have a lower predictive value than in vivo models. Currently different in vitro 
models are being used for screening of drug candidates’ abilities to permeate across blood-brain 
barrier. It seems that primary brain endothelial cells mimic best the in vivo blood-brain barrier, 
but expression levels of several proteins and their functionalities may be downregulated in 
vitro. In addition, primary cells are labor intensive and require regular isolation from fresh brain 
tissue. In contrast, immortal cell lines are readily available and easy to maintain but they may 
change their protein expression characteristics during passaging. At the moment, none of these 
models is able to predict adequately such a complex process as blood-brain barrier penetration 
of drugs in human. Therefore, at the moment, the combinations of the in vitro, in vivo and in 
silico technologies in the early drug development are still needed to construct an accurate 
picture about the blood-brain barrier traversing potential of a drug candidate. 
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3 Aims of the Study 
In the early drug development, cell based in vitro models are commonly used to predict the 
blood-brain barrier permeability of new drug candidates. In order to make reliable predictions 
of the drug permeability across blood-brain barrier based on in vitro data, it is important to 
thoroughly characterize the in vitro models to assess the advantages and limitations of each of 
the in vitro models being used. In addition, the in vitro drug permeability data needs to be 
correlated against in vivo counterpart, to allow reliable predictions based on in vitro data. The 
general objective of this study was to evaluate the suitability of the monocultured BBMECs as 
an in vitro blood-brain barrier model for use in drug permeability studies. 
 
The specific aims of the study were: 
 
1. To optimize the monoculture conditions and characterize BBMEC model in 
terms of tightness, expression of tight junction proteins and specific brain 
endothelial cell markers and metabolic enzymes. The tightness, expression of 
tight junction proteins and metabolic enzyme activities in the monocultured 
BBMEC model were also compared with two generally used epithelial cell 
models, Caco-2 and MDCKII-MDR1. 
 
2. To evaluate the expression, localization and functionality of P-glycoprotein in 
the monocultured BBMECs. 
 
3. To examine the molecular descriptors determining the passive permeability of 
model drugs across the monocultured BBMEC model, and to compare these 
descriptors to those previously determined for epithelial cell models for 
assessing and classifying drugs. 
 
4. To assess the in vivo relevance of the BBMEC, Caco-2 and MDCKII-MDR1 cell 
models with an in vitro-in vivo correlation analysis by using the brain 
microdialysis in the rat and unbound brain/blood ratio as the in vivo measure. 
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4 Materials and Methods 
4.1 ENDOTHELIAL CELL ISOLATION AND CULTURE 
4.1.1 Isolation of the BBMECs 
Isolation of the BBMECs was performed as described previously (Audus and Borchardt, 1987, 
Audus et al., 1996). Bovine brains were obtained from a local slaughterhouse (Atria Suomi Oy, 
Kuopio, Finland) and microvessel fragments from two brains were isolated as schematically 
described in Figure 5. The isolation protocol yielded 12 ml of microvessels from two bovine 
brains. The microvessels were stored in the liquid nitrogen for up to three months. 
 
Figure 5. Schematic chart describing the main points of the isolation protocol Audus and Borchardt, 1987, 
Audus et al., 1996. 
4.1.2 BBMEC culture 
Collagen-fibronectin coating - Tendons were removed aseptically from rat tails and sterilized with 
70 % ethanol.  Dried tendons were weighed and collagen was dissolved with 0.1 % acetic acid 
solution to give a final concentration of 3 mg/ml. The solution was stirred at 4 °C for 48-72 h. 
Collagen solution was centrifuged at 4000 × g at 4 °C for 2 h. The pellet was discarded and 
collagen solution was stored at 4 °C. All of the cell culture materials in use were coated (0.4 
mg/cm2) with 3 mg/ml collagen solution as described earlier (Audus and Borchardt, 1987). 
Collagen-coated cell culture materials were sterilized under UV light in laminar flow hood for 
two hours and stored at 4 °C and used within one week. Prior to seeding the BBMECs, collagen-
coated cell culture materials were further coated with 50 µg/ml fibronectin (Sigma-Aldrich, St. 
Louis, MO, USA) (5 µg fibronectin/cm2) in phosphate buffered saline (PBS, 129 mM NaCl, 2.5 
mM KCl, 7.4 mM Na2HPO4, 1.3 mM KH2PO4) for 45 min. 
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Plating the brain microvessel fragments - Briefly, a sufficient number of cryovials were thawed 
(one cryovial per ~42 cm2) in plating medium [45 % minimum essential medium (Invitrogen, 
Carlsbad, CA, USA), 45 % Ham’s F12 nutrient mixture (Invitrogen), 10 % horse serum, 10 mM 
N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 13 mM NaHCO3, 50 µg/ml 
polymyxin B, 100 µg/ml penicillin G, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin B, all 
supplied by Sigma-Aldrich] and centrifuged for 10 min at 1000 × g. The pellet of microvessel 
fragments was resuspended in plating medium and heparin (Sigma-Aldrich) was added to a 
final concentration of 0.15 mg/ml just prior to seeding the microvessel fragments onto collagen-
fibronectin coated cell culture materials. The microvessel fragments were cultured for three 
days at 37 °C, 5 % CO2. Thereafter, cultures were grown in culture medium (45 % minimum 
essential medium, 45 % Ham’s F12 nutrient mixture, 10 % horse serum, 10 mM HEPES, 13 mM 
NaHCO3, 100 µg/ml penicillin G, 100 µg/ml streptomycin, 50 µg/ml heparin, 20 µg/ml bovine 
endothelial cell growth factor (Roche, Basel, Switzerland). The culture medium was changed 
three times a week until the endothelial cells formed a confluent cell monolayer within 9-12 
days. The experiments were performed with non-passaged primary monocultured BBMECs. 
4.1.3 Tested cell culture medium supplements 
The effects of different cell culture medium supplements and ACMs (Table 7) were tested to the 
Papp of [14C]sucrose and the functionality of the efflux proteins assessed with calcein 
acetoxymethyl ester (calcein-AM) assay (see section 4.4.2) in the BBMECs. 
 
Table 7. Tested cell culture medium supplements. 
Supplement Concentration Source 
ascorbic acid 30 µM Sigma-Aldrich 
hydrocortisone 550 nM Sigma-Aldrich 
rat C6 glioma medium 50 % (v/v) in-house 
adult mice astrocyte medium 50 % (v/v) a kind gift from Cerebricon Ltd. (Kuopio, Finland) 
4.2 EPITHELIAL CELL CULTURE 
4.2.1 Caco-2 
Caco-2 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and 
cultured in Eagle’s minimal essential medium (LGC Promochem, Teddington, UK) 
supplemented with 10 % heat-inactivated fetal calf serum (LGC Promochem), 100 IU/ml 
penicillin and 100 μg/ml streptomycin (LGC Promochem). Cells were cultured at 37 °C, 5 % CO2 
and subcultured twice a week at 80-90 % confluence with 0.25 % trypsin, 0.53 mM 
ethylenediaminetetraacetic acid (EDTA, LGC Promochem) and used between passages 45-49. 
Caco-2 cells were seeded at a density of 82 × 103 cells/cm2 onto 12 well Transwell® permeable 
supports with 0.4 µm pore size polycarbonate (Corning, Corning, NY, USA). Cells were grown 
for 21 days before experiments and medium was changed three times a week. For 
immunostaining, the cells were seeded 50 × 103 cells/well onto 96 well plates (Nunc, Rochester, 
NY, USA) and cells were grown for 4 days. 
4.2.2 MDCKII-MDR1 
MDCKII-MDR1 cells were obtained from Netherlands Cancer Institute, Amsterdam. MDCKII-
MDR1 cells were cultured in Gibco® Dulbecco’s modified Earle’s medium (Invitrogen) 
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supplemented with 10 % heat-inactivated fetal calf serum (LGC Promochem), 100 IU/ml 
penicillin and 100 μg/ml streptomycin (LGC Promochem). Cells were incubated at 37 °C, 5 % 
CO2. Cells were subcultured twice a week at ~90 % confluence with 0.05 % trypsin, 1 mM EDTA 
(Lonza, Basel, Switzerland) and used between passages 33-59. MDCKII-MDR1 cells were 
seeded at a density of 39 × 103 cells/cm2 onto Transwell® permeable supports (12 well, 0.4 µm 
pore size polycarbonate, Corning) or 50 × 103 cells/well onto 96 well plates (Nunc) and cells 
were grown for 4 days. 
4.3 CHARACTERIZATION OF THE CELL MODELS 
The cell-based in vitro model needs to exhibit appropriate blood-brain barrier properties, such 
as expression and functionality of tight junction proteins, active transporter proteins and 
specific enzymatic activities (Table 2). Therefore, selected proteins and enzyme activities were 
characterized from the BBMECs and compared with those from Caco-2 and MDCKII-MDR1 
cells. 
4.3.1 Protein expressions 
ZO-1, occludin and vWF immunostaining (III) - The endothelial cell characteristics of the BBMECs 
were confirmed by assaying the vWF protein by immunostaining. In addition, the expressions 
of two tight junction proteins, ZO-1 and occludin, were determined by immunostaining. For 
immunostaining, the cells were fixed with methanol at -20°C for 10 min, blocked with 5 % 
normal goat serum in PBS for 10 min and permeabilized with 0.1 % Triton X-100 in PBS for 10 
min. Primary antibodies were rabbit anti-human vWF (1/1000) (Dako, Glostrup, Denmark), 
rabbit anti-ZO-1 (1 µg/ml) (Zymed Laboratories, San Francisco, CA, USA) and rabbit anti-
occludin (5 µg/ml) (Zymed Laboratories). Secondary antibody was goat anti-rabbit fluorescein 
isothiocyanate conjugate (10 µg/ml) (Zymed Laboratories). The endoplasmic reticulum was 
stained with concanavalin A Texas Red (100 µg/ml) (Molecular Probes, Eugene, OR, USA). The 
fluorescent images were obtained with a Nikon Eclipse Inverted Microscope (Nikon 
Corporation, Tokyo, Japan) with UltraVIEW confocal Imaging System (PerkinElmer, Waltham, 
MA, USA). 
 
P-glycoprotein immunoblotting (III) - Cell lysates of the BBMECs cultured either on filter inserts 
or on filters on petri dishes, and MDCKII-MDR1 cells cultured on filter inserts were prepared as 
described earlier (Hamilton et al., 2001). Total protein concentrations were determined with a 
protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) using bovine serum albumin (BSA) 
as a standard. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed as 
described earlier (Laemmli, 1970). Proteins were transferred onto a nitrocellulose membrane by 
electroblotting (Towbin et al., 1979). P-glycoprotein was detected with monoclonal antibody 
(C219) (1/50). Monoclonal anti-β-tubulin antibody (1/5000) (Sigma-Aldrich) was used as a 
loading control. Secondary antibody was anti-mouse-HRP (1/8000) (Pierce, Thermo Fisher 
Scientific, Rockford, IL, USA) and SuperSignal West Femto chemiluminescence substrate 
(Pierce) was used for antibody detection. 
 
P-glycoprotein immunostaining (III) - P-glycoprotein localization was characterized from the 
BBMECs cultured either on filter inserts or on filters on petri dishes, and MDCKII-MDR1 cells 
cultured on filter inserts. For immunostaining, cells were fixed with 4 % paraformaldehyde, 
blocked with 1 % BSA and permeabilized with 0.1 % Triton X-100, 1 % BSA in PBS. P-
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glycoprotein was recognized with primary monoclonal antibody against P-glycoprotein (1/5) 
(C219, Covance Research Products, Dedham, MA, USA). The secondary antibody was anti-
mouse IgG Texas Red (1/500) (Vector Laboratories, Burlingame, CA, USA). Nuclei were labeled 
with 1 μg/ml 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich). The 
fluorescent images were obtained with a Zeiss Axio Observer inverted microscope (40×NA 1.3 
oil objective) equipped with LSM 700 confocal module (Carl Zeiss Microimaging, Jena, 
Germany). ZEN 2009 software (Carl Zeiss Microimaging) was used for image processing and 
3D rendering. The intensity of the P-glycoprotein fluorescence was measured from four 
randomly selected images of 160 × 160 μm areas using ZEN 2009 software. The negative control 
images were measured identically. P-glycoprotein intensity was calculated as mean intensity × 
area after subtracting the intensity of the negative control sample. 
4.3.2 Enzyme activities 
ALP activity was measured as described earlier (Korjamo et al., 2005). Briefly, cells were 
homogenized and cellular supernatant was used for the reaction. ALP from bovine intestinal 
mucosa (Sigma-Aldrich) was used as the standard. Absorbance was measured at 405 nm by 
Victor2 microplate reader (PerkinElmer). The protein concentration of the cellular supernatant 
was determined as described above. ALP activities were expressed as pmol/min/µg protein. 
The COMT activity assay was modified from the method described earlier (Forsberg et al., 
2003). Briefly, cells were homogenized and cellular supernatant was used for the reaction. The 
reaction products were quantified by using high-performance liquid chromatography (HPLC) 
with electrochemical detection. The total COMT activity (including both membrane bound and 
cytosolic COMT) was normalized with the protein concentration of cellular supernatant 
determined as described above. COMT activities were expressed as pmol/min/mg protein. 
4.4 CELLULAR UPTAKE STUDIES 
4.4.1 Cellular uptake in the BBMECs 
BBMECs were cultured on 24 well plates until confluence. The uptake studies were carried out 
as previously described (El Hafny et al., 1997, Silverstein et al., 2004) with minor modifications. 
Briefly, cells were washed and pre-incubated with and without P-glycoprotein inhibitors 
GF120918 (3 µM) and quinidine (100 µM) (Table 8) in uptake buffer (129 mM NaCl, 0.63 mM 
CaCl2, 2.5 mM KCl, 0.74 mM MgSO4, 7.4 mM Na2HPO4, 1.3 mM KH2PO4, 5.3 mM D-glucose, 10 
mM HEPES, pH 7.4) for 30 min. The cellular uptake of P-glycoprotein substrates [3H]paclitaxel 
and [3H]vinblastine (Table 9) were determined with and without the inhibitors for 120 min at 37 
°C. After incubation, the cells were rapidly washed three times with ice-cold uptake buffer and 
then lysed with 0.1 M NaOH overnight on ice. The retained radioactivity was determined by 
liquid scintillation counting (see section 4.8.1) and the amount of drug was normalized with 
protein concentration and expressed as pmol/mg protein. 
4.4.2 Calcein-AM assay 
Calcein-AM assay was performed in the BBMECs and MDCKII-MDR1 cells as described earlier 
(Vellonen et al., 2004). Efflux protein function was inhibited by using cyclosporine A (15 µM), 
progesterone (150 µM), verapamil (300 µM) and MK-571 (50 µM) (Table 8) containing 1 % 
dimethylsulfoxide in PBS. The fluorescence intensity was determined in a Victor2 microplate 
reader (PerkinElmer) at wavelengths 485 nm (ex) and 550 nm (em). The retained fluorescence of 
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inhibitor treated wells was calculated and expressed as a percentage of fluorescence in the 
control wells (% of control). 
 
Table 8. Efflux protein inhibitors. 
Drug Inhibitor for Source Reference 
GF120918 P-glycoprotein, 
BCRP 
a kind gift from GlaxoSmithKline 
(Research Triangle Park, NC, USA) 
Hyafil et al., 1993, Wallstab et al., 1999, de Bruin et 
al., 1999, Maliepaard et al., 2001b 
cyclosporine A P-glycoprotein, 
Mrp2 
Sigma-Aldrich Jetté et al., 1995, Giacomini et al., 2010 
MK-571 Mrp proteins Cayman Chemical Company 
(Ann Arbor, MI, USA) 
Gekeler et al., 1995, Gutmann et al., 1999, Weiss et 
al., 2007, Reid et al., 2003 
progesterone P-glycoprotein Sigma-Aldrich Yang et al., 1989, Jetté et al., 1995 
quinidine P-glycoprotein Sigma-Aldrich Kamimoto et al., 1989, Jetté et al., 1995, Giacomini 
et al., 2010 
verapamil P-glycoprotein, 
Mrp1 
ICN Biomedicals (Irvine, CA, USA) Kamimoto et al., 1989, Jetté et al., 1995, Giacomini 
et al., 2010, Potschka et al., 2004, Goh et al., 2002 
4.5 DRUG PERMEABILITY STUDIES 
4.5.1 Drugs 
In this study, [14C]sucrose and [14C]diazepam were used as a low and high permeability 
reference compounds, respectively. The basic physicochemical properties (MW, LogP, PSA and 
number of hydrogen-bonding interactions) for sucrose (342.3, -4.49, 189.5 Å2, 19, respectively) 
and diazepam (284.7, 2.80, 32.7 Å2, 3, respectively) were calculated by the ACD/PhysChem 
Suite, version 12.01, 2009 (Advanced Chemistry Development, Toronto, ON, Canada). In the 
BBMEC model, 0.1 µCi/ml [14C]sucrose (625 mCi/mmol, American Radiolabeled Chemicals, St. 
Louis, MO, USA) and 1 µCi/ml [3H]diazepam (76.0 Ci/mmol, PerkinElmer) or 0.1 µCi/ml 
[14C]diazepam (56.0 mCi/mmol, Amersham Biosciences, Uppsala, Sweden) were used. In the 
Caco-2 and MDCKII-MDR1 models, 2 µCi/ml [14C]sucrose (625 mCi/mmol, American 
Radiolabeled Chemicals) and 0.1 µCi/ml [14C]diazepam (56.0 mCi/mmol, Amersham 
Biosciences) were used. 
The model drugs used in this study are listed in Table 9. The model drugs were selected to 
cover a wide range of physicochemical properties; MW (136.1 to 1202.6), LogP (-4.49 to 5.92), 
PSA (23.6 to 278.8 Å2) and hydrogen-bonding interactions (3 to 28). 
4.5.2 BBMEC model 
The permeability experiment in the BBMECs cultured both on filters on petri dishes (I-III) and 
on filter inserts (III). The permeability experiments were conducted in an apical-to-basolateral 
(A-B) direction (I-II) but bidirectional transport studies (A-B direction and the basolateral-to-
apical (B-A) direction) were also performed (III). Drugs were dissolved in transport buffer (129 
mM NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4, 1.3 mM KH2PO4, 0.63 mM CaCl2, 0.74 mM MgSO4, 
5.3 mM D-glucose, 0.1 mM ascorbic acid, pH 7.4 (Borges et al., 1994)) and the solutions were 
adjusted to pH 7.4 when applicable. The BBMECs cultured on filters were transferred to side-
by-side diffusion chambers (PermeGear, Bethlehem, PA, USA) (Figure 6). Pre-warmed drug 
solution was introduced into the donor chamber (3 ml) and pure transport buffer solution was 
added into the receiver chamber (3 ml). Both chambers were stirred with magnetic stirring and 
external water circulation was used to maintain the temperature at 37 °C. Samples were 
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withdrawn from both receiver (100 µl) and donor (10 µl) chambers at 5, 10, 20, 30, 45 and 60 min 
time points. Fresh buffer was used to replace the fluid lost from the receiver chamber. 
Bidirectional transport studies of [3H]paclitaxel with or without P-glycoprotein inhibitor, 
GF120918, were conducted in the BBMECs cultured on filter inserts (III). The [3H]paclitaxel was 
prepared either in transport buffer or in transport buffer supplemented with 5 µM GF120918 
(Evers et al., 2000) (Table 8). Prior to the transport studies, the BBMECs were pre-incubated with 
or without GF120918 for 30 min at 37 °C. The studies were performed in A-B and B-A directions 
at 37 °C as described above. The samples were taken from the receiver and donor side at 15, 30, 
60, 90, 120 and 180 min time points and receiver samples were replaced with an equal volume 
of fresh transport buffer or transport buffer supplemented with GF120918. Sample drug 
concentrations were determined by using liquid scintillation counting, HPLC or liquid 
chromatography-mass spectrometry (LC-MS) analyses (see section 4.8.2). 
 
 
Figure 6. Schematic illustration of the side-by-side diffusion chamber system in the BBMEC model (A) and filter 
insert system in the Caco-2 and MDCKII-MDR1 cells (B) used for the permeability experiments. The apical and 
basolateral sides of the cell monolayers are shown. 
 
4.5.3 Caco-2 and MDCKII-MDR1 
The permeability studies of model drugs (alprenolol, atenolol, metoprolol, pindolol, 
entacapone, tolcapone, ondansetron, baclofen, midazolam, sucrose, diazepam) were conducted 
in the A-B direction in the Caco-2 and MDCKII-MDR1 cells grown on filter inserts (Figure 6) (I). 
Drug solutions were dissolved in Hank’s balanced salt solution (HBSS; BioWhittaker, Lonza) 
supplemented with 25 mM HEPES, 0.02 % NaCl (BioWhittaker, Lonza) the pH values of the 
solutions were adjusted to 7.4 when applicable. Cells were washed twice with HBSS buffer and 
pre-incubated at 37 °C for 15 min. The transport studies were performed at 37 °C in an orbital 
shaker (Titramax 1000, Heidolph, Germany). In the A-B transport studies, pre-warmed drug 
solution was introduced into the donor chamber (0.5 ml) and pure HBSS-HEPES buffer was 
added into the receiver chamber (1.5 ml). Samples (100 µl) were withdrawn at 15, 30, 60, 120 
and 180 min from receiver chambers. Receiver samples were replaced with an equal volume of 
fresh HBSS buffer. Samples (100 µl) from the donor solution were taken at the beginning and 
the end of the experiment. 
In addition, the bidirectional transport studies of [3H]paclitaxel  in the absence and presence 
of 5 µM GF120918 were performed in the MDCKII-MDR1 model as described above with a few 
slight modifications (III). In the B-A transport studies, the basolateral chamber (1.5 ml) being 
the donor and apical chamber (0.5 ml) being the receiver. Samples were withdrawn at 15, 30, 60, 
90, 120 and 180 min from the receiver chamber and samples were replaced with an equal 
volume of fresh HBSS buffer or buffer supplemented with GF120918 to replace the fluid loss 
from the receiver chamber. 
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Table 9. Physicochemical properties of the model drugs. 
Model drug In vitro 
concentr. 
Drug class MWa LogPa PSA 
(Å2)a 
H- 
bondinga 
Original 
publ. 
Source 
alprenolol 20 μM beta-adrenoceptor 
antagonist 
249.4 2.91 41.5 5 I Sigma-Aldrich 
atenolol 100 μM beta-adrenoceptor 
antagonist 
266.3 0.33 84.6 9 I Sigma-Aldrich 
metoprolol 20 μM beta-adrenoceptor 
antagonist 
267.4 1.63 50.7 6 I Sigma-Aldrich 
pindolol 20 μM beta-adrenoceptor 
antagonist 
248.3 1.68 57.3 7 I Sigma-Aldrich 
entacapone 20 μM COMT inhibitor 305.3 2.12 130.4 10 I Orion Pharma 
(Espoo, Finland) 
tolcapone 20 μM COMT inhibitor 273.2 3.02 103.4 8 I synthesized by Dr. 
Aino Pippuri, Orion 
Pharma 
ondansetron 20 μM antiemetic 293.4 1.55 39.8 4 I Sigma-Aldrich 
(±)-baclofen 20 μM γ-aminobutyric 
acid analog 
213.7 0.78 63.3 6 I Sigma-Aldrich 
midazolam 20 μM benzodiazepine 
derivative 
325.8 3.80 30.2 3 I Roche 
JTP-4819 20 μM prolyl 
oligopeptidase 
inhibitor 
359.4 0.72 90.0 9 Jalkanen 
et al., 
2011 
synthesized by Dr. 
Elina Jarho, 
University of Eastern 
Finland 
KYP-2047 20 μM prolyl 
oligopeptidase 
inhibitor 
339.4 2.17 64.4 5 Jalkanen 
et al., 
2011 
synthesized by Dr. 
Elina Jarho, 
University of Eastern 
Finland 
acyclovir 20 μM antiviral 225.2 -1.48 144.8 12 II Recordati industria 
chimica E 
Pharmaceutica 
(Milan, Italy) 
allopurinol 20 μM purine analog 136.1 -0.14 70.1 7 II Sigma-Aldrich 
antipyrine 20 μM antipyretic, 
analgesic 
188.2 0.44 23.6 3 II Sigma-Aldrich 
ibuprofen 20 μM nonsteroidal anti-
inflammatory 
206.3 3.50 37.3 3 II Sigma-Aldrich 
metronidazole 20 μM antibacterial 171.2 -0.14 83.9 7 II Sigma-Aldrich 
(±)-propranolol 20 μM beta-adrenoceptor 
antagonist 
259.3 2.90 41.5 5 II Sigma-Aldrich 
cephalexin 100 μM antibacterial 347.4 0.35 138.0 11 II ICN Biomedicals 
(Aurora, OH, USA) 
(±)-verapamil 8 μM calcium channel 
blocker 
454.6 4.02 64.0 6 II ICN Biomedicals 
theophylline 20 μM methylated 
xanthine derivative 
180.2 -0.02 69.3 7 II Orion Pharma 
paracetamol 20 μM antipyretic, 
analgesic 
151.2 0.48 49.3 5 II Orion Pharma 
[3H]cyclosporine A 
(9 Ci/mmol) 
1 μCi/ml immunosuppres-
sant 
1202.6 2.79 278.8 28 II PerkinElmer 
[3H]digoxin 
(21.8 Ci/mmol) 
0.5 μCi/ml cardiac glycoside 780.9 1.29 203.1 20 II, III PerkinElmer 
[3H]paclitaxel 
(54.6 Ci/mmol) 
0.2 μCi/ml antitumor 853.9 3.95 221.3 19 III Moravek 
Biochemicals. 
[3H]vinblastine 
(10 Ci/mmol) 
0.5 μCi/ml antitumor 811.0 5.92 154.1 16 III American 
Radiolabeled 
Chemicals 
aValues calculated by the ACD/PhysChem Suite, version 12.01, 2009 (Advanced Chemistry Development). 
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4.6 DESCRIPTORS DETERMINING THE IN VITRO PERMEABILITY OF DRUGS 
4.6.1 Conformational analysis and calculation of molecular descriptors 
Twenty-five model drugs (acyclovir, allopurinol, alprenolol, antipyrine, atenolol, baclofen, 
cyclosporine A, cephalexin, diazepam, digoxin, entacapone, ibuprofen, JTP-4819, KYP-2047, 
metoprolol, metronidazole, midazolam, ondansetron, paracetamol, pindolol, propranolol, 
sucrose, theophylline, tolcapone and verapamil) were minimized using the ChemBioDraw 
Ultra, version 12.0 (CambridgeSoft, Cambridge, MA, USA). Conformational analysis was 
performed using MOE (Molecular Operating Environment, version MOE 2010.10, Chemical 
Computing Group, Montreal, Canada). The lowest found potential energy conformation was 
selected for use in the descriptor calculation. The molecular descriptors are numerical values 
that describe the chemical properties of the molecule. The molecular descriptors were calculated 
by VolSurf, version 4.1.4, (Molecular Discovery, Middlesex, UK). 
4.6.2 Principal component analysis 
Principal component analysis (PCA) was performed using SIMCA-P, version 12.0 (Umetrics, 
Umeå, Sweden) to define the molecular descriptors influencing the in vitro drug permeability 
across the BBMECs cultured on filters on petri dishes. The PCA model was created by using 102 
calculated molecular descriptors. From the PCA model, possible strong outliers were 
determined by Hotelling’s T2 distribution at 95% confidence level. Permeability values of the 
model drugs were added into the PCA model. This PCA model was used to interpret which 
molecular descriptors correlate with the permeability of model drugs across the monocultured 
BBMEC model (Figure 3 in II). 
4.7 IN VIVO BRAIN MICRODIALYSIS 
Dual probe brain mircodialysis in the male Wistar rats was used to measure unbound drug 
concentrations in the blood and brain ECF and to determine the unbound brain/blood ratio. A 
rat was anesthetized, the intravenous microdialysis probe was inserted into the left femoral vein 
and the brain probe was placed into the striatum. The probes were perfused with Krebs Ringer 
at a flow rate of 2 μl/min for 80 min before drug administration. Nine model drugs (alprenolol, 
atenolol, metoprolol, pindolol, entacapone, tolcapone, baclofen, midazolam and ondansetron) 
were administered intraperitoneally at a dose of 50 μmol/kg. Dialysates were collected in 20 
min fractions for 5 h. Drug concentrations were determined by using HPLC or LC-MS analyses 
(Table 10). 
4.8 ANALYTICAL METHODS 
4.8.1 Radiotracer samples 
The radioactivity of the samples were analyzed by using liquid scintillation counting (1450 
MicroBeta Trilux Liquid Scintillation Counter, Wallac, Finland) after the addition of 500 µl 
scintillation cocktail (PerkinElmer). 
4.8.2 HPLC and LC-MS analyses 
HPLC and LC-MS analyses (Table 10) were used for quantification of model drug 
concentrations in both the in vitro permeability studies and in vivo microdialysis. 
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Table 10. High-performance liquid chromatography and liquid chromatography-mass spectrometry 
analysis used for determination of in vitro permeability samples and in vivo microdialysis samples. 
Drug Method Instrumentation Column Mobile phase Detection Reference 
acyclovir 
paracetamol 
 
HPLC Unipoint LC system 
(Gilson, Middleton, WI, 
USA) 
Inertsil ODS-3, 
4.0 × 150 mm 
(GL Sciences, 
Tokyo, Japan) 
isocratic elution: 0.03 % 
TFA in acetonitrile (A) and 
0.03 % TFA in water (B); 
acyclovir A/B 5/95, 
paracetamol A/B 20/80 
UV/Vis 254 nm II 
 
allopurinol 
metronidazole 
theophylline 
 
HPLC Unipoint LC system 
(Gilson) 
Inertsil ODS-3, 
4.0 × 150 mm 
(GL Sciences) 
isocratic elution: 0.1 % 
TFA in acetonitrile (A) and 
0.1 % TFA in water (B); 
allopurinol A/B 5/95, 
metronidazole A/B 10/90, 
theophylline A/B 15/85 
UV/Vis, 
allopurinol 254 
nm, 
metronidazole 
315 nm, 
theophylline 
272 nm 
II 
 
alprenolol 
pindolol 
 
 
LC-MS Surveyor HPLC system 
and LTQ linear ion trap 
MS (Thermo Scientific, 
Waltham, MA, USA). 
Zorbax XDB C18, 
2.1 × 100 mm, 
3.5 µm (Agilent 
Technologies, 
Santa Clara, CA, 
USA) 
gradient elution: 0.1 % 
formic acid in water (A) 
and 0.1 % formic acid in 
acetonitrile (B) 
MS transitions, 
alprenolol m/z 
250→116, 
pindolol m/z 
249→116 
I 
 
 
 
antipyrine 
cephalexin 
ibuprofen 
 
HPLC Beckman System Gold 
(Beckman Coulter, 
Brea, CA, USA) 
Xterra C18, 20 × 
2.1 mm, 2.5 µm 
(Waters, Milford, 
MA, USA) 
gradient elution: 0.05 % 
trifluoracetic acid (A) and 
90 % acetonitrile, 10 % 
water, 0.038 % 
trifluoracetic acid (B) 
UV/Vis 205 nm Palmgrén 
et al., 2004 
atenolol 
 
 
HPLC HPLC 1100 system 
(Agilent Technologies) 
Zorbax SB-
phenyl-column, 
2.1 × 100 mm, 
3.5 µm (Agilent 
Technologies) 
isocratic elution: 0.05 M 
potassium dihydrogen 
phosphate and 0.01 M 1-
octanesulfonate, pH 3 (A) 
and methanol (B); (A/B 
62/38) 
fluorescence 
230 nm (ex) 
310 nm (em) 
II 
 
baclofen 
 
LC-MS Acquity UPLC and 
Quattro Premier triple 
quadrupole MS 
(Waters). 
BEH C18 column, 
2.1 × 50 mm, 
1.7 µm (Waters) 
gradient elution: 0.1 % 
formic acid (A) and (B) 
acetonitrile 
MRM 
transitions m/z 
214→116 and 
m/z 214→151 
I 
 
entacapone 
tolcapone 
 
LC-MS Surveyor HPLC system 
and LTQ linear ion trap 
MS (Thermo 
Scientific). 
Zorbax XDB C18, 
2.1 × 100 mm, 
3.5 µm (Agilent 
Technologies) 
isocratic elution: 50 % 
acetonitrile with 0.1% 
formic acid 
MS transitions, 
entacapone 
m/z 306→233, 
tolcapone m/z 
274→182 
I 
 
 
metoprolol 
propranolol 
verapamil 
HPLC Beckman System Gold 
(Beckman Coulter) 
Xterra C18, 20 × 
2.1 mm, 2.5 µm 
(Waters) 
gradient elution: 0.05 % 
trifluoracetic acid (A) and 
90 % acetonitrile, 10 % 
water, 0.038 % 
trifluoracetic acid (B) 
fluorescence 
230 nm (ex) 
302 nm (em) 
Palmgrén 
et al., 2004 
midazolam 
 
LC-MS Acquity UPLC, Quattro 
Premier triple 
quadrupole MS 
(Waters). 
BEH C18 column, 
2.1 × 50 mm, 
1.7 µm (Waters) 
gradient elution: 2 mM 
ammonium acetate (A) 
and acetonitrile (B) 
MRM 
transitions m/z 
326→291 
I 
 
ondansetron LC-MS Acquity UPLC, Quattro 
Premier triple 
quadrupole MS 
(Waters). 
BEH C18 column, 
2.1 × 50 mm, 
1.7 µm (Waters) 
gradient elution: 10 mM 
ammonia (A) and 
acetonitrile (B) 
MRM 
transitions m/z 
295→170 and 
m/z 295→184 
I 
HPLC, high-performance liquid chromatography;  LC, liquid chromatography; UPLC, ultra-performance LC; TFA, trifluoroacetic 
acid; LC-MS, liquid chromatography-mass spectrometry; MS, mass spectrometer; UV/Vis ultraviolet/visible spectroscopy; 
MRM, multiple reaction monitoring, The analytical methods were partially validated with regard to specificity, selectivity, 
linearity precision and accuracy based on the U.S. Food and Drug Administration, Guidance for Industry, Bioanalytical Method 
Validation, 2001. 
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4.9 DATA ANALYSIS AND STATISTICS 
 
Immunoblot analysis 
The density of bands was quantified from three independent experiments with triplicate 
samples by using ImageJ software (Rasband WS, U.S. National Institutes of Health, Bethesda, 
MD, USA, http://imagej.nih.gov/ij/). Densitometry of P-glycoprotein bands was normalized 
with β-tubulin bands (loading control). Statistical significance of differences in the density of 
bands between the BBMECs cultured either on filters on petri dishes or on filter inserts was 
tested by unpaired Student’s t-test with GraphPad Prism 5.03 software (San Diego, CA, USA). 
Statistical significance was set at P<0.05. 
 
P-glycoprotein immunostaining 
Statistical significance of differences in the P-glycoprotein intensities (mean intensity × area) 
between the BBMECs cultured either on filters on petri dishes, the BBMECs cultured on filter 
inserts and MDCKII-MDR1 cultured on filter inserts was tested by one-way ANOVA followed 
by Tukey’s test by GraphPad Prism 5.03 software. Statistical significance was set at P<0.05. 
 
Cellular uptake and calcein-AM assays 
Statistical significance of differences in cellular uptake assays and calcein-AM assays was tested 
by one-way ANOVA followed by Dunnett’s tests by using GraphPad Prism 5.03 software. 
Statistical significance was set at P<0.05. 
 
Permeability experiments 
The permeability experiments were used to study the transport of several model drugs (Table 
9). The apparent permeability coefficient (Papp, cm/s) for the model drugs was calculated 
according to equation 1: 
 
d
app
CA
tQr
P



/
                          (Equation 1) 
 
where ∆Qr/∆t is the steady state flux of drug, i.e., the slope of the linear region of the cumulative 
amount of drug in receiver chamber versus time (h) plot; Cd is the drug concentration in the 
donor chamber; and A is the surface area (cm2) available for transport. Sink conditions (receiver 
concentration <10% of the donor concentration) were taken into account. 
Statistical significance of differences in the Papp values was tested by unpaired Student’s t-test 
with GraphPad Prism 4.03 (I) and 5.03 software (III). Statistical significance was set at P<0.05. 
 
The efflux ratio (ER) was calculated according to equation 2: 
 
BAP
ABP
ER
app
app



                          (Equation 2)
 
 
where Papp B-A is the Papp of drug in the basolateral-to-apical direction; Papp A-B is Papp of drug in 
the apical-to-basolateral direction. 
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Comparison between the Papp values in the BBMEC, Caco-2 and MDCKII-MDR1 models 
The pair-wise linear regressions between the Papp values determined in the BBMEC, Caco-2 and 
MDCKII-MDR1 models were calculated by using GraphPad Prism 4.03 software. The 
relationship between the Papp values was analyzed with two-tailed Pearson correlation 
coefficients (r). The correlation was considered statistically significant when P<0.05. 
 
Bi-directional transport assays 
Statistical significance of differences in the Papp values were statistically compared by Student’s 
unpaired t-test in GraphPad Prism 5.03 software. Statistical significance was set at P<0.05. 
 
In vivo brain microdialysis 
AUC, i.e., area under the concentration-time curve from 0 to ∞, values were calculated from 
individual data for each of the model drugs both in brain ECF and blood with the trapezoidal 
rule by using GraphPad Prism 4.03 software. The unbound brain/blood ratio in vivo was 
determined according to equation 3: 
 


0
0
blood
ECF
AUC
AUC
ratiodbrain/bloounbound
                  (Equation 3) 
 
where AUCECF is the AUC in brain extracellular fluid and AUCblood is AUC in blood. 
 
In vitro-in vivo correlations 
The Papp values determined in the BBMEC (× 105 cm/s), Caco-2 and MDCKII-MDR1 (× 106 cm/s) 
models were log-normalized. The linear regression between the in vitro log(Papp) and the in vivo 
unbound brain/blood ratio was calculated and two-tailed Pearson correlation coefficients were 
determined by using GraphPad Prism 4.03 software. The correlation was considered 
statistically significant when P<0.05. 
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5 Results 
5.1 ISOLATION AND CULTURE CONDITIONS OF BBMECS 
5.1.1 Tightness 
The isolation protocol of the BBMECs used in this study has been described previously (Audus 
and Borchardt, 1987, Audus et al., 1996). In order to obtain pure capillaries without any other 
cell types, such as pericytes, an optimization of the isolation process was needed. The 
concentration of enzymes and the incubation times for enzyme digestions were optimized to 
achieve a good dissociation of the brain capillaries and a high viability of the endothelial cells. 
Therefore, the isolation procedure and cell culture of the BBMECs needed refinement, i.e., there 
had to be pure capillaries and low paracellular permeability before acceptable repeatability 
could be achieved. 
The tightness of the BBMECs cultured on filters on petri dishes was assessed by determining 
the Papp of paracellular marker [14C]sucrose. Steady and repeatable tightness was achieved from 
the isolation batch number eight onward (Figure 7). The paracellular tightness obtained was in 
line with the earlier studies with comparable culture and experimental conditions (Eddy et al., 
1997, Rice et al., 2005). The cell isolation batches before batch number eight contained 
contaminating cells, presumably pericytes and their presence led to a loosening of the BBMEC 
monolayer. 
 
Figure 7. Tightness of the BBMEC monolayer determined with the apparent permeability coefficient (Papp) × 10
6 
(cm/s) of [14C]sucrose at different isolation batch numbers (mean±SD, n=2-10) (unpublished results). 
5.1.2 Effects of different culture medium supplements 
Tightness - Different cell culture supplements and ACMs were tested in the BBMECs cultured 
on filters on petri dishes (Figure 8). BBMECs cultured with ACM (Rubin et al., 1991b) or co-
cultured with astrocytes (Tao-Cheng et al., 1987, Dehouck et al., 1995) have previously been 
reported to enhance tight junctions. In addition, hydrocortisone has been shown to tighten 
primary porcine endothelial cell cultures (Hoheisel et al., 1998) and ascorbic acid induces cell 
differentiation (Pasonen-Seppänen et al., 2001). Unfortunately, in this study, neither 
supplements nor ACMs had any ability to improve but in fact, they seemed to loosen in some 
cases the tightness of the paracellular barrier in the monocultured BBMECs with the present 
culture conditions. It was observed that ascorbic acid accelerated the growth of the BBMECs, 
whereas BBMECs cultured in the presence of adult mice ACM seemed to deteriorate based on 
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the morphology of the BBMECs. The loosening of the paracellular barrier in the presence of 
adult mouse ACM may be due to the fact that it is an unsuitable culture medium for the 
composition of the BBMECs.  
 
Figure 8. The effect of different culture medium supplements and ACMs to the apparent permeability coefficient 
(Papp) × 10
6 (cm/s) of [14C]sucrose in the BBMECs cultured on filters on petri dishes. Data are mean±SD 
(unpublished results). 
 
Efflux proteins - P-glycoprotein expression has been improved by co-culturing the BBMECs with 
astrocytes (Fenart et al., 1998, Gaillard et al., 2000). Therefore, the effects of the different culture 
medium supplements and ACMs on the functionality of the efflux proteins were tested by 
using calcein-AM assay. In general, no clear changes in the functionality of the efflux proteins 
were found when BBMECs grown in the presence of different culture medium supplements 
and ACMs were compared to those grown in normal culture medium (Figure 9). However, the 
BBMECs cultured with adult mice ACM exhibited a trend towards lower efflux protein 
functionality compared to BBMECs cultured in the normal culture medium (P<0.05). In our 
studies, neither the different cell culture supplements nor ACMs seemed to tighten the 
monocultured BBMECs or increase the functionality of efflux proteins in the BBMECs. For this 
reason, the BBMECs were cultured subsequently in the normal culture medium (Audus and 
Borchardt, 1987, Audus et al., 1996). 
 
 
Figure 9. The effect of the different culture medium supplements and ACMs to the functionality of the efflux 
proteins. The functionality of the efflux proteins was assessed by using calcein-AM assay. Efflux protein 
inhibitors used were cyclosporine A (P-glycoprotein, Mrp 2), progesterone (P-glycoprotein), verapamil (P-
glycoprotein, Mrp 1) and MK-571 (Mrp proteins). Different culture medium supplements and ACMs were 
compared to normal culture medium. The studies were conducted in quadruplicate and performed in three 
different experiments in the BBMECs. The results are expressed as a percentage of retained fluorescence of 
inhibitor treated wells vs. control wells (% of control). Data are mean±SD (unpublished results). 
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5.2 CHARACTERIZATION OF THE CELL MODELS 
5.2.1 Morphology and protein expressions 
 
Morphology 
A spindle-shaped morphology is a characteristic for brain endothelial cells (Goldstein et al., 
1986, Isobe et al., 1996). Thus, the spindle-shaped morphology was always checked during the 
cell culture by phase contrast microscopy. The morphology of the monocultured BBMECs was 
demonstrated to be spindle-shaped (Figure 10A) indicating that the isolation protocol of 
BBMECs produced relatively pure brain endothelial cells. 
 
vWF 
Endothelial cells are commonly characterized by the expression of vWF which is almost 
exclusively found in the endothelial cells (Goldstein et al., 1986, Deli, 2007). The monocultured 
BBMECs were positively stained with vWF antibody (Figure 10B). This confirmed that the 
primary cells isolated from bovine brain gray matter were truly endothelial cells. 
 
 
Figure 10. Phase contrast image of monocultured BBMECs (A) and the expression of vWF in the BBMECs by 
immunofluorescence staining (green) and endoplasmic reticulum stained with concanavalin A (red) (B), 
(unpublished results). 
 
ZO-1 and occludin 
The expression of ZO-1 and occludin were characterized from the BBMECs and the non-brain 
originating epithelial cells, Caco-2 and MDCKII-MDR1 (Figure 11). ZO-1 creates an important 
link between the cellular cytoskeleton and the transmembrane tight junction protein, occludin 
(Furuse et al., 1994). ZO-1 is required for occludin to be localized correctly in the tight junction 
(Fanning et al., 1998), while occludin is responsible for the paracellular barrier between the cells 
(Furuse et al., 1993, Hirase et al., 1997). 
It was shown that ZO-1 formed a continuous band around the BBMECs (Figure 11A), Caco-2 
(Figure 11B) and MDCKII-MDR1 cells (Figure 11C). This indicates that the foundation for 
occludin localization was present in all cells. In addition, occludin was observed to be located 
mainly between the cell interfaces in all cells (Figure 11D-F) but, interestingly, also intracellular 
perinuclear (near nucleus) staining in the BBMECs was observed (Figure 11D). This 
demonstrates that occludin may not be completely assembled in the tight junctions of the 
BBMECs. 
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Figure 11. The expression of tight junction proteins ZO-1 (A-C) and occludin (D-F) in the BBMECs (A,D, III), 
Caco-2 (B,E, unpublished results) and MDCKII-MDR1 (C,F, III) detected by immunofluorescence staining 
(green). Endoplasmic reticulum was stained with concanavalin A (red). Scale bar 50 µm. 
 
Figure 12. P-glycoprotein expression in the BBMECs cultured on filters on petri dishes and on filter inserts. P-
glycoprotein overexpressing MDCKII-MDR1 cells were used as a positive control and β-tubulin was used as a 
loading control. P-glycoprotein was recognized at ~155 kDa in the BBMECs (Beaulieu et al., 1995) and in the 
MDCKII-MDR1 cells. Modified from Figure 3 in III. 
 
 
Figure 13. P-glycoprotein expression and localization in the BBMECs cultured on filter inserts (A), and on filters 
on petri dishes (B). MDCKII-MDR1 cells cultured on filter inserts were used as a positive control (C). The upper 
picture of each panel (A-C) represents the confocal optical section of the cells from the apical membrane (x-y 
plane) and the lower image is the stack of various x-y planes showing the vertical sections of the cells (x-z 
plane). Immunofluorescence staining of P-glycoprotein (red) and nuclei (blue). Scale bar 10 µm. Modified from 
Figure 4 in III. 
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P-glycoprotein 
Expression and localization of P-glycoprotein were shown in the BBMECs cultured both on 
petri dishes and on filter inserts and MDCKII-MDR1 cells grown on filter inserts by using 
immunoblot analysis (Figure 12) and confocal microscopy (Figure 13). 
The densitometry of the immunoblot bands revealed that P-glycoprotein expression was ~3-
fold higher (P<0.001) in the BBMECs cultured on filter inserts (2.8±1.0, mean±SD) than those 
cultured on filters on petri dishes (1.0±0.4) highlighting the influence of culture conditions on P-
glycoprotein expression in the BBMECs. In addition, the expression of P-glycoprotein in the 
monocultured BBMECs was nearly as high as the expression in the MDCKII-MDR1 cells 
overexpressing P-glycoprotein (estimated by visual inspection) (Figure 12). 
Confocal microscopy studies revealed that P-glycoprotein was localized predominantly on 
the apical side in the BBMECs cultured on the filter inserts (Figure 13A), and on filters on petri 
dishes (Figure 13B) and in the MDCKII-MDR1 cells (Figure 13C) demonstrating the correct 
localization of P-glycoprotein in all of the studied cell models. In addition, a significantly, ~46-
fold, higher (P<0.001) intensity of P-glycoprotein immunostaining was found in the BBMECs 
cultured on filter inserts than those on filters on petri dishes (Figure 4D in III). This again 
indicates that culture conditions have a clear influence on P-glycoprotein expression in 
agreement with the immunoblot data. In addition, the intensity of P-glycoprotein 
immunostaining was significantly ~2-fold higher (P<0.05) in the BBMECs cultured on filter 
inserts than in the P-glycoprotein overexpressing MDCKII-MDR1 cells (Figure 4D in III) 
indicating that P-glycoprotein is expressed at high level in the BBMECs cultured on filter 
inserts. 
5.2.2 Enzyme activities 
ALP enzyme activities were 1125, 290, 10 pmol/min/µg protein in the BBMECs, Caco-2 and 
MDCKII-MDR1 cells, respectively (unpublished results). ALP enzyme activity was 4- and 113-
fold higher in the BBMECs than in the Caco-2 and MDCKII-MDR1 cells, respectively, revealing 
substantial differences in the ALP enzyme activities between the cells. ALP is a specific marker 
for the blood-brain barrier (Deli, 2007) and it has also been used as a biochemical characteristic 
of the BBMECs (Audus and Borchardt, 1987). In addition, the ALP enzyme has been used as a 
marker for cell differentiation in the Caco-2 cells (Matsumoto et al., 1990). Furthermore, ALP has 
also been found in the MDCK cells (Veronesi, 1996). 
Total COMT enzyme activities were 3.4, 151.0 and 68.5 pmol/min/µg protein in the BBMECs, 
Caco-2 and MDCKII-MDR1 cells, respectively (unpublished results). COMT activity was 20- 
and 44-fold lower in the BBMECs than in the MDCKII-MDR1 and Caco-2 cells, indicating clear 
differences in the COMT enzyme activities between the cells. It is known that COMT enzyme is 
expressed in various tissues, e.g., liver, kidney, brain and intestine (Kaplan et al., 1979, Nissinen 
et al., 1988, Karhunen et al., 1994) and it is also found in the BBMECs (Baranczyk-Kuzma et al., 
1986). 
5.3 DRUG PERMEABILITY 
5.3.1 Papp of the model drugs across the BBMEC model 
The Papp values of low (sucrose) and high (diazepam) reference compounds were used to define 
the low and high permeability categories. In order to specify the permeability limit between the 
medium and high permeability categories previously defined limit was applied with BBMECs 
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in an identical experimental set-up (Eddy et al., 1997). In this study, three categories for drug 
permeability across monocultured BBMEC model were used; low, Papp <40 × 10-6 (cm/s); 
medium, Papp 40-70 × 10-6 (cm/s) and high, Papp >70 × 10-6 (cm/s). The Papp values of the model 
drugs were determined from the A-B direction across the BBMECs cultured on filters on petri 
dishes (Figure 14). 
Based on the Papp values, the model drugs could be divided into three categories; low, 
medium (Figure 14A) and high (Figure 14B). The drugs representing low permeability across 
the BBMEC model were cyclosporine A, JTP-4819, acyclovir, digoxin, entacapone, sucrose and 
baclofen. Cephalexin, atenolol, paclitaxel, allopurinol and paracetamol were categorized as 
drugs with medium permeability across the BBMEC model. Finally, pindolol, metronidazole, 
theophylline, vinblastine, verapamil, KYP-2047, metoprolol, antipyrine, ondansetron, 
midazolam, ibuprofen, propranolol, diazepam, alprenolol and tolcapone were categorized as 
drugs with high permeability across the BBMEC model. These results show that the 
monocultured BBMEC model is able to differentiate the model drugs into three different 
permeability categories. 
 
 
Figure 14. The apparent permeability coefficient (Papp) × 10
6  (cm/s) of model drugs from A-B direction across 
the BBMECs cultured on filters on petri dishes were classified as drugs with low and medium permeability (A) 
and drugs with high permeability (B). Categories for low, Papp <40 × 10
-6 (cm/s); medium, Papp 40-70 × 10
-6 
(cm/s); high, Papp >70 × 10
-6 (cm/s) were defined as described in section 5.3.1. Data are mean±SD. 
A 
B 
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5.3.2 Molecular descriptors determining the permeability of drugs across the BBMEC model 
PCA analysis was used to determine the key molecular descriptors depicting the Papp of the 
model drugs across the monocultured BBMEC model (Table 11). The passive permeation of 
drugs across the cell membranes is highly dependent on their physicochemical properties (van 
de Waterbeemd et al., 1996, Lipinski et al., 1997, Abraham et al., 1994, Kelder et al., 1999, Palm et 
al., 1997). High descriptor values for LogP, ratio between the hydrophobic/hydrophilic parts of 
a molecule, the amphiphilic moment, vectors pointing from the center of mass to the center of 
the hydrophilic regions, and hydrophobic regions all attribute to designation of high Papp values 
for the model drugs. In contrast, high descriptor values of ratio between the hydrophilic 
region/molecular surface, ratio between the hydrophilic/hydrophobic regions, hydrogen-
bonding capabilities and polar volume of the molecule lead to low Papp values for the model 
drugs. This indicates that the key molecular descriptors determining the drug permeability 
across monocultured BBMECs were mainly related to hydrophobic and hydrophilic 
interactions, the balance between the hydrophilic and hydrophobic moieties of the drug and the 
potential for hydrogen bonding interactions. 
It has also been demonstrated that the key molecular descriptors for monocultured BBMECs 
were in parallel to those previously described for Caco-2 and MDCK cells (Table 4 in II). 
Hydrophobic and hydrophilic interactions, the potential for hydrogen-bonding interactions, 
molecular size and flexibility were the most important physicochemical properties influencing 
the in vitro Papp across the epithelial cell models (Table 4 in II). In the monocultured BBMEC 
model, the molecular descriptors describing the molecular volume or surface properties were 
not clearly apparent from the set of molecular descriptors depicting the Papp of the model drugs, 
which may be result from the leakier paracellular route. Taken together, the molecular 
descriptors depicting the passive permeability of drugs across the monocultured BBMECs and 
epithelial cell models are similar. 
 
Table 11.Twelve key molecular descriptors determining the apparent permeability coefficient (Papp) 
of model drugs across the BBMECs cultured on filters on petri dishes. Modified from Table 3 in II. 
Molecular descriptor Attributes leading 
to high Papp 
Attributes leading 
to low Papp 
1. Octanol/water partition coefficient (LogP) 
  
2. Amphiphilic moment (vector pointing from the center of the hydrophobic 
region to the center of the hydrophilic region) (A) 
  
3. Vectors pointing from the center of mass of a model drug to the center of the 
hydrophilic regions (IW1-6) 
  
3. Hydrophobic interactions (D1-8) 
  
5. Local minima of interaction energy between hydrophilic probe and the model 
drug (EWmin) 
  
6. Ratio between the hydrophobic and hydrophilic parts (CP) 
  
7. Ratio between the hydrophilic regions and the molecular surface (CW1-8) 
  
8. Ratio between the hydrophilic regions and the hydrophobic regions (HL1-2) 
  
9. Hydrophilic regions (W1-8) 
  
10. Hydrogen-bonding capabilities (HB) 
  
11. Polar volume (Wp) 
  
12. Vectors pointing from the center of mass of a model drug to the center of 
the hydrophobic regions (ID) 
              _  
high descriptor value,  low descriptor value, – does not differ from average values 
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5.3.3 Comparison of the Papp values between the cell models 
The permeability experiments were performed by using the apparatus typical for each cell 
model (i.e., the BBEMC model in side-by-side diffusion chambers (Kuhnline Sloan et al., 2012) or 
Caco-2 and MDCKII-MDR1 models in filter inserts system (Braun et al., 2000) (Figure 6). 
The permeability of the low permeability reference compound, [14C]sucrose, in the BBMEC 
model was 13- and 21-fold higher than that in the Caco-2 and MDCKII-MDR1 cells, respectively 
(Table 12) demonstrating a leakier cell monolayer in the BBMEC model. The tight junctions, 
responsible for the paracellular barrier between the cells, are not so tightly closed in the 
paracellular route in the BBMECs as in the epithelial cells. The higher Papp values for drugs with 
low and medium permeability in the BBMEC model (Figure 14A) than in the Caco-2 and 
MDCKII-MDR1 models (Table 12) may result from the leakier paracellular route between the 
BBMECs. In addition, lower Papp values for efflux protein substrates in the Caco-2 and MDCKII-
MDR1 cells than in the BBMECs are evidence of more robust efflux protein activity. 
The Papp of the high permeability reference compound, [14C]diazepam, in the BBMEC model 
was 5- and 6-fold higher than in the Caco-2 and MDCKII-MDR1 cells, respectively (Table 12). In 
addition, the Papp values of the model drugs (Table 12) show that the ranges of the determined 
Papp values were clearly different between the BBMEC and Caco-2 or MDCKII-MDR1 models, 
this being partially attributable to the different experimental set-ups (Figure 6). The wider 
unstirred water layer formed in the Caco-2 and MDCKII-MDR1 models may limit the exact 
measurement of Papp values for highly permeable drugs. Therefore, the Papp values for drugs 
with high permeability in the BBMEC model (Figure 14B) are clearly higher due to the well 
stirred system. 
In addition, BBMECs are substantially thinner (0.2-2 μm) than Caco-2 (~30 μm) or MDCKII-
MDR1 cells (~15 μm). As a result, diffusion distance across BBMECs is lower than in Caco-2 or 
MDCKII-MDR1 cells which may have an influence on the higher Papp values obtained in the 
BBMEC model (Brodin et al., 2009). It should also be noted that the interlaboratory variation is 
evident in all cell models (Table 12). 
The dynamic range describes how efficiently the cell model can discriminate between 
different Papp values, i.e., a resolution power of the cell model. The dynamic range defined as 
Papp [14C]diazepam/Papp [14C]sucrose, was 11, 28 and 43 in the BBMEC, Caco-2 and MDCKII-MDR1 models, 
respectively. The dynamic range was 2.5- and ~4-fold greater in the Caco-2 and MDCKII-MDR1 
models, respectively, than in the BBMEC model. This indicates that the BBMEC model 
possesses a lower dynamic range, although higher Papp values of high permeability compound 
can be achieved. The leakier paracellular barrier may explain the lower dynamic range in the 
BBMEC model. 
 
Table 12. The apparent permeability values (Papp) × 10
6 (cm/s) A-B direction in the BBMECs cultured 
on filters on petri dishes, Caco-2 and MDCKII-MDR1 cell models. Data are mean±SD (n=3-60, I-
III) highlighted with bold and supplemented with the reference data. 
Model drug Primary transport 
mechanism 
BBMECs Caco-2 MDCKII-MDR1 
cyclosporine A Transcellular/Effluxa,b 17 ± 3 (II) 0.7-3c-e 0.2-0.7c,e  
JTP-4819 Paracellularf 25 ± 13f n.a. n.a. 
acyclovir Paracellular/Influx
g
 30 ± 9 (II) 0.3-2
h,i
 2
j
 
    (Continued). 
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Table 12. The apparent permeability values (Papp) × 10
6 (cm/s) A-B direction in the BBMECs 
cultured on filters on petri dishes, Caco-2 and MDCKII-MDR1 cell models. Data are mean±SD 
(n=3-60, I-III) highlighted with bold and supplemented with the reference data. (Continued). 
Model drug Primary transport 
mechanism 
BBMECs Caco-2 MDCKII-MDR1 
digoxin Paracellular/Effluxb,k 31 ± 15 (II) 0.5-2c-e,l 0.3-1.9c,e,m 
entacapone Paracellularn 31 ± 14 (I) 2.5 ± 0.6 (I), 1o 11 ± 3 (I) 
sucroseLow Paracellularb 33 ± 14 (I-III), 18-
53p-s 
2.4 ± 1.4 (I), 1.4-1.7c,h 1.5 ± 1.4 (I,III), 
0.3-0.4c,t 
baclofen Paracellular/Influxu 36 ± 14 (I) 0.9 ± 0.7 (I), 0.4v,w 0.7 ± 0.4 (I), 0.9w,* 
cephalexin Paracellular/Influxx 42 ± 15 (II) 0.3v,y 0.5y,§ 
atenolol Paracellulark 49 ± 23 (I) 0.9 ± 0.2 (I), 0.2-
3h,z,v,y,å 
0.7 ± 0.2 (I), 0.3-
1j,ä,ö 
paclitaxel Paracellular/Effluxa,b 56 ± 14 (III), 8.8s 0.8-4.4e,l,aa 6.2 ± 1.9†, 0.5-1.5e,m 
allopurinol Transcellularab 63 ± 29 (II) n.a. n.a. 
paracetamol Transcellularac 67 ± 15 (II) 5-100y,ad 35y,§ 
pindolol Paracellularb 84 ± 16 (I) 29 ± 4 (I), 17-96h,y 24 ± 4 (I), 27j 
metronidazole Transcellular
ae 115 ± 7 (II) n.a. 11af,# 
theophylline Paracellularb 151 ± 76 (II), 40r 45-67ag,ah 30j 
vinblastine Paracellular/Effluxa,b 169 ± 60 (III), 5.5p 1-5c,e,aa,ai,aj <0.2-0.5c,e,m,ai 
verapamil Transcellulara,b 210 ± 61 (II) 16-155c,e,z,v,ah 16-59c,e,j,ö,ak 
KYP-2047 Transcellularf 214 ± 31f n.a. n.a. 
metoprolol Paracellularb 240 ± 63 (I) 55 ± 7 (I), 23-43h,o,z,å 63 ± 15 (I), 30-41j,ä 
antipyrine Transcellularb,k 271 ± 31 (II), 40-73r,al 43-150c,v,y 53-79c,ä,ö 
ondansetron Transcellular/Efflux
am
 276 ± 27 (I) 47 ± 5 (I), 18-110
y,an
 38 ± 4 (I), 110
y,§
 
midazolam Transcellulara,b 295 ± 79 (I) 39 ± 6 (I), 38ao 42 ± 6 (I), 61-70ä,ak 
ibuprofen Transcellular/Influx
ap 341 ± 54 (II) 10-53z,i,v 31af,# 
propranolol Transcellularb 363 ± 55 (II), 80-
147p,r,al 
22-110d,h,i,z,v,y,å 38-50j,ä,ö,ak 
diazepamHigh Transcellularb 376 ± 62 (I-III), 158p 67 ± 23 (I), 33-71c,h,i 65 ± 18 (I), 53c 
alprenolol Transcellular
aq 438 ± 53 (I) 52 ± 4 (I), 25-170h,y,å 53 ± 7 (I), 46ä 
tolcapone Transcellularar 445 ± 99 (I) 63 ± 12 (I) 64 ± 17 (I) 
a Polli et al., 2001; b Avdeef, 2011; c Garberg et al., 2005; d Crowe and Lemaire, 1998; e Troutman and Thakker, 
2003; f Jalkanen et al., 2011; g Takeda et al., 2002; h Yazdanian et al., 1998; i Yee, 1997; j Thiel-Demby et al., 2009; 
k Hellinger et al., 2012; l Mease et al., 2012; m Taub et al., 2005; n Heimbach et al., 2003; o Heimbach et al., 2003; p 
Eddy et al., 1997; q Johnson and Anderson, 1999; r Otis et al., 2001; s Rice et al., 2005; t Mashayekhi et al., 2010; u 
van Bree et al., 1988; v Korjamo et al., 2005; w R-baclofen, Lal et al., 2009; x Dantzig and Bergin, 1990; y Irvine et 
al., 1999; z Yazdanian et al., 2004; å Artursson, 1990; ä Mahar Doan et al., 2002; ö Carrara et al., 2007; aa Walle and 
Walle, 1998; ab Turnheim et al., 1999; ac Duggin and Mudge, 1975; ad Khan et al., 2011; ae Land and Johnson, 1999; af 
Varma et al., 2012; ag Camenisch et al., 1998; ah Bergström et al., 2003; ai Lentz et al., 2000; aj Chan et al., 2005; ak 
Polli et al., 2001; al Shah et al., 1989; am Schinkel et al., 1996; an Gan et al., 1993; ao Tolle-Sander et al., 2003; ap 
Ogihara et al., 1996; aq Cogburn et al., 1991; ar Ceravolo et al., 2002; n.a. not available, permeability values have not 
been reported for Caco-2 or MDCK cells; Low low permeability reference compound; * MDCK cells; § MDCKII cells; † 
unpublished data; # low efflux transporter MDCKII cells; High high permeability reference compound. 
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Linear regressions of the Papp values of model drugs (sucrose, baclofen, entacapone, atenolol, 
pindolol, metoprolol, ondansetron, midazolam, alprenolol, tolcapone and diazepam) between 
the BBMEC, Caco-2 and MDCKII-MDR1 models are shown in Figure 15. Pearson correlation 
coefficients were r=0.91, r=0.93 and r=0.98 (P<0.001) for BBMEC vs. MDCKII-MDR1, BBMEC vs. 
Caco-2 and Caco-2 vs. MDCKII-MDR1, respectively. The fact that there were no clear 
differences in the Pearson correlation coefficients indicates that there is a linear correlation 
between Papp values of each cell model despite the clearly different Papp values and ranges. 
In general, classification of the drugs based on their permeability is used in the early drug 
discovery (Amidon et al., 1995, Li, 2005, U.S. Food and Drug Administration, Guidance for 
Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release 
Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000). Based on 
the Papp values, the model drugs could be divided into three categories; low, medium and high 
(Figure 15). Since the Papp values were determined in the Caco-2 and MDCKII-MDR1 models 
with different permeability set-ups than that used in the BBMEC model, previously determined 
categories for drug permeabilities were used for these models; low, Papp <18 × 10-6 (cm/s); 
medium, Papp 18-40 × 10-6 (cm/s) and high, Papp >40 × 10-6 (cm/s) as presented earlier (Polli et al., 
2000). The Papp limits for the categories in the BBMEC model are described in section 5.3.1. 
It was shown that the BBMEC model ranks the model drugs into the same categories as 
Caco-2 (Figure 15A) and MDCKII-MDR1 models (Figure 15B) with the exception of atenolol 
and pindolol that were categorized into low and medium categories, respectively, in the Caco-2 
and MDCKII-MDR1 models but medium and high categories, respectively, in the BBMEC 
model. In addition, the Caco-2 and MDCKII-MDR1 models rank the model drugs into the same 
categories with the exception of the P-glycoprotein substrate, ondansetron, which had a 
significantly (P<0.001) lower Papp value in the MDCKII-MDR1 model than in the Caco-2 model 
(37.6 vs. 47.1 × 10-6 cm/s) (Figure 15C). This is caused by the stronger functionality of P-
glycoprotein in the MDCKII-MDR1 cells than in the Caco-2 cells. 
 
 
 
 
 
 
Figure 15. The apparent permeability coefficients (Papp) × 10
6 (cm/s) between the different cell models were 
compared by using pair-wise linear regressions between BBMEC vs. MDCKII-MDR1 (A), BBMEC vs. Caco-2 (B), 
Caco-2 vs. MDCKII-MDR1 (C). Relationships were analyzed with Pearson correlation coefficient (r). For BBMEC 
model, the limits for low, medium (Med) and high permeability categories were set as described in section 
5.3.1. and for Caco-2 and MDCKII-MDR1, the limits were were set as described in section 5.3.3. Figure 3 in I. 
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5.4 P-GLYCOPROTEIN MEDIATED DRUG TRANSPORT 
5.4.1 Functionality of P-glycoprotein in the BBMECs 
In cellular uptake studies with two known P-glycoprotein substrates, paclitaxel and vinblastine, 
P-glycoprotein was shown to be functional in the BBMECs (Figure 16). Paclitaxel and 
vinblastine displayed a low cellular uptake in the absence of P-glycoprotein inhibitor, 
GF120918, but in the presence of the inhibitor the cellular uptake of paclitaxel and vinblastine 
was significantly increased by 9- and 3-fold, respectively, indicating that P-glycoprotein was 
functional in the BBMECs. In the presence of the second P-glycoprotein inhibitor, quinidine, the 
cellular uptake of paclitaxel was increased by 7-fold (Figure 16A), whereas the cellular uptake 
of vinblastine remained unchanged (Figure 16B). This indicates that quinidine is not able to 
inhibit the P-glycoprotein mediated efflux of vinblastine in the BBMECs, probably due to the 
different binding sites of vinblastine and quinidine in the P-glycoprotein (Martin et al., 2000). 
 
 
Figure 16. Functionality of P-glycoprotein was demonstrated by using cellular uptake studies of P-glycoprotein 
substrates paclitaxel (A) and vinblastine (B) in the BBMECs. P-glycoprotein was inhibited by using known 
inhibitors GF120918 (3 μM) and quinidine (100 μM). Cellular uptake studies were performed in three separate 
experiments and conducted in duplicate. Data are mean±SD. Statistical significance of differences vs. control 
was tested by one-way ANOVA followed by Dunnett’s test, P<0.001 (***), ns=not significant. Figure 5 in III. 
5.4.2 Functionality of efflux proteins in the BBMECs and MDCKII-MDR1 cells 
The functionality of efflux proteins in the BBMECs and MDCKII-MDR1 cells was further 
confirmed by using the calcein-AM assay. Lipophilic non-fluorescent calcein-AM enters into the 
cells by passive transcellular diffusion. It is known that intracellular esterases metabolize 
calcein-AM to fluorescent calcein and calcein retention in the cells increases after inhibition of 
efflux proteins (Eneroth et al., 2001). 
In the BBMECs, the calcein retention was significantly increased by 2.4-, 2.8-, 3.4- and 3.2-fold 
when P-glycoprotein was inhibited with cyclosporine A, progesterone, verapamil and MK-571, 
respectively (Figure 17A). In the MDCKII-MDR1 cells, P-glycoprotein inhibition with 
cyclosporine A, progesterone or verapamil increased calcein retention by 6-fold or more, 
whereas MK-571 increased calcein retention by 3.9-fold (Figure 17B). Since all efflux protein 
inhibitors significantly increased the calcein retention, one can conclude that the efflux proteins 
are functional in both cell models. Similar results have also been obtained earlier in the BBMECs 
when P-glycoprotein was inhibited with verapamil (Iwanaga et al., 2011), and in the MDCKII-
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MDR1 cells when P-glycoprotein and MRP proteins were inhibited with verapamil or MK-571, 
respectively (Vellonen et al., 2004). 
The calcein-AM assay was used to test the efflux protein interactions of two model drugs, 
ondansetron and tolcapone, that were suspected to undergo efflux protein mediated transport. 
Ondansetron and tolcapone showed efflux protein inhibitory activity both in the BBMECs (~2-
fold increase compared to control) and in the MDCKII-MDR1 cells (1.5 to 2-fold increase 
compared to control), but statistical significance of differences was not achieved (Figure 17). 
However, the slight increase in the calcein retention may indicate that ondansetron and 
tolcapone do exert some inhibitory activity against efflux protein(s) that are functional both in 
the BBMECs and MDCKII-MDR1 cells. 
 
 
Figure 17. Calcein retention (% of control) in the BBMECs (A) and MDCKII-MDR1 (B) in the presence of known 
efflux protein inhibitors, cyclosporine A (15 μM), progesterone (150 μM), verapamil (300 μM) and MK-571 (50 
μM). The studies were conducted in quadruplicate and performed in four different experiments in the BBMECs 
with the exception of ondansetron and tolcapone where one experiment was performed. One experiment in the 
MDCKII-MDR1 cells was performed. Data are mean±SD. Statistical significance of differences vs. control 
(dashed line) was tested by one-way ANOVA followed by Dunnett’s test, P<0.001 (***). Note the differences in 
the scales on the y-axis. Modified from Figure 6 in III. MK-571, ondansetron and tolcapone are unpublished 
results. 
5.4.3 P-glycoprotein mediated transport of drugs across the BBMECs 
The functionality of P-glycoprotein as demonstrated in the uptake assays does not entirely 
reflect situation in the drug permeability assays, since both paracellular and transcellular 
permeability of drug across the cell monolayer have an impact on drug permeability assays. 
The P-glycoprotein mediated efflux in the drug permeability assays needs to exceed 
significantly the passive intrinsic permeability of drug in order to be detectable (Sugano et al., 
2010). Therefore, the functionality of P-glycoprotein was also assessed with the drug 
permeability assays. 
Papp values of paclitaxel and digoxin were significantly lower (P<0.001 and P<0.05) in the 
BBMECs cultured on filter inserts in comparison to those cultured on filters on petri dishes 
(Figure 18A,B). This is explained by the higher expression of P-glycoprotein in the BBMECs 
cultured on filter inserts than those on filters on petri dishes observed by immunoblot 
experiments (Figure 12) and immunofluorescent staining (Figure 13). 
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The bidirectional transport assay is commonly used to estimate efflux protein functionality in 
in vitro models (Polli et al., 2001) and is also approved by the regulatory authorities for 
identification of the involvement of transporters affecting the disposition of a novel drug 
(European Medicines Agency, Guideline on the Investigation of Drug Interactions, 2012). The 
criterion for functionality of the efflux proteins is normally accepted as ER≥2 (Giacomini et al., 
2010, Zhang et al., 2006a). 
The BBMECs cultured on filter inserts demonstrated ER values 1.7, 1.4 and ~1 for digoxin, 
paclitaxel and vinblastine, respectively (Figure 18). The corresponding ER values for BBMECs 
grown on filters on petri dishes were ~1 (Figure 18). Since the ER values in the BBMEC model 
did not reach criterion for efflux (ER≥2) for known P-glycoprotein substrates, it can be 
concluded that the functionality of P-glycoprotein is not detectable in the BBMEC model, if one 
considers the normal criteria for bidirectional transport applied. 
 
Figure 18. Apparent permeability coefficients (Papp) × 10
6 (cm/s) of three P-glycoprotein substrates digoxin (A), 
paclitaxel (B) and vinblastine (C) in the apical to basolateral (A-B) and in the basolateral to apical (B-A) 
directions in the BBMECs cultured on filter inserts and on filters on petri dishes. Permeation studies were 
conducted in triplicate and performed in at least three different experiments. Data are mean±SD (n=9-12). 
Efflux ratio (ER) was calculated by equation Papp,B-A/Papp,A-B. Statistical significance of differences was tested by 
Student’s t-test, P<0.05 (*), P<0.001 (***). Figure 7 in III. 
 
Bidirectional transport studies of [3H]paclitaxel with or without GF120918 were conducted in 
the BBMECs cultured on filter inserts (III). It was shown that the ER value for paclitaxel 
decreased from ER 1.4 to 0.8 as a result of increased Papp in the A-B direction (Figure 19). This 
confirmed the hypothesis that the trend towards higher ER values in the BBMECs cultured on 
filter inserts (Figure 18) was attributable to the higher P-glycoprotein expression. 
In the MDCKII-MDR1 cells overexpressing P-glycoprotein, the ER value for paclitaxel was 6 
indicating that clear efflux was observed in the MDCKII-MDR1 cells. In addition, in the 
presence of GF120918 the ER value for paclitaxel did not decrease to unity but residual ER 2 
was observed. 
 
Figure 19. Apparent permeability coefficients (Papp) × 10
6 (cm/s) of paclitaxel in the apical to basolateral (A-B) 
and in the basolateral to apical (B-A) directions in the BBMECs cultured on filter inserts in the absence and 
presence of GF120918. Data are mean±SD (n=9). Efflux ratio (ER) was calculated by equation Papp,B-A/Papp,A-B. 
Figure 8 in III. 
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5.5 IN VITRO-IN VIVO CORRELATION OF THE CELL MODELS 
5.5.1 In vivo unbound brain/blood ratio 
The in vivo unbound brain/blood ratios are shown in Table 13. The extrapolated AUC portion 
was <20 % except in the case of tolcapone 35 % and baclofen 26 % in brain and atenolol 39 %, 
entacapone 21 % and baclofen 34 % in blood. After administration of a single dose, all model 
drugs were quantifiable in the rat brain ECF indicating that all these model drugs were able to 
cross the blood-brain barrier, at least to some extent. However, clear differences between the 
unbound brain/blood ratios can be found. The unbound brain/blood ratio was highest for 
alprenolol (0.77±0.15, mean±SD) and lowest for baclofen (0.08±0.10). These results indicate that 
the evaluation of in vivo unbound brain/blood ratios can help in the differentiation of drugs 
based on their ability to cross the blood-brain barrier and to enter into the brain (Table 13). 
 
Table 13. Unbound brain/blood ratios were calculated using dual probe in vivo microdialysis AUC 
data. Data are mean±SD. 
Model drug Unbound brain/blood ratio 
alprenolol 0.77 ± 0.15 (n=9) 
metoprolol 0.64 ± 0.06 (n=6) 
midazolam 0.61 ± 0.19 (n=6) 
pindolol 0.34 ± 0.08 (n=8) 
ondansetron 0.19 ± 0.07 (n=6) 
tolcapone 0.17 ± 0.12 (n=6) 
atenolol 0.16 ± 0.08 (n=5) 
entacapone 0.14 ± 0.11 (n=10) 
baclofen 0.08 ± 0.10 (n=9) 
5.5.2 In vitro-in vivo correlation of the cell models 
In vitro-in vivo correlation of the BBMEC, Caco-2 and MDCKII-MDR1 models were assessed by 
the linear regression between the in vitro log(Papp) and in vivo unbound brain/blood ratio (Figure 
20). Significant in vitro-in vivo correlations were observed only if ondansetron and tolcapone 
were excluded from the data analysis, probably because they act as substrates for efflux 
transporters. The resulting Pearson correlation coefficients were r=0.99 (P<0.001) in the BBMEC 
model, r=0.91 (P<0.01) in Caco-2 model and r=0.85 (P<0.05) in MDCKII-MDR1 model. Apparent 
differences in the correlation coefficients between cell models may result from the fact that the 
paracellular leakiness of the BBMEC model restricts the differentiation between low 
permeability drugs. In addition, in a small model drug set (n=7), minor variations in the single 
data point exert a great impact on the r value. Therefore, no clear differences in the in vitro-in 
vivo correlations between the cell models were found, although the Papp values were 
substantially different in the BBMEC model than in the Caco-2 and MDCKII-MDR1 models. 
This indicates that the in vitro-in vivo correlations between the cell models are comparable when 
the rat brain microdialysis method is used as the in vivo measure. 
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Figure 20. In vitro-in vivo correlations of the BBMEC (A), Caco-2 (B) and MDCKII-MDR1 (C) models. Each in 
vitro Papp values were log-normalized. In vivo brain/blood ratio represents the ratio of unbound drug 
concentration from the AUC from the rat brain ECF and unbound drug concentration from the AUC from the rat 
blood. Data are mean±SD. Dashed line (---) represents the linear regression with all data points and the solid 
line (—) represents the linear regression after exclusion of two data points (•). Pearson’s correlation coefficients 
(r) were defined. P<0.001***, P<0.01**, P<0.05*, ns=not significant. Figure 4 in I. 
 
5.5.3 Relationship between physicochemical properties, in vitro and  in vivo parameters 
The physicochemical properties of drugs have been shown to influence their blood-brain barrier 
permeabilities in vivo (Abraham et al., 1994, Gratton et al., 1997). In order to further evaluate the 
in vitro-in vivo correlations obtainable with the cell models, a third dimension of selected 
physicochemical properties of drugs (LogP, PSA and hydrogen bonding interactions) was 
added into the in vitro-in vivo correlations to create three dimensional plots (Figure 21). 
The three dimensional scatter plots demonstrate the influence of different physicochemical 
properties of models drugs for in vivo and in vitro parameters. In general, low LogP value 
(Figure 21A-C) and high hydrogen bonding interaction capabilities (Figure 21G-I) are 
reflections of lower in vivo unbound brain/blood ratios and low Papp values. In contrast, high 
LogP, low PSA (Figure 21D-F) and a low amount of hydrogen bonding interactions translate 
into higher in vivo unbound brain/blood ratios and high Papp values. 
Ondansetron and tolcapone are two model compounds that were excluded from the in vitro-
in vivo correlation analysis in Figure 20; they are designated with black pins in the three 
dimensional scatter plots (Figure 21). There are differences in the physicochemical properties 
(LogP, PSA and hydrogen bonding interactions) between these two model drugs. Tolcapone 
displays higher values for LogP, PSA and hydrogen bonding interactions than ondansetron. 
The higher PSA and hydrogen bonding interactions of tolcapone may partly explain its low in 
vivo unbound brain/blood ratio, although the LogP value is rather high and, thus, for it the in 
vitro-in vivo correlation is poor. 
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Figure 21. Influence of different physicochemical properties of model drugs for in vitro apparent permeability 
coefficients (Papp × 10
6) and in vivo unbound brain/blood ratios (in vivo). Physicochemical properties; 
octanol/water partition coefficient (LogP, A-C), polar surface area (PSA, D-F) and hydrogen bonding interactions 
(H-bonding, G-I) in the BBMEC (A,D,G), Caco-2 (B,E,H) and MDCKII-MDR1 (C,F,I) cell models. In vitro and in 
vivo data are described in Table 12 and 13, respectively. Physicochemical properties of the model drugs are 
described in Table 9. Two model drugs (ondansetron and tolcapone that were excluded from the in vitro-in vivo 
correlation analysis in Figure 20) are marked with black pins. The dashed lines represent the limits for low, 
medium and high in vitro Papp categories. For BBMEC model, the limits were set as described in section 5.3.1. 
and for Caco-2 and MDCKII-MDR1 models, the limits were set as described in section 5.3.3. 
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6 Discussion 
6.1 CHARACTERISTICS OF THE BBMEC MODEL 
6.1.1 Tightness 
The permeability of sucrose into the rat brain in vivo is extremely low (Ohno et al., 1978), in fact 
to all intents and purposes, it is negligible, and, therefore, sucrose is the most commonly used 
low permeability compound in the characterization of the tightness of the in vitro models 
representing the blood-brain barrier. In this study, the Papp values for sucrose obtained with the 
monocultured BBMECs were in line with previous studies conducted with the monocultured 
BBMECs under similar culture and experimental conditions (Eddy et al., 1997, Rice et al., 2005). 
In general, however, the permeability of sucrose in the monocultured BBMECs has been shown 
to be very variable ranging from 4 to 85 × 10-6 cm/s (Pardridge et al., 1990, Eddy et al., 1997, 
Glynn and Yazdanian, 1998, Cecchelli et al., 1999, Johnson and Anderson, 1999, Polli et al., 2000, 
Otis et al., 2001, Karyekar et al., 2003, Rice et al., 2005) evidence for the extensive inter-laboratory 
variability in evaluations of the tightness of monocultured BBMECs. One of the reasons for this 
variability may be the success or failure in the isolation of pure BBMECs, i.e., contamination of 
BBMECs with other cells, such as pericytes, that are known to loosen the BBMEC monolayer as 
also observed in the present. 
Since the permeability of sucrose was interpreted as a leaky paracellular barrier in the 
BBMEC model, different culture medium supplements (hydrocortisone, ascorbic acid and two 
different ACMs) were tested. However, it was found that these supplements did not improve 
the tightness of the monocultured BBMECs. 
One possible explanation for the inability to achieve adequate tightness in the BBMECs 
cultured under ACMs may be that the ACM alone is not sufficient to tighten gaps between cells 
in the BBMEC model. In fact, it has been shown that astrocytes need to be in close contact with 
BBMECs in order to enhance the tight junctions (Tao-Cheng et al., 1987). In addition, cultured 
endothelial cells might need synergistic enhancement from both astrocytic factors and agents 
that increase cAMP levels (Wolburg et al., 1994). Recently, the BBMECs co-cultured in close 
contact with rat astrocytes and several different culture medium supplements (cAMP, 
phosphodiesterase inhibitor and dexamethasone) demonstrated increased TEER values which 
ranged from 760 to 1014 Ωcm2 (Helms et al., 2010, Helms et al., 2012). In this co-culture BBMEC 
model, the permeability of mannitol was relatively low varying from 0.3 to 3.2 × 10-6 cm/s, 
suggesting that this novel BBMEC model may promote the development of tighter endothelial 
cell based in vitro models in the future. 
One possible factor leading to leaky paracellular route in the BBMECs may be the present 
finding that the transmembrane tight junction protein, occludin, which is responsible for the 
paracellular barrier between the endothelial cells of blood-brain barrier (Hirase et al., 1997) was 
found to be located in the perinuclear space in the BBMECs. As far as is known, this has not 
been previously demonstrated in the BBMECs. Incomplete localization of occludin may weaken 
the tight junctions between the BBMECs and, thus, may partly explain the leaky paracellular 
characteristics of the monocultured BBMEC model. One could speculate that occludin may be 
internalized, e.g., by endocytosis, since also the adherens junction protein (VE-cadherin) has 
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been demonstrated to be internalized by endocytosis (Gavard and Gutkind, 2006). In addition, 
endocytic recycling of occludin has been indicated in epithelial cells (Morimoto et al., 2005). In 
the future, this finding may also help in the development of tighter paracellular barrier between 
the BBMECs. In order to fully understand the association between possible internalization of 
occludin and paracellular transport of compounds across the BBMECs, however, further studies 
are needed. 
In the present study, the tightness of the non-brain originating epithelial cell models, Caco-2 
and MDCKII-MDR1, were compared with the monocultured BBMEC model. The paracellular 
permeability of sucrose in the BBMEC model was ~13-fold higher than the Caco-2 model and 
~21-fold higher than the MDCKII-MDR1 model, which is in line with previous studies (Eddy et 
al., 1997, Yazdanian et al., 1998, Garberg et al., 2005, Rice et al., 2005, Mashayekhi et al., 2010). 
This indicates that the epithelial cell models are able to form relatively tight junctions also in 
vitro but the brain endothelial cells may require more enhancement factors in vitro, such as 
astrocytic factors and compounds which increase the cAMP level, as discussed above. It should 
be remembered that brain endothelial cells at the blood-brain barrier in vivo are surrounded by 
other cell types present in the neurovascular unit that maintains the brain homeostasis by 
interactive regulatory mechanisms (Iadecola, 2004) and the isolation of the endothelial cells 
from this unit may attenuate the endothelial cell properties in vitro. Overall, however, in all in 
vitro models the tightness is still several orders of magnitude leakier than the in vivo blood-brain 
barrier. Therefore, achieving the tightness of the blood-brain barrier in vivo is an extremely 
demanding, perhaps even impossible, task in vitro. 
6.1.2 Expression of P-glycoprotein 
P-glycoprotein is one of the most extensively studied efflux protein. Since it is expressed at high 
levels in the blood-brain barrier (Cordon-Cardo et al., 1989), it has an important role in the 
distribution of the drugs into the brain (Schinkel et al., 1994). In addition, P-glycoprotein has 
been considered as being one of the most important transporters playing a role in 
pharmacokinetics in human (Fromm, 2004, Sasongko et al., 2005, Wagner et al., 2009). Therefore, 
P-glycoprotein was used as a model efflux transporter in this study; its expression and 
localization were confirmed before conducting functionality assays in the monocultured 
BBMECs. 
Confocal images revealed that P-glycoprotein was localized predominantly in the apical cell 
membrane in the monocultured BBMECs cultured on filter inserts or on filters on petri dishes. 
This appears to be the first time that the apical localization of P-glycoprotein has been 
demonstrated in BBMECs by using confocal microscopy. The results correspond to the in vivo 
localization of P-glycoprotein at the blood-brain barrier, since apical localization of the P-
glycoprotein in the fresh bovine brain tissue and BBMECs have been demonstrated previously 
with electron microscopy (Tsuji et al., 1992). 
In addition, these studies indicated that P-glycoprotein expression in the monocultured 
BBMECs was dependent on the culture conditions. When BBMECs are grown on filter inserts, 
the culture medium gains access to the cells also from the basolateral side of the BBMECs and 
this situation resembles more closely the in vivo situation. This most likely explains the higher 
P-glycoprotein expression of BBMECs cultured on filter inserts. Generally, the expression of P-
glycoprotein in the BBMECs cultured on filter inserts seemed to be almost comparable with the 
P-glycoprotein overexpressing MDCKII-MDR1 cells when immunoblot assay (normalized to 
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protein concentration) was used, which has also supported by others (Zhang et al., 2004). 
Furthermore, the immunofluorescence of P-glycoprotein was significantly higher (normalized 
to area) in the BBMECs cultured on filter inserts than in the MDCKII-MDR1 cells evidence also 
for high P-glycoprotein expression in the BBMECs. 
6.1.3 Functionality of P-glycoprotein 
The expression level of P-glycoprotein may not always correlate with protein functionality 
(Bailly et al., 1995). Therefore, the functionality of P-glycoprotein was demonstrated in the 
BBMECs by using cellular uptake studies. The cellular uptake of known P-glycoprotein 
substrates was significantly increased when P-glycoprotein mediated efflux was inhibited by a 
P-glycoprotein inhibitor(s), which is in agreement with earlier cellular uptake studies which 
have investigated functional P-glycoprotein in the BBMECs (Tsuji et al., 1992, Lechardeur and 
Scherman, 1995, Rice et al., 2005, Joly et al., 1995, Silverstein et al., 2004). 
The calcein-AM assay is generally used to demonstrate the functionality of P-glycoprotein, 
since calcein-AM, but not calcein, is good substrate for P-glycoprotein (Homolya et al., 1993). 
Therefore, higher calcein retention in the presence of P-glycoprotein inhibitors is evidence for 
functional P-glycoprotein in the cells. However, also other efflux proteins such as MRP1 and 
MRP2 have an impact on the calcein-AM assay, since calcein-AM has been demonstrated to 
have interaction with MRP1 (Feller et al., 1995, Holló et al., 1996) and calcein undergoes 
interactions with both MRP1 and MRP2 (Evers et al., 2000). In the present study, all efflux 
protein inhibitors used, including both P-glycoprotein and MRP inhibitors, significantly 
increased calcein retention in the BBMECs. Since P-glycoprotein and MRP1 (Zhang et al., 2004) 
are known to be expressed in the BBMECs but MRP2 is absent (Zhang et al., 2000), the higher 
calcein retention in the presence of P-glycoprotein or MRP inhibitors indicates that both P-
glycoprotein and MRP1 are functional in the BBMECs. Similarly, all of the efflux protein 
inhibitors tested here significantly increased calcein retention in the MDCKII-MDR1 cells used 
as a control. In summary, the present results demonstrate that the P-glycoprotein, probably also 
MRP1, are functional in the BBMECs. 
We also assessed the functionality of P-glycoprotein by using bidirectional transport assays 
in the monocultured BBMECs cultured on both filter inserts and on filters on petri dishes. P-
glycoprotein mediated efflux was not observed in the monocultured BBMECs, even though the 
functionality of P-glycoprotein had been demonstrated. In fact, there is no consensus about 
whether the BBMECs should demonstrate sufficient efflux or not. The failure to detect P-
glycoprotein mediated efflux is in line with the previous studies which have been performed 
with both monocultured BBMECs and BBMECs cultured with astrocytes for doxorubicin, 
rhodamine 123, zidovudine or paclitaxel (Masereeuw et al., 1994, Rice et al., 2005, Gaillard et al., 
2000). However, also contradictory results showing ER values between 2-4 for rhodamine 123 
(Batrakova et al., 2001, Karyekar et al., 2003, Letrent et al., 1999) and vinblastine (Eddy et al., 
1997, Otis et al., 2001) have been published with monocultured BBMECs. The inconsistencies in 
the reported ER values may be due to differences in the P-glycoprotein expression as a result of 
different culture conditions as described in the present study (Figure 12 and 13). In addition, it 
should be noted that the ER values obtained in the BBMEC model, as well as other endothelial 
cell models based on RBMECs and PBMECs (ER<2.5) (Zhang et al., 2006b, Hellinger et al., 2012), 
are intrinsically clearly lower in the brain endothelial cell models than those in epithelial cell 
models, such as in the Caco-2 or MDCKII-MDR1. The Caco-2 model has produced ER values for 
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vinblastine of 11-17 and for digoxin of 5-24 (Troutman and Thakker, 2003, Garberg et al., 2005, 
Hellinger et al., 2012). In addition, ER values for vinblastine and digoxin have been reported as 
23-370 and 53-60, respectively, in the MDCKII-MDR1 model (Garberg et al., 2005, Hellinger et 
al., 2012, Polli et al., 2001) evidence that the ER values are significantly higher in the epithelial 
cell models. It may be difficult to evaluate the functionality of the active transport mechanisms 
in endothelial cells in vitro. Brain endothelial cells may rapidly lose their highly differentiated 
characteristics after isolation from the in vivo neurovascular environment and, thus, the 
functionality of several transport mecanisms may be lower in vitro than in the in vivo situation. 
High passive permeability (including both paracellular and transcellular transport) may 
result in undetected efflux in bidirectional assays. Passive permeability can overwhelm the P-
glycoprotein mediated efflux in the monocultured BBMECs; the passive transport processes 
have been reported to overcome P-glycoprotein mediated efflux in other cell models, such as 
MDCKII-MDR1 (Eytan et al., 1997, Eytan, 2005, Lentz et al., 2000, Varma et al., 2005). The 
paracellular permeability of sucrose was relatively high in the monocultured BBMECs and, 
thus, it is most likely that the passive paracellular transport of compounds is dominant in drug 
permeability assays. In fact, the low ER value for rhodamine 123 (ER 1.7) has also been 
demonstrated in the PBMECs cultured in conjunction with ACM which has a leaky paracellular 
barrier (Papp of sucrose 80 × 10-6 cm/s) further confirming the suspicion that the leaky cell models 
may not be able to detect the efflux in bidirectional transport assays and, thus, they cannot be 
used for prediction of P-glycoprotein mediated efflux potential of drug candidates in early drug 
development. Taken together, since monocultured BBMECs were not able to reveal efflux in the 
bidirectional transport studies, their use in bidirectional transport studies may pose a real risk 
of obtaining false negative results in assessing ER values for drug candidates that are potential 
efflux transporter substrates. 
6.2 DRUG PERMEABILITY 
6.2.1 Dynamic range 
The dynamic range describes how efficiently the cell model can discriminate between drugs 
with low and high Papp values. The lower dynamic range in the BBMEC model in comparison to 
the epithelial cell models seems to be a typical finding for the BBMEC model (Polli et al., 2000) 
which can be explained partly by the leakier paracellular barrier. Similarly, a lower dynamic 
range has been observed earlier in the RBMECs co-cultured with astrocytes and pericytes 
(Hellinger et al., 2012). Due to the low dynamic ranges, the leakier cell models may not be able 
to efficiently distinguish the Papp values of drugs. 
6.2.2 Molecular descriptors determining passive drug permeability 
The paracellular transport of drugs across the blood-brain barrier in vivo is negligible due to the 
fact that the tight junctions restrict passage through the paracellular route. Therefore, the drugs 
targeted into the brain need to be transported across the brain endothelial cells. The intrinsic 
molecular properties of a drug determine its ability to be transported via the transcellular 
pathway. The most important molecular properties influencing the passive brain penetration of 
drugs are lipophilicity (LogP), hydrogen bonding potential, polarity (e.g., PSA) and MW 
(Rapoport and Levitan, 1974, Abraham et al., 1994, Abraham, 2004, Gratton et al., 1997, Kelder et 
al., 1999, Pardridge, 2005, Fischer et al., 1998). A better potential for blood-brain barrier 
permeability of drugs can be achieved when LogP is 2-5 or <3, hydrogen bonding interactions 
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(HBD <3-4 and HBA <8), PSA <90 Å2 and MW less than 450-500 Da (Hitchcock and Pennington, 
2006, Reichel, 2006). These limits are stricter than Lipinski’s rule of five limits (i.e., LogP <5, 
hydrogen bonding interactions (HBD <5 and HBA <10) and MW <500 Da (Lipinski et al., 1997). 
However, there are no comprehensive studies available which have evaluated the molecular 
properties which influence drug permeability across the blood-brain barrier in vitro, such as 
with the BBMEC model. Only a few molecular descriptors affecting the passive transport across 
the BBMEC model have been described; lipophilicity and molecular size (Usansky and Sinko, 
2003), hydrogen bonding interactions of peptides (Chikhale et al., 1994) and computed free 
energy of solvation parameter (Lombardo et al., 1996). There are no other reports assessing the 
influence of descriptors in the permeability of drugs across BBMEC model. In the present study, 
twelve key molecular parameters of drugs from a set of 102 molecular parameters were 
identified as influencing the passive cell membrane permeability across the BBMEC model. 
These key molecular parameters were mainly related to lipophilic and hydrophilic interactions, 
the balance between the hydrophilic and lipophilic moieties of the drug and hydrogen bonding 
interactions, in parallel with those determining the passive brain penetration of drugs in vivo 
(Rapoport and Levitan, 1974, Abraham et al., 1994, Gratton et al., 1997, Fischer et al., 1998, Kelder 
et al., 1999, Abraham, 2004, Pardridge, 2005). The passive drug permeability in vivo and in vitro 
is determined with the comparable molecular properties of drugs. However, the brain entry of 
drugs in vivo is a complex process that is also influenced by active mechanisms, such as active 
transporters and metabolism. 
At present, Caco-2 is the most widely used in vitro model for predicting the oral absorption of 
drug candidates in early drug development. Therefore, the molecular properties determining 
the permeability of drugs across Caco-2 monolayers have been rather extensively investigated 
(van de Waterbeemd et al., 1996, Krarup et al., 1998, Ertl et al., 2000, Österberg and Norinder, 
2000, Stenberg et al., 2001, Guangli and Yiyu, 2006, Di Fenza et al., 2007, Paixão et al., 2010, 
Shinde et al., 2011), whereas the permeability of drugs across MDCK cell monolayers is far less 
well understood (Chen et al., 2005, Groenendaal et al., 2008). The molecular properties 
determining the in vitro permeability of drugs in the Caco-2 and MDCK models are mainly 
lipophilicity, hydrophilicity, hydrogen bonding interactions, MW, molecular size and shape. In 
fact, these are in agreement with those determined for the BBMEC model in the present study 
with the exception of molecular size and shape properties that were not clearly apparent from 
the set of molecular descriptors in the BBMEC model. This may result from the paracellular 
leakiness of the BBMEC model. These results are in accordance with the molecular properties 
that have been associated with the passive permeability of drugs across the cell membranes 
(van de Waterbeemd et al., 1996, Lipinski et al., 1997, Abraham et al., 1994, Kelder et al., 1999, 
Palm et al., 1997). The molecular descriptors determining the passive drug permeability across 
the endothelial and epithelial cells are similar, despite the cellular differences, e.g., tightness, 
height of the cell monolayer and phospholipid composition of cell membranes (Siakotos and 
Rouser, 1969, Dias et al., 1992, Hansson et al., 1986, Di et al., 2009, Hellinger et al., 2012). For this 
reason, one could speculate that either an endothelial or an epithelial cell monolayer could be 
used when only passive transport is being evaluated in vitro and one is attempting to classify 
drugs into different categories. 
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6.2.3 Comparison of drug permeabilities between the in vitro models 
The present study clearly demonstrated that the BBMEC model indicated generally higher Papp 
values for model drugs than Caco-2 or MDCKII-MDR1 models, but nonetheless the BBMEC 
model was able to rank the model drugs into the same categories as the Caco-2 and MDCKII-
MDR1 models with a few exceptions, despite its leakiness and its lower dynamic range. This 
suggests that the BBMEC model and Caco-2 and MDCKII-MDR1 models, particularly when 
passive permeability is being evaluated, are able to classify the drugs and measure the drug 
permeation process similarly but the Papp scales are different. One explanation for this could be 
the different experimental set-ups. In this study, experimental set-ups typical for each cell 
model, i.e., BBMECs in the well stirred side-by-side diffusion chambers (Hansen et al., 2002) and 
Caco-2 or MDCKII-MDR1 cells in the filter insert system (Braun et al., 2000) were applied. The 
side-by-side diffusion chamber system has more efficient stirring and, thus, the breadth of the 
unstirred water layer is narrower than in the filter insert system. The wider unstirred water 
layer formed in the filter insert systems is known to reduce the Papp values of lipophilic drugs 
(Korjamo et al., 2008, Korjamo et al., 2009) indicating that the higher unstirred water layer in the 
filter insert system, limits the exact measurement of Papp values for highly permeable drugs. 
Therefore, lipophilic drugs tend to have higher Papp values across the cell membranes when 
there is a narrow unstirred water layer and this does not cause a rate-limiting barrier. In this 
study, diazepam was used as high permeability reference compound and the Papp value of 
diazepam was observed to be higher in the BBMEC model than in the Caco-2 and MDCKII-
MDR1 model, which is dependent on the thickness of the unstirred water layer in the different 
experimental set-ups. In a previous study by Zhang et al. 2006b, the permeability of lipophilic 
diazepam was substantially higher in stirred when compared to the unstirred conditions 
(Zhang et al., 2006b). In addition, the thinner cell monolayer of the BBMECs and, thus, the lower 
diffusion distance may partially explain the higher Papp values obtained for both the low and 
high permeability model drugs. 
Interlaboratory variation is a common problem in many in vitro models. Interlaboratory 
variation has been clearly demonstrated in Caco-2 cells (Walter and Kissel, 1995, Hayeshi et al., 
2008) and, thus, it complicates the comparison of the in vitro drug permeability values 
conducted in different laboratories. Therefore, the culture conditions and protocols for all cell 
models used for in vitro drug permeability testing should be standardized in an attempt to 
reduce the interlaboratory variation. Furthermore, the standardized protocols should include 
the relevant controls to reflect the entire dynamic range and also the robustness of active 
transport mechanisms before investigators will be able to systemically evaluate the properties 
of the in vitro model used. However, these kinds of standardized culture conditions or protocols 
for the endothelial cell models are still lacking. 
6.3 IN VITRO-IN VIVO RELEVANCE 
In vitro-in vivo correlation studies are generally undertaken to assess the relevance of in vitro 
models when they are used to predict in vivo parameters. The in vitro-in vivo correlation 
describes the mathematical relationship between the parameters determined in vitro and in vivo. 
In the present study, linear regressions between Papp values determined for nine model drugs in 
three in vitro models (BBMEC, Caco-2 and MDCKII-MDR1) and the in vivo unbound 
brain/blood ratios determined by the microdialysis method were calculated. Currently, the in 
vivo brain microdialysis method, which assesses the unbound drug concentrations from both 
sides of the blood-brain barrier, is considered as the most relevant method with which to assess 
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the unbound drug concentrations that are able to exert the pharmacological response 
(Hammarlund-Udenaes et al., 2008). The unbound brain/blood ratio was determined after a 
single dose and it describes mainly the rate of the drug transport across the blood-brain barrier. 
However, the unbound brain AUC determined by in vivo brain microdialysis also illustrates the 
distribution of a drug from the extracellular compartment into the intracellular compartments 
and elimination from the brain similarly as the unbound AUC in blood takes into account 
absorption, distribution and elimination throughout the body. The present study indicated that 
the in vitro-in vivo correlations between BBMEC, Caco-2 or MDCKII-MDR1 model were similar 
when mainly passively transported compounds were examined in the analysis. 
When model drugs known to undergo interaction with efflux proteins (ondansetron and 
tolcapone) were included, the in vitro-in vivo correlations were deteriorated. Ondansetron has 
previously been identified as a substrate for P-glycoprotein (Schinkel et al., 1996) and the 
calcein-AM assay showed that tolcapone may undergo interactions with efflux protein(s) in the 
BBMECs and MDCKII-MDR1 cells as well. However, the specific efflux transport mechanism(s) 
involved in the transport of tolcapone remains to be clarified. On the other hand, the 
physicochemical properties of drugs also influence the brain penetration together with 
transporter mediated efflux. Therefore, the in vitro-in vivo correlations were evaluated further 
by using three dimensional plots that were generated by including physicochemical properties 
into the in vitro-in vivo correlations. The three dimensional plots showed general trends of the 
physicochemical properties differentiating between lower or higher in vivo and in vitro 
parameters. However, deviations from the in vitro-in vivo correlation trends, namely 
ondansetron and tolcapone, were only partially explained in terms of physicochemical 
properties. Thus, other restrictive mechanisms, such as functionality of efflux proteins, are the 
most likely reasons for their poor in vitro-in vivo correlations. This approach indicates that it is 
the multiple characteristics of drug, not only one individual physicochemical property, which 
determine a drug’s potential to cross the blood-brain barrier in vivo. 
Several in vitro-in vivo correlation studies utilizing different in vitro and in vivo models have 
been published (Table 5 and 6). However, the results are highly variable and there is neither 
consensus nor statistical evidence of whether endothelial or epithelial cell models are better. 
This argument is based on statistical analyses of the literature results (r) in Table 5 and 6; 
statistical significance of differences between cell models or between endothelia and epithelial 
cell models was tested by one-way ANOVA followed by Tukey’s test by GraphPad Prism 5.03 
software with statistical significance set at P<0.05. Most of the in vivo methods measure the total 
drug concentrations at a single time point. In this study, the in vivo microdialysis method was 
applied. The paracellular leakiness of the BBMEC model restricts the differentiation between 
low permeability drugs and, thus, may apparently improve the in vitro-in vivo correlation in the 
BBMEC model. In addition, in a small model drug set (n=7), a minor variation in single data 
point may have a great impact on r values. The present in vitro-in vivo correlation results 
indicate no clear difference between the cell models and are consistent with the previous 
literature findings (Table 5 and 6). No in vitro-in vivo correlation was found in a previous study 
when a higher number of model drugs (n=22 including passively transporting drugs, efflux and 
influx protein substrates) were used to study in vitro-in vivo correlations between co-cultured 
BBMEC, Caco-2 or MDCKII-MDR1 models (Garberg et al., 2005). However, also better in vitro-in 
vivo correlations were achieved when only passively transported compounds (n=10) were 
examined (Garberg et al., 2005). These poor in vitro-in vivo correlations of efflux protein 
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substrates can be explained by the fact that the efflux proteins are functioning in their natural 
rate in vivo but in vitro models may not be able to reproduce the actual efflux protein 
functionality corresponding to the in vivo situation. In summary, the similarities in the in vitro-in 
vivo correlations between different in vitro models indicate that in vitro models are able to 
classify drugs into categories and predict mainly passive drug entry into brain in vivo. This 
highlights the need to use in vivo methods to supplement the in vitro predictions in the early 
development of CNS drugs. 
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7 Conclusions and Future Prospects 
This study aimed to clarify the relevance of the monocultured BBMEC model for use as an in 
vitro blood-brain barrier model in drug permeability studies. The BBMECs has been used 
already for several decades but there are still uncertainties about the reliability of monocultured 
BBMECs as a relevant in vitro blood-brain barrier model. The present study investigated the 
factors influencing passive drug permeability, role of the P-glycoprotein mediated efflux and 
the in vivo relevance of the monocultured BBMEC model. Furthermore, the properties of the 
BBMEC model were compared to two epithelial cell models (Caco-2 and MDCKII-MDR1) that 
are generally in use in academic laboratories and the pharmaceutical industry to assess drug 
permeability. On the basis of this study, the following specific conclusions can be drawn: 
 
1. The tested cell culture conditions neither tightened the paracellular barrier nor 
enhanced the functionality of efflux proteins in the BBMECs. BBMECs were pure 
endothelial cells expressing several endothelial cell and blood-brain barrier markers. 
However, the BBMEC model was leakier and as a result it had a lower dynamic 
range than the Caco-2 or MDCKII-MDR1 cell models. One reason for this could be 
the partial perinuclear localization of the tight junction protein, occludin. The 
BBMEC model may be suitable for use in the studies of cellular mechanisms, such as 
in cellular uptake studies, where the tightness of the cell monolayer is not the 
principal requirement. 
 
2. P-glycoprotein was expressed and correctly localized in the monocultured BBMECs. 
Culture conditions were found to affect P-glycoprotein expression in the BBMECs. P-
glycoprotein expression was significantly higher in the BBMECs cultured on filter 
inserts. In cellular uptake studies, P-glycoprotein was shown to be functional, but no 
efflux was detected in the bidirectional transport studies. The failure to detect efflux 
suggests that the use of monocultured BBMECs may pose a real risk of obtaining 
false negative results for drug candidates that are potential P-glycoprotein substrates. 
 
3. Lipophilicity, the balance between hydrophilic and lipophilic moieties, hydrophilic 
interactions and hydrogen bonding capabilities were the molecular descriptors 
determining the passive drug permeability across the BBMEC model and they were 
similar in both Caco-2 and MDCKII-MDR1 models, suggesting that there are no clear 
differences between passive drug permeability across the endothelial and epithelial 
cell models when one attempts to classify drugs into categories. Thus, either 
endothelial or epithelial cell monolayers could be used when passive transport of 
drugs needs to be evaluated in vitro. 
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4. The monocultured BBMEC model was able to predict the in vivo brain entry of 
mainly passively transported drugs as assessed by the in vivo unbound brain/blood 
ratio. However, no clear differences in the in vitro-in vivo correlations between 
BBMEC, Caco-2 and MDCKII-MDR1 models were found, indicating that the 
predictive value of endothelial and epithelial cell models is similar when it is mainly 
passive drug permeability that is being assessed and drugs are being classified into 
categories. 
 
Despite much progress made during several decades in blood-brain barrier research, there is 
still no easily maintained and standardized cell culture model available. Ideal in vitro model 
should have the following characteristics: 
 human brain endothelial cell origin 
 stable genome without aneuploidy 
 tightness comparable to in vivo situation 
 functional expression of active transporters equivalent to in vivo situation 
 correct cellular localization of the active transporters 
 metabolic properties similar as in vivo blood-brain barrier 
 realistic cellular and tridimensional blood-brain barrier architecture 
 relevant in vitro-in vivo correlations for each transport mechanisms (e.g., passive 
paracellular and transcellular diffusion, active efflux transport, active carrier 
mediated transport, endocytosis) 
 easy to maintain and use, non-laborious, suitable for high-throughput screening 
 
Despite recent developments, the currently available models are still far from ideal. However, 
recently a new approach in the development of in vitro models, i.e., stem cell research, was 
introduced by developing endothelial cells which represent human blood-brain barrier cells 
derived from pluripotent stem cells (Lippmann et al., 2012). The stem cell derived endothelial 
cells expressed the relevant tight junction and transporter proteins. In addition, the tightness of 
this blood-brain barrier model was clearly improved in comparison to other human brain 
endothelial cell-based models. Hence, this new sophisticated in vitro model might be the key to 
the development of next generation in vitro models for blood-brain barrier. 
The number of people suffering from neurodegenerative disorders will grow substantially in 
the future, and they are becoming one of the leading causes of death (for review see Palmer, 
2011). Therefore, there is a clear need to develop new drugs for the treatment of CNS disorders. 
One stumbling block is that the in vitro models especially those mimicking diseased blood-brain 
barrier do not exist at all. The lack of suitable models could well have been hampered the 
development of drugs for neurodegenerative disorders. However, the development of in vitro 
models for diseased blood-brain barrier will remain fraught with difficulties, as long as the 
pathogenesis, mechanisms and effects on blood-brain barrier dysfunctions of the 
neurodegenerative diseases are poorly understood. 
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